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Abstract 
    
Background and research questions 
The characterization of chronic persistent asthma in an older adult population is not 
well defined.  This is due to the difficulties in separating the diagnosis of asthma 
from that of chronic obstructive pulmonary disease (COPD), the latter being a 
condition which primarily consists of emphysema and chronic bronchitis, and in 
some cases asthma. 
The studies in this thesis focus on middle-aged and older adults with chronic 
irreversible asthma, or ‘fixed airway obstruction asthma’ (FAOA).  Individuals who 
have FAOA are frequently labeled as having COPD and as such are rarely studied in 
isolation.  As a consequence, little is known about FAOA and to what extent 
treatment strategies for COPD are relevant to individuals who present with the 
condition.  The specific aims of the studies in this thesis were to: (i) implement and 
evaluate a supervised exercise training programme in middle-aged and older adults 
(aged 40 years and over) who had moderate to severe asthma and a degree of fixed 
airways obstruction; (ii) determine the similarities and differences in 
cardiorespiratory and dyspnoea responses with exercise testing between this 
population and in a cohort of subjects with COPD; and (iii) describe the burden of 
both asthma and COPD on hospital services in Western Australia (WA). 
The primary study in this thesis was a randomised controlled trial (RCT) that 
evaluated the effects of a 6 week supervised exercise training program in subjects 
with FAOA.  The purpose of the study was to determine whether individuals with 
FAOA achieve significant improvements with a program that adhered to the 
guidelines for exercise training in COPD. 
The second study compared measures commonly collected prior to the prescription 
of exercise training in a cohort of individuals with COPD and a cohort of individuals 
with FAOA.  This study arose because of unanticipated findings of low dyspnoea 
and a high 6 minute walk distance (6MWD) at baseline in the FAOA subjects who 
participated in the RCT.  The FAOA and COPD cohorts were matched on the basis 
of pulmonary hyperinflation, or air trapping, at rest as quantified by the ratio of 
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residual volume to total lung capacity (RV/TLC), gender and age.  Comparisons 
were made between the groups of cardiorespiratory and dyspnoea data collected 
during the 6 minute walk test (6MWT), resting lung function and peripheral muscle 
strength.  
The third study utilized geographic information systems (GIS) technology to explore 
the distribution of respiratory health services throughout WA and hospital 
admissions secondary to asthma or COPD in adults aged 40 years and over during a 
5 year period 2000-2004.  The purpose of this study was to: (i) gain insights into 
issues facing the provision of respiratory services for middle-aged and older adults 
with asthma and COPD throughout WA; and (ii) explore the burden of asthma and 
COPD in middle-aged and older adults across the State. 
 
The following research questions were addressed: 
1. What are the effects of a 6 week supervised exercise training program in 
subjects who have FAOA on quality of life (QOL), functional exercise capacity, 
anxiety and depression, asthma control and peripheral muscle strength? 
2. What, if any, characteristics differentiate individuals who have FAOA and 
individuals with COPD with respect to measures of resting lung function, functional 
exercise capacity and peripheral muscles strength collected prior to the prescription 
of exercise and what is the physiological basis for any differences? 
3. Does the distribution of hospital admissions for asthma and COPD in middle-
aged and older adults relate to the distribution of respiratory support services for 
these conditions throughout WA, and are there any trends in admissions data for 
asthma and COPD admissions in relation to age, gender and numbers of admissions 
during the 5 year period of data collection? 
 
Methods 
Study 1  
Study 1 was a prospective RCT in which 35 subjects (16 males) were randomised 
using a stratified process to match for gender into an ‘exercise’ and a ‘control group’.  
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Subjects initially participated in a 3 week run-in period during which asthma control 
using the Asthma Control Questionnaire (ACQ), was assessed weekly to ensure 
stability of the subject’s asthma. This was followed by the collection of baseline data 
prior to the intervention period.  The run-in period was extended if a subject reported 
an increase in asthma symptoms as reflected by their responses to the ACQ, a 
variation in forced expiratory volume in one second (FEV1) of >10% or a change in 
their asthma medications.  Health care utilization data, comprising the number of 
hospitalizations and emergency department visits, exacerbations in the year 
preceding study entry, medications taken for asthma and co-morbid conditions were 
recorded. 
Subjects randomised to the exercise group participated in a fully supervised 6 week 
exercise training program consisting of three exercise classes each week at Sir 
Charles Gairdner Hospital.  The control group received standard medical care during 
this 6 week period.  Baseline measures were repeated immediately following the 6 
week intervention period (post-intervention assessment) and at 3 months following 
completion of the intervention period (3 month follow-up).   
The measurements collected pre- and post-intervention comprised resting lung 
function, functional exercise capacity (6MWD), ACQ, QOL [Asthma Quality of Life 
Questionnaire (AQLQ) and the Medical Outcomes Study 36-item Short-Form Health 
Survey (SF-36)], anxiety and depression (Hospital Anxiety and Depression Scale; 
HAD) and peripheral muscle strength (quadriceps force and hand-grip strength).   
The timing of assessments was delayed if a subject experienced an exacerbation or 
other medical problem such that all measurements were made when subjects were in 
a stable condition and taking their usual medications.  Health care utilization data 
and number of exacerbations for a 1 year period that commenced immediately after 
the 3 month follow-up were also collected. 
Study 2  
Study 2 was a cross-sectional matched comparison study comparing respiratory 
function functional exercise capacity, cardiorespiratory and dyspnoea measures 
obtained during the 6MWT and peripheral muscle strength in 16 subjects (10 male) 
with a diagnosis of FAOA to 16 subjects (10 male) with COPD.  The two groups 
were chosen on the basis of similar age (±5 years), gender and resting hyperinflation 
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or air trapping (RV/TLC ±0.05).  Resting lung function measurements comprised 
measures of airflow, lung volumes and single-breath diffusing capacity of the lung 
for carbon monoxide corrected for alveolar volume (DLCO/VA).  All subjects 
completed the 6MWT during which cardiorespiratory and dyspnea responses and 
6MWD were measured.  The 6MWT was performed twice and data from the 
maximum 6MWD were used in the analyses. Quadriceps force was measured in 
triplicate using a strain gauge and the maximum value obtained on the subjects’ 
dominant leg recorded.  Handgrip strength was measured using a Jamar 
dynamometer, and the maximum force obtained from three measurements on the 
subject’s dominant side recorded.  The following data were compared in the two 
subject cohorts: resting lung function expressed as a percentage of predicted normal 
value (% predicted); maximum 6MWD; % predicted 6MWD; cardiorespiratory 
[oxygen saturation (SpO2) and heart rate] and dyspnoea responses to the 6MWT and 
peripheral muscle strength expressed as % predicted normal value.  Data for the 32 
subjects were then combined to investigate relationships between resting lung 
function and 6MWT data. 
Study 3  
Study 3 was a record-linked prevalence investigation to define the prevalence, 
demographic characteristics and regional distribution of asthma and COPD 
admissions in adults aged 40 years and over in relation to the distribution of 
respiratory services within WA. Data on the distribution of hospitals, respiratory 
physicians, pulmonary rehabilitation programs and asthma educators were obtained 
for WA.  Population data of adults aged 40 years and over were then extracted from 
the 2001 census released by the Australian Bureau of Statistics, and hospital 
admission data were obtained in a de-identified format from the Health Department 
of WA for the period 2000-2004 for all asthma and COPD cases.  All data were 
aggregated according to the 30 health service areas for the State of WA which were 
the administrative boundaries used by the Health Department of WA at the time of 
data collection.  Data were linked together in a geo-database using specialized GIS 
software and graphically displayed to show the distribution of respiratory services.  
Thematic maps were developed to show the proportion of adults aged 40 years and 
over with a primary diagnosis of asthma, a primary diagnosis of COPD, and 
combined data showing adults with a primary diagnosis of asthma or COPD in order 
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to determine the proportion of admissions relative to the population size within each 
health service.  Finally, data were aggregated in graphical format and trends in 
admissions data for each health service over the period 2000-2004 by gender and by 
age groups were identified. 
 
Results 
Study 1  
A total of 266 adults matched the selection criteria for the study and of these, 39 
adults attended an initial screening interview.  Thirty-five subjects were enrolled in 
the study and randomised to the exercise group or control group, of whom 34 
subjects (15 male; exercise group n=19, control group n=15) completed the 
intervention period.  The participation rate for this study was 14.7% which decreased 
to 12.8% with subject withdrawals.  Subjects demonstrated moderate to severe 
airflow limitation (FEV1 59.4±15.8% predicted) with evidence of lung hyperinflation 
and gas trapping (mean RV/TLC 125±19% predicted) at study entry.  Subjects were 
aged 68±11 years.  Baseline measures showed subjects to have well preserved 
peripheral muscle strength but significantly impaired QOL.  The physical component 
summary score for the SF-36 was 38.1±10.0 which was significantly lower than age 
and gender matched Australian and WA normative data (p<0.05).  The subjects had a 
high level of functional exercise capacity with 6MWDs close to predicted values 
(88±12% predicted).  Dyspnoea was not a significant factor limiting performance on 
the 6MWT.  The 6 week exercise intervention improved disease-specific QOL with 
the improvement being maintained at the 3 month follow-up.  The magnitude of 
improvement in the symptoms domain and the activity limitation domain were 
significantly greater than any changes seen in the control group (p=0.001 and p=0.04 
respectively). Six minute walk distance and anxiety levels were not significantly 
changed in relation to the control group though were improved in the exercise group 
against baseline measures.  
Study 2 
The main findings of this study were that, despite comparable levels of pulmonary 
hyperinflation and air trapping, individuals with FAOA were characterized as having 
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significantly greater 6MWD (571±88m, 95±11% predicted versus 488±11m, 
80±16% predicted p<0.005), lower scores for dyspnoea at the end of the 6MWT (2.7 
±1.8 versus 5.9±2.5, p<0.001) and preserved SpO2 during the 6MWT (post-exercise 
SpO2 94.7±1.9% versus 84.3±2.7%, p<0.001) than individuals with COPD. 
Peripheral muscle strength was similar between the two groups.  
Study 3 
A total of 4,159 cases with a primary diagnosis of asthma and 19,970 cases with a 
primary diagnosis of COPD were extracted as respiratory admissions within WA 
during the years 2000-2004.  Maps generated through GIS technology revealed a 
disproportionate number of hospital admissions in rural and remote areas compared 
to metropolitan data for adults aged 40 years and over.  In addition, many parts of 
WA lacked the services of a respiratory physician, a hospital emergency department 
and access to a pulmonary rehabilitation program.  Trends in admissions data showed 
a gradual decline in asthma admissions over the 2000-2004 time period but a rise in 
COPD admissions.  The hospital separations for Aboriginal and Torres Strait 
Islander adults were high (6.7% of the COPD admissions and 16.1% of the asthma 
admissions) considering only 3.2% of all adults aged 40 years and over in WA are of 
Aboriginal and Torres Strait Islander descent. The numbers of admissions for 
females with asthma were consistently higher than for males within all health 
services whilst this pattern was reversed for the COPD admissions.  With increasing 
age, the proportion of COPD admissions increased, and in contrast a small decline 
was observed in asthma admissions with increasing age.   
 
Discussion and conclusions 
It is generally assumed that rehabilitation for middle-aged and older adults with 
chronic asthma should be similar to that prescribed for individuals with COPD 
subjects as the disability arising from the respiratory disease is considered to be 
similar.  The RCT undertaken in this thesis (study 1) showed that despite the 
recruitment of asthmatics with fixed airflow limitation, these individuals had a higher 
functional exercise capacity at baseline as evidenced by 6MWDs that were close to 
their predicted normal values and better functional capacity than individuals with 
COPD recruited to studies of pulmonary rehabilitation.  Participation in the exercise 
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program for these subjects with FAOA improved QOL, however compared to a 
control group, the effects of the program on functional exercise capacity, asthma 
control, anxiety and depression, and peripheral muscle strength were not significant.  
A high baseline 6MWD in this cohort may however have limited the responsiveness 
of the 6MWT to detect a meaningful change in functional exercise capacity 
following training.   
The study comparing subjects with FAOA to those with COPD (study 2) illustrated 
regardless of the observations of a similar magnitude of pulmonary hyperinflation at 
rest in these two cohorts, the degree to which functional exercise capacity was 
limited differed between the two conditions and this was most likely attributable to 
the preservation of gas transfer in the FAOA cohort.   
The record linked prevalence study provided an overview of the distribution of 
admissions to hospitals for middle-aged and older adults with asthma and COPD and 
the burden placed on health services particularly in regional WA.  The lack of 
essential respiratory services in many parts of the State and the disproportionate 
number of hospital admissions in rural areas compared to metropolitan areas 
highlighted a need for further research.  The focus of this research would identify 
opportunities to improve the provision of health services for middle-aged and older 
adults with asthma and COPD in regional and remote parts of WA which may follow 
on to better patient outcomes for these individuals.  
The three studies in this thesis highlight the necessity of a correct diagnosis of an 
individual who has FAOA and distinguishing this from COPD as the assessment and 
treatment modalities for the two cohorts in terms of exercise differ.  The differences 
in the distribution of hospital admissions data, and trends in this data with time 
further illustrate that a correct diagnosis of asthma versus COPD in middle-aged and 
older adults is important to ensure accurate evaluation of the burden of these diseases 
on the health care system and to plan for future services based on the need for these 
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Chapter 1: Introduction 
 








    
 
Asthma is one of the most common chronic diseases in the world, and has been 
associated with an unprecedented acceleration in social, economic and health burden 
on individuals, communities and governments (1). Asthma is a chronic inflammatory 
disease of the airways characterized by widespread but variable airflow obstruction 
which is reversible spontaneously or with treatment.  Airway inflammation results in 
episodes of wheezing, dyspnoea, chest tightness and coughing. These symptoms 
have a major impact on an individual who needs to control the disease through 
medications, avoidance of triggers and frequent monitoring (2, 3) 
Older adults with chronic, moderate to severe asthma comprise a considerably under-
researched population. Often these individuals present with airway obstruction that is 
only partially reversible, because repetitive episodes of asthma induced inflammation 
have caused permanent structural changes to the airways (4, 5). For the purpose of 
this thesis, the presence of this chronic irreversible form of asthma will be referred to 
as ‘fixed airway obstruction asthma’ or FAOA. 
This thesis contains three studies which all seek to advance the characterization of 
the condition FAOA in middle-aged and older adults. The primary focus of this 
thesis involves the evaluation and implementation of a supervised exercise training 
program, carried out in a group setting, for individuals with FAOA. This involved a 
randomised controlled trial (RCT) with 35 subjects randomised to either an 
intervention group that received a 6 week exercise training program in addition to 
usual care or to a control group that received usual care only. Exercise training is a 
Chapter 1: Introduction 
 
   -2- 
mandatory component of pulmonary rehabilitation and significantly improves 
exercise tolerance, decreases dyspnoea and fatigue, reduces disability and handicap 
and improves quality of life (QOL) in individuals with chronic obstructive 
pulmonary disease (COPD) (6, 7). It is reasonable to assume that middle-aged and 
older adults who have a diagnosis of FAOA will benefit from exercise training in a 
similar way to those with COPD, given that symptoms of dyspnoea, reduced exercise 
tolerance, and impaired QOL have been reported in both patient groups (4, 8). 
There is limited research evaluating the benefits of exercise training programmes in 
older adults with asthma. A Cochrane review of exercise training for individuals with 
asthma consisted of 13 studies, of which only two were in adults. The authors of this 
review concluded that exercise training improves cardiopulmonary fitness in the 
absence of any changes in lung function. Notably, none of these 13 studies included 
QOL as an outcome measure (9). 
Following on from this first study, the secondary aim of this thesis was to compare 
outcomes in a subgroup of the individuals with FAOA who participated in the RCT 
with a cohort of subjects with COPD. Care was taken to ensure that both subject 
groups were comparable with respect to resting pulmonary hyperinflation, age and 
gender. A retrospective analysis was carried out to compare resting lung function 
measurements, functional exercise capacity as measured by 6 minute walk distance 
(6MWD), cardiorespiratory and dyspnoea responses to the 6 minute walk test 
(6MWT), and peripheral muscle strength measurements between the two groups.   
The third component of this thesis involved a study that examined the community 
burden of asthma and COPD in older adults within Western Australia (WA), 
particularly in rural and remote areas outside the Perth metropolitan area.  A 
descriptive study was carried out which mapped asthma and COPD admissions of 
adults aged 40 years and over across the State over a five year period (2000-2004). 
This study identified trends in the admissions data over this period and located the 
distribution of support services for individuals with asthma and COPD (such as 
pulmonary rehabilitation programmes, asthma educators and respiratory physicians) 
in regional areas. This study identified where services were lacking in regional 
Western Australia and regional ‘hot spots’ for asthma and COPD could be 
visualized.   
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The thesis is divided into five main chapters. The first chapter (chapter 2) presents a 
critical review of the existing literature relevant to each of the three studies 
conducted. This chapter is followed by individual chapters for each of the three 
studies (chapters 3-5). The final chapter (chapter 6) summarises the main findings of 
the research and discusses their clinical implications.  The scope of this thesis is 
deliberately broad as it focuses on addressing novel issues related to asthma 
treatment, management and prevalence in middle-aged and older adults. Specifically, 
the studies aimed to evaluate the efficacy of a clinical intervention, i.e. exercise 
training, as a means of improving QOL, and to investigate prevalence and service 
issues related to asthma and COPD management in regional areas in WA. The 
findings of these studies are clinically relevant and applicable to the management of 
chronic asthma in middle-aged and older adults around the world. 
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2.1 Introduction 
Asthma is one of the most common chronic diseases world-wide with over 300 
million people affected, and represents a significant burden to governments, health 
care services, family and patients (1). The chronic irreversible airways obstruction 
resulting from long-term asthma shares many similarities in its clinical presentation 
and management with chronic obstructive pulmonary disease (COPD), particularly in 
middle-aged and older individuals (10). The treatment approaches to chronic asthma 
and COPD do differ, however, which make it important to clearly differentiate 
between the two conditions. The first line of therapy for the management of COPD is 
pharmacological, which is used to prevent and control symptoms and to reduce the 
frequency and severity of exacerbations, however once this is optimised pulmonary 
rehabilitation, of which exercise is the major component, has been shown to have a 
substantial effect (7, 11). To date, the role this therapeutic option in middle-aged and 
older adults with chronic asthma remains unexplored. 
This literature review is divided into three sections. Part 1 (Sections 2.2 and 2.3) 
outlines the definition, characterisation of, and distinction between fixed airway 
obstruction asthma (FAOA) and COPD. Because there are currently such broad 
definitions pertaining to asthma and COPD, the difficulties that are faced in the 
diagnosis of FAOA are explored, as well as the concepts of asthma severity and 
asthma control.  
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Part 2 (Sections 2.4 to 2.8) discusses the disability associated with chronic asthma in 
middle-aged and older adults. The presence of anxiety and depression, dyspnoea, 
exercise limitation, and a reduced ability to carry out activities of daily living in 
adults with asthma are reviewed, together with the impact of the condition on quality 
of life (QOL). This section includes a summary of the management of chronic 
asthma with an emphasis on the role of exercise training for adults with asthma. 
Part 3 (Sections 2.9 and 2.10) explores the impact of asthma at a community level. 
This includes a summary of the health burden resulting from the ageing Western 
Australian population, particularly in relation to the burden associated with asthma 
and COPD. To effectively examine the health burden resulting from chronic asthma 
in Western Australia (WA), a general overview of the organisation of the health 
service in the State is provided. Management issues which relate to the delivery of 
effective care in metropolitan, rural and remote parts of the State are described. The 
section concludes with an introduction to the use of geographic information systems 
(GIS) in the health sector and the role GIS can play in understanding health service 
accessibility issues which might arise for older adults with chronic asthma. Methods 
by which GIS can assist in health planning and determining areas that are in need of 
further health services, such as exercise training for individuals with chronic 
respiratory disease, are also examined. 
 
Part 1 
2.2 Obstructive airways diseases   
There are three main disease entities that cause limitation to airflow in the lungs.  
These are asthma, chronic bronchitis and emphysema. Each of these three diseases 
can be present to a greater or lesser degree in a given individual (Figure 2.1) (12).   
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2.2.1 Asthma 
Asthma is a chronic inflammatory disease of the airways, characterized by 
widespread but variable airflow obstruction that is at least partially reversible, either 
spontaneously or with treatment (1, 3).  Inflammation of the airways can cause 
episodes of wheezing, chest tightness, dyspnoea and coughing (3). The definition of 
asthma is non-specific, as there are several causes for the aetiology of the disease and 
there is no unifying pathology by which it can be defined (13).   
Understanding the cause of asthma is a key priority area in asthma research (1). 
Despite improved understanding of the links between genetic determinants and 
environmental factors such as diet, obesity, lack of physical activity, exposure to 
allergens, pollutants and viral infections in the development of asthma, the 
pathophysiological basis for the disease is incompletely understood (14). Numerous 






Figure 2.1   Obstructive airways diseases 
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and have shown that changes associated with a move towards Western culture and 
urbanization contribute significantly to the development of asthma and other atopic 
diseases (15).  
The prevalence of asthma is now of epidemic proportions, and it is one of the most 
common chronic diseases worldwide (1). Over 300 million people have asthma and it 
is expected an additional 100 million people will be diagnosed with the disease by 
2025 (1).  In Australia, it is estimated that over 2 million individuals have current 
asthma, representing 10.3% of the population (16). In the 2004-2005 financial year, 
the health expenditure for asthma amounted to A$606 million which represented 
1.2% of the total allocated health expenditure in that year (16).  Most asthmatics 
have mild disease, and although they can be affected by acute episodes of 
bronchoconstriction in response to well-recognised triggers within the environment, 
they are usually well controlled with pharmacotherapy (1).   
It is estimated 10% to 15% of adults in Australia are diagnosed with current asthma 
and one third of these have moderate or severe disease (16). In children, asthma is 
more prevalent in males than females, whereas in adults (over 20 years of age) there 
is a shift towards a higher proportion of women being diagnosed with the condition 
than males (17, 18). Potential reasons for this shift include hormonal changes (19, 
20), a smaller airway calibre size in females (21), or obesity (22). Mortality rates 
from asthma in Australia reached a peak in the late 1980s and since then rates have 
fallen by 28% (23). Mortality due to asthma is highest in the elderly (>65 years of 
age), with statistics from 1999-2003 suggesting average rates of death for males >65 
years were 34.45 (95% CI 34.5 - 42) per 100,000 of the population and 60.42 (95% 
CI 56.1 - 64.4) per 100,000 of the population for women (24).   
 
2.2.2  Emphysema and chronic bronchitis 
Emphysema is defined as the permanent dilatation and destruction of air spaces distal 
to the terminal bronchiole. Respiratory tissue is progressively destroyed, which 
causes a loss in elastic recoil and the area for gas exchange is reduced. Emphysema 
is caused by an imbalance in the activity of proteases and protease inhibitors, often in 
response to contact with inhaled irritants and/or genetic predisposing factors 
(discussed below).  This condition eventually leads to a decrease in gas transfer (12).   
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Chronic bronchitis is a functional disorder that does not have any characteristic 
radiologic features, but is diagnosed primarily on an individual’s history of “a cough 
productive of sputum on most days for 3 months of the year for at least 2 successive 
years”. Airway obstruction occurs due to mucus plugging and the narrowing of the 
lumen (12).  
In Australia in 2001, 3.6% of the population (665,000 people) self-reported they had 
either bronchitis or emphysema (25).  There are approximately 14 million cases of 
chronic bronchitis and 2 million cases of emphysema reported each year in the 
United States (US) (26).   
 
2.2.3 Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease is the third most burdensome disease in 
Australia and the fourth most common cause of mortality. More than 2.1 million 
Australians are estimated to have the condition and of these individuals, 1.2 million 
have moderate to severe COPD (27). In 2008 the financial cost of COPD in Australia 
was $A8.8 billion and it was estimated there were around 16,000 deaths due to 
COPD (27). Worldwide, it is estimated that 210 million people have COPD and more 
than 3 million people died from the condition in 2005 (28).  
Chronic obstructive pulmonary disease is defined by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) as “a preventable and treatable disease with some 
significant extrapulmonary effects that may contribute to the severity in individual 
patients. Its pulmonary component is characterised by airflow limitation that is not 
fully reversible. Airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lung to noxious particles or gases. The 
airflow limitation in COPD is caused by a mixture of small airway disease 
(obstructive bronchiolitis) and parenchymal destruction (emphysema)” (11). This 
definition has been adopted in the American Thoracic Society and European 
Respiratory Society guidelines.  Chronic obstructive pulmonary disease is therefore 
an umbrella term which encompasses the more familiar terms of ‘chronic bronchitis’ 
and ‘emphysema’. Spirometry provides a description of disease severity and is 
important in the diagnosis of COPD (Table 2.1) (1, 11). 
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Table 2.1 GOLD (2008) outline of the stages of severity of COPD  
Stage Severity FEV1/FVC FEV1 
Stage I Mild <0.70 ≥ 80% 
Stage II Moderate <0.70 50- 80% 
Stage III Severe <0.70 30-50% 
Stage IV Very severe <0.70 < 30%* 
GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; *plus chronic 
respiratory failure (arterial partial pressure of oxygen <60mmHg with or without 
arterial partial pressure of CO2 >50mmHg while breathing air at sea level) 
(www.goldcopd.com) (11). 
 
Exposure to cigarette smoke is the most important cause of COPD and accounts for 
up to 85% of the risk associated with the development of the disease. Genetic 
predisposition also plays a role with the best documented genetic risk factor being a 
hereditary deficiency of alpha-1 antitrypsin deficiency that can result in the early 
onset of emphysema, even in non-smokers.  This is a rare recessive trait that is more 
often seen in individuals of North European origin. Other risk factors include 
occupational or environmental pollution and recurrent respiratory infections in 
childhood (11). Asthma itself may also be a risk factor for the development of 
COPD, although the evidence is not conclusive (29). Symptoms of COPD are the 
presence of chronic, progressive dyspnoea, cough and sputum production. Of these 
symptoms, it is the dyspnoea experienced by an individual with COPD that interferes 
most with their activities of daily living and health status (11). 
 
2.2.4 Where does fixed airway obstruction asthma fit among the spectrum of 
obstructive airways disease? 
Traditionally, the reversible nature of airway obstruction in asthma has not been 
considered to cause any long-term damage to the airways, in contrast to emphysema 
and chronic bronchitis (8, 10). Only in the last decade has it been appreciated that 
repetitive episodes of inflammation can lead to permanent structural changes in the 
airways (30). In severe chronic asthma, airway obstruction is persistent despite 
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optimum pharmacological management, and therefore individuals with severe 
chronic asthma most often present with both an irreversible and a reversible 
component to their disease (1, 10, 29, 31). 
A challenge is how to define FAOA: that is, is it asthma or COPD or both? The 
concept of there being a condition such as FAOA is controversial in the light of the 
historical classification for obstructive lung conditions. Continued widespread 
differences in opinion about the presentation and definition of both asthma and 
COPD remain (13, 32).  
Because FAOA involves an irreversible degree of airways obstruction, it meets the 
criteria used to describe COPD. It also shares many clinical similarities, not only in 
relation to the objective measures of airflow, but also symptoms of dyspnoea on 
exertion, reduced exercise tolerance and impaired QOL (4, 8). The goals of treatment 
in both patient groups are also similar: to prevent acute exacerbations, maintain lung 
function, optimize levels of habitual physical activity and to reduce symptoms. It is 
logical, therefore, that the primary and secondary intervention strategies for the 
management of FAOA should be similar to those for COPD. Indeed many older 
adults who present with FAOA are (rightly or wrongly) diagnosed as having COPD.   
The argument remains, however, whether or not the ‘FAOA group’ should remain 
distinct from COPD and thus be treated differently. The natural histories of the two 
conditions are markedly different and their responses to various pharmacological 
medications are not comparable (4). For example, adults with FAOA display greater 
therapeutic benefit in response to corticosteroids than those with COPD (4). Disease 
progression differs for someone with FAOA compared to COPD. For an individual 
with FAOA, lung function remains stable, a normal life expectancy is forecast and 
the individual is unlikely to display any of the secondary co-morbidities associated 
with COPD such as weight loss, skeletal muscle dysfunction and nutritional 
abnormalities (4). This is in contrast to the accelerated decline in lung function and 
poorer prognosis following a diagnosis of COPD (11, 33).   
Perhaps the biggest reason for the differences seen in the natural progression of the 
two diseases is their underlying histopathology. Individuals with FAOA may not 
present with any chronic bronchitic or emphysematous changes in the lung; both of 
which are usually present to some degree in COPD (33, 34). It is estimated that as 
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many as one fifth of elderly asthmatic adults have an improper diagnosis of COPD, 
rather than asthma (35, 36). Large databases in both the US and United Kingdom 
(UK) suggest there is considerable overlap between the two diseases (37). 
 
2.2.5 Diagnosing fixed airway obstruction asthma 
Due to a lack of a gold standard for diagnosing asthma, differential diagnosis of 
asthma - let alone FAOA - in an older adult population remains a challenging task 
(38-40). Table 2.2 outlines some of the factors which can assist in differential 
diagnosis of asthma and COPD in older adults (39).   In addition, investigation of 
trigger factors for exacerbations, family history, bronchial hyper-responsiveness (by 
histamine or metacholine challenge tests), significant variability in symptoms over 
time, past bronchodilator reversibility, and the measurement of peak expiratory flow 
to identify any evidence of diurnal variability are also important (41). 
 
Table 2.2 Differential diagnosis of asthma and COPD in older adults 
 Asthma COPD 
Age at onset Any age Older 
Allergy Often Sometimes 
Sudden symptom onset Often Sometimes 
Wheezing Often Sometimes 
Dyspnoea Often Often 
Coughing Sometimes Often 
Smoking history Sometimes Almost always 
Sputum production Seldom Almost always 
COPD: Chronic obstructive pulmonary disease.  
Source: An algorithmic approach to diagnosing asthma in older patients in general 
practice (39) 
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Other diagnostic tests include detailed lung function tests which are undertaken when 
an individual’s condition is stable (42).  This can confirm the presence of airflow 
limitation and can assist in excluding other lung conditions.  In COPD, particularly in 
moderate to severe disease, gas exchange is often impaired.  This is reflected by a 
reduction in measurements of gas transfer, in particular the reduction in single breath 
diffusing capacity of the lung for carbon monoxide corrected for alveolar volume 
(DLco/VA) which is often <80% of predicted in COPD whilst DLco/VA is either 
normal or elevated in adults with a history of asthma (42, 43).  Asthma is only likely 
to cause an impairment of gas exchange during severe attacks (1, 10). Spirometry 
and trial of therapy (to assess an acute bronchodilator response and longer term 
changes to peak expiratory flow with therapy) can confirm a diagnosis of asthma, 
however if uncertainty remains, the gold standard of a high resolution computed 
tomography (HRCT) scan is useful to exclude the presence of underlying structural 
emphysematous changes or bronchiectatic changes (29, 39). 
Despite these imaging and physiological testing techniques mentioned above, 
individuals with FAOA may still be considered as having a combination of COPD 
and asthma as the distinction from COPD is often not possible. However, it must be 
recognised that this subgroup of individuals with asthma may not necessarily present 
with the progressive lung deterioration or extrapulmonary co-morbidities associated 
with COPD (11). 
 
2.3 Assessing asthma severity and control 
2.3.1  Definition of asthma severity and asthma control 
Guidelines developed to assist in grading the severity of asthma commonly 
incorporate measures of pulmonary function, frequency and intensity of symptoms, 
bronchodilator response and medication usage. The guidelines used in this thesis to 
grade the severity of an individual’s asthma are those currently recommended by the 
National Asthma Council of Australia (2). These are based on the Global Initiative 
for Asthma Guidelines (1) and are provided in Tables 2.3 and 2.4.  
Asthma severity is assigned to one of four categories: intermittent, mild persistent, 
moderate persistent and severe persistent when first diagnosed and prior to treatment 
(Table 2.3) (2). Once treatment is commenced, severity is then determined by the 
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requirement and dosage of pharmaceutical medications (inhaled corticosteroids and 
long acting beta-agonists) to control the disease, in conjunction with clinical 
symptoms and the results of spirometry (Table 2.4). Severity is classified when an 
individual’s condition is stable, not during an acute episode. Due to the reversible 
nature of the disease an individual can move between categories in a classification 
system throughout the course of the disease (1, 2). 
The majority of adults with asthma (80%) have mild or very mild disease.  It is 
estimated only 6% have severe or very severe disease (44).  The severity of asthma 
has been shown to influence health-related QOL (HRQOL) (45) and health care 
utilisation (46).  Individuals with the most severe asthma tend to underestimate their 
symptoms and may present with very severe obstruction but with little perception of 
any deterioration in their condition (47). Though asthma severity per se is not a 
patient-focused measure, a patient’s perception of their severity is influenced by not 
only their level of symptoms, but also restrictions to physical activity and social life 
(48). These relationships are explored further in Part 2 of this literature review 
(Section 2.4).   
There is a distinction between an individuals’ level of asthma control and underlying 
severity of the disease (49). Asthma symptoms may be well controlled with 
appropriate treatment, but an individual may in fact have severe ’underlying‘ asthma 
(50). With increasing asthma severity however, achieving the guideline targets for 
asthma control becomes more difficult despite appropriate treatment (51). It has been 
postulated that evaluating the clinical features of asthma over the course of a year 
provides a more valid assessment of disease severity, while assessing symptoms over 
the preceding month better reflects the degree of asthma control, or disease activity 
(52).  Table 2.5 illustrates the currently accepted definitions of the various levels of 
asthma control- i.e. good, fair and poor that are used in clinical practice within 
Australia (1, 2). It is estimated that of the adult population in Australia who have 
been diagnosed with asthma, 45% have asthma that is considered to be poorly 
controlled (44). 
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Table 2.3 Classification of asthma severity in an individual with untreated, newly diagnosed asthma 










FEV1 at least 80% predicted 
FEV1 variability less than 20% 
Mild persistent  More than weekly and less 
than daily 
More than 2 per 
month but not weekly 
Occasional 
May affect activity or sleep 
 
FEV1 at least 80% predicted 
FEV1 variability 20-30% 
Moderate persistent Daily Weekly or more often Occasional 
May affect activity or sleep 
 
FEV1 60-80% predicted 
FEV1 variability more than 30% 
Severe persistent Daily 
Physical activity is restricted 
 
Frequent Frequent FEV1 60% predicted or less 
FEV1 variability more than 30% 
An individual's asthma pattern (intermittent, mild persistent, moderate persistent or severe persistent) is determined by the level in the 
table that corresponds to the most severe feature present. Other features associated with that classification need not be present. 
FEV1: forced expiratory volume in one second 
Sources: (1, 2) 
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Table 2.4 Classification of asthma severity in an individual with treated asthma 
Clinical features and lung function No inhaled ICS Low dose ICS Low- to 
medium dose 
ICS and LABA 
 
High dose ICS 
and LABA +/- 
other agents 
Day-time symptoms occurring <1/week 
Night-time symptoms occurring <1/month 
Exacerbations are brief 
FEV1 between episodes is at least 80% predicted and 90% of 
personal best 
 
Intermittent Mild persistent Moderate 
persistent 
Severe persistent 
Day-time symptoms >1/week but not every day 
Night-time symptoms >2/month but not weekly 
FEV1 between episodes is >80% predicted and 90% of personal 
best 
 
Mild persistent Moderate 
persistent 
Severe persistent Severe persistent 
Day-time symptoms daily 
Night-time symptoms at least weekly 
Exacerbations affect sleep and activity 
SABA use daily 






Severe persistent Severe persistent 
Day-time symptoms every day and restrict physical activity 
Night-time symptoms frequent 
Exacerbations are frequent 
FEV1 is <60% predicted and <70% of personal best 
 
Severe persistent Severe persistent Severe persistent Severe persistent 
Asthma severity in an individual with treated asthma is classified according to medications, symptoms and spirometry. ICS: inhaled 
corticosteroids; LABA: long acting beta agonists; FEV1: forced expiratory volume in one second; SABA: short acting beta agonists.  
Sources: (1, 2) 
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Table 2.5  Assessment of asthma control 
 Level of control 
Parameters Good Fair Poor 
Day-time symptoms None <3 days/week >3 days/week 
Night-time symptoms Not woken <1 night/week >1 night/week 
Physical activity Normal Normal Restricted 
Exacerbations None Mild, infrequent Moderate, severe frequent 
Missed school/work due to asthma None None Any 
Reliever use* None <3 doses/week <3 doses/week 
FEV1, FEV1/FVC Normal  >90% personal best <90% personal best 
PEF Normal >90% personal best <90% personal best 
FEV1: forced expiratory volume in one second; FVC forced vital capacity obtained by spirometry; PEF: peak expiratory flow obtained 
with a portable peak flow meter.  *Does not include one dose/day for prevention of exercise induced symptoms.   
This assessment classification is applicable to adults and older children.   
Lung function parameters are not appropriate measures of asthma control in young children
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2.3.2 Evaluating asthma control 
A number of questionnaires have been validated to measure the goals of asthma 
management as defined by international guidelines. Use of these questionnaires 
enables the identification of individuals whose asthma management is suboptimal 
and therefore those who have poor asthma control (53). 
To achieve good asthma control, an individual is required to have minimal day and 
night-time symptoms, rarely demonstrate activity limitation and bronchoconstriction, 
and require minimal use of rescue medication (54). Three questionnaires that have 
been validated specifically for measuring asthma control are reviewed in this section, 
two of which, the Asthma Control Questionnaire (ACQ) and the Asthma Control 
Test (ACT), are recommended by the International Primary Care Respiratory Group 
in their Users Guide to Asthma Control Tools {http://www.theipcrg.org/}.    
The ACQ is a 7 item, self-complete questionnaire developed by Juniper and 
colleagues (55) with input from 100 asthma physicians who were members of asthma 
management guidelines committees across 18 countries, and were opinion leaders in 
asthma management or asthma clinicians with recognised expertise in the 
measurement of asthma severity. The overall score for the ACQ is the mean of 
responses to the 7 items with a score of 0 representing totally controlled asthma and a 
maximum score of 6 representing severely uncontrolled asthma (55).   
The ACQ has been shown to be responsive to changes in asthma control, and is able 
to differentiate between adults who have well controlled and poorly controlled 
asthma. The cross-over point between an individual considered to have well 
controlled asthma, as defined by a composite score based on the National Institute 
for Health and Global Initiative for Asthma Guidelines, to poorly controlled asthma 
is a mean score of 1 on the ACQ. To accurately separate a given individual with well 
controlled versus poorly controlled asthma, the suggested value on which to base 
clinical decisions is ≤0.75 for well controlled asthma, and ≥1.5 for poorly controlled 
asthma (56).  
The ACT (57) has been validated in 4,313 individuals with asthma and takes 2 to 3 
minutes to complete. The instrument uses a 4 week recall period and a 5 point scale 
{1-5} to grade asthma control in relation to day-time symptoms, night-time 
symptoms, rescue beta agonist use, daily activity limitation and the individual’s 
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perception of control. An individual with a composite score of 25 has complete 
control whilst a score of 5 indicates very poor control (57).   
The Asthma Therapy Assessment Questionnaire (ATAQ) (52) consists of a self-
complete questionnaire with a 5 level measure of asthma  control from 0 (no control 
problems) to 4 (4 control problems). To assess the level of control, questions ask 
about nocturnal symptoms, missed activities, medication usage, and self-perception 
of control. Control is assessed relative to the last 4 weeks and also to the preceding 
12 months, with separate control scores calculated for each time period.  In addition, 
the questionnaire contains items which relate to health care utilisation and patient 
attitudes to treatment to assist in the identification of possible disease management 
problems. However, these items have not been independently validated. Table 2.6 
illustrates a comparison of the components of asthma control that these three 
questionnaires measure.  
 
Table 2.6 Components of asthma control measured in three questionnaires 
 ACQ ACT ATAQ 
Limits daily activity Yes Yes Yes 
Shortness of breath Yes Yes No 
Disrupts sleep Yes Yes Yes 
Rescue medication Yes Yes Yes 
Effect on global control No Yes Yes 
Frequency of wheeze Yes No No 
ACQ: Asthma Control Questionnaire ; ACT: Asthma Control Test ; ATAQ: Asthma 
Therapy Assessment Questionnaire. Sources: (49, 58) 
 
 




2.4 Impact of chronic asthma on an individual and the role of 
exercise training 
To date, little research has been dedicated to the characterisation of FAOA in 
middle-aged and older adults. Studies which illustrate the impact of asthma in adult 
populations are reviewed in this section. Co-morbid conditions such as significant 
depression, anxiety, disability, impairment of QOL and reduced mobility occur in 
association with asthma, and the prevalence of these conditions has been shown to 
increase with age (59, 60). Disability associated with asthma has been reported to be 
greater in individuals with more severe disease, those who are older and in 
individuals who have poorer control of their asthma (61). These associations are 
reviewed in this section, as well as the impact of chronic asthma on an individual’s 
QOL, and the effects of anxiety, depression, dyspnoea and exercise limitation in this 
population.   
The section concludes with a synthesis of the literature related to the benefits of 
exercise training in adults with asthma and adults with COPD. Due to the lack of 
studies of exercise specifically in adults with FAOA, studies of exercise training in 
these two adult populations are used to explore the potential benefits of exercise 
training in a cohort of individuals who have chronic asthma with irreversible airflow 
limitation. 
 
2.4.1 Quality of life and health-related quality of life  
Quality of life is defined as an individual’s perception of health-related issues such as 
physical, emotional and mental well-being as well as nonmedical aspects of  life such 
as relationships, occupation and social standing (62). Socio-economic and 
environmental factors as well as the impact of a disease can influence overall QOL 
(63). 
In health, when referring to the concept of QOL, HRQOL is defined as the part of an 
individual’s overall QOL that is determined primarily by the functional effects of an 
illness and its consequent treatment perceived by that individual (54, 64, 65). 
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2.4.2 Measurement of health–related quality of life 
A number of generic questionnaires and disease-specific questionnaires have been 
used to measure HRQOL in individuals with asthma in both clinical practice and the 
research setting (54, 64). The most commonly used questionnaires are outlined in 
Table 2.7 along with their relative merits and limitations.   
Generic questionnaires measure impairment over a broad spectrum of functions and 
have the advantage of the potential to compare outcomes across a wide range of 
medical conditions. The broad nature of the questions may, however, mask small but 
important changes following a given treatment because of the limited depth of the 
questions. This is because impairments important to individuals with a specific 
condition may not be addressed (54, 66). In adults with asthma, the most often 
reported and best validated generic questionnaire is the Medical Outcomes Study 36-
Item Short-Form Health Survey (SF-36) (67).   
Disease-specific questionnaires include items which pertain to symptoms and 
functional impairments that are most important to an individual with a specific 
disease. A number of studies have demonstrated these questionnaires to be more 
responsive to change than generic health profiles (66, 68). Many disease-specific 
HRQOL questionnaires now have a minimal clinical important difference (MCID) 
estimate which refers to “the smallest difference in score which patients perceive as 
beneficial and would mandate, in the absence of troublesome side-effects and 
excessive cost, a change in the patients management” (69). The most widely used 
disease-specific questionnaire in adults with asthma is the Asthma Quality of Life 
Questionnaire (AQLQ) developed by Juniper and colleagues (66, 70, 71). The 
AQLQ has been shown to have strong evaluative and discriminative properties with 
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Table 2.7 Generic and disease-specific instruments for measuring HRQOL in adults 
Questionnaire Description {Domains} 
 
Administration format, time 
taken to complete and scoring 
Advantages Limitations 








36 items grouped in 8 domains:  
• Physical functioning  
• Role-physical  
• Bodily pain  
• General health  
• Vitality  
• Social functioning  
• Role-emotional 
• Mental health  
A separate item assesses change 
in health from the previous year, 
called ‘health transition’ 
Self-administered 
5-10 minutes 
Score  0-100 (higher score 
indicates better QOL) 
Scoring algorithms can be 
applied to produce combined 
physical and mental component 
summary scores 
Valid and reliable  
(67, 75, 76) 
Normative data available for 
Australians (77) 
Domains are responsive to 
clinical manifestations (physical 
functioning) and global 
psychiatric (mental health) 
conditions, and the instrument is 
overall responsive to change 
More commonly used for cross-
sectional studies than for 
evaluating interventions 
Moderate correlation with lung 
function in asthma  
Internal consistency in 
individuals with asthma 
determined and is good for 
physical functioning, role-
physical, bodily pain, general 
health and vitality domains; 
moderate for mental health and 
role-emotional; lower but 
acceptable for social functioning 





Generic 136 items in 2 domains 
with the following dimensions: 
• Physical: ambulation, 
mobility and body care 
• Social: general well-being, 
work/ social role 
performance, social support 
and participation, global 
social function, personal 




Higher scores indicate more 
severe dysfunction   
Good repeatability and internal 
consistency 
Moderate or strong correlations 
with other measures of health 
status  
Used most extensively in patients 
with COPD 
Not strictly a QOL questionnaire, 
instead assesses behaviours, 
many which are closely related to 
factors that affect a subject’s 
QOL 
Good evidence that it is not 
useful for measuring the impact 
of asthma on QOL (82, 83) 




Questionnaire Description {Domains} 
 
Administration format, time 
taken to complete and scoring 
Advantages Limitations 
Disease-specific     
Asthma Quality of 
LifeQuestionnaire- 
McMaster 




limitations in QOL experienced 
during the past two weeks 
32 items grouped in 4 domains:  
• Activity limitation  
• Symptoms  
• Emotional function 
• Environmental stimuli 
Three versions available: 
1) Individualised: items in 
activity limitations 
individualised, i.e. activities to 
be rated are provided by the 
respondents themselves 
2) Standardised version: items in 
activity limitations standardised 
(84) 
3) Mini AQLQ: shortened 
version comprises 15 of the 32 
items of the standardised AQLQ 
(85) 
Interviewer or self-administered 
15 minutes 
Item scores range from 
1(maximal impairment) to 7 (no 
impairment) 
Subscale scores expressed as 
average of all items within each 
domain  
Overall QOL score derived by 
calculating the mean across all 
subscales. 
 
Optimized for longitudinal 
designs and responsive to small 
within-subject changes over 
time, with good responsiveness 
to change and longitudinal 
construct validity 
Was found to be most sensitive 
to improvements in health status 
compared to other QOL 
measures (LWAQ, SIP) (66)  
Responsiveness indexes ranged 
from 1.28 to 1.46 in total scores 
(86) 
Effect size shown to be larger for 
the total AQLQ score and the 
Activities and Symptoms 
domains (86) 
The MCID for subscales is 0.5, 
changes of 1.0 are considered 
moderate and changes of 2.0 are 
large (68) 
Highly repeatable  
Has acceptable levels of content 
and construct validity and 
reliability (84) 
 
Individualised version less 
suitable for cross-sectional 
designs however a standardised 
version is available 
Individualised version increases 
signal-to-noise ratio caused by 
personalised items which does 
make it less responsive to 
within-person change than other 
survey tools (87) 
The internal consistency of the 
scale has not been reported  
Scores are skewed to less impact 
on QOL (higher scores)   
Empirical method was used to 
select items  




Questionnaire Description {Domains} 
 
Administration format, time 








Original version- 20 items with 
domain scores in 4 areas: 
• Breathlessness and physical 
restrictions (Breathlessness) 
• Mood disturbance due to 
asthma (Mood) 
• Social disruption from 
asthma (Social) 
• Concerns about health and 
future (Concerns) 
Changes in modified version are: 
 i) change from a 5 point to 7 
point Likert-type response scale 
ii) 2 items that had 2 indicator 
activities were separated to 
produce 4 items. Thus the 
modified version consists of 22 
items overall in the 4 domain 
areas 
Interviewer or self-administered  
5 minutes  
Looks at affect of each item in 
preceding 3 months 
Response items 0-not at all to 4- 
very severely 
Computation of four asthma 
specific subscale scores (each 
subscale scored out of 10 - mean 
of all items associated with it 
multiplied by 2.5)  
Also overall score.   
Total scales score (out of 10) is 
the mean of all item scores 
multiplied by 2.5 
Higher scores = more adverse 
impact on QOL  
Responsive to change 
Reliable and relatively 
independent of subject 
characteristics (89) 
Moderate correlation between 
total score and other subjective 
measures of disease severity  
Discriminates between subjects 
who would be expected to differ 
in HRQOL 
A change of > 0.5 is the MCID in 
scores (90) 
 
Floor effect (zero values- have 
fallen within the lowest quartile 
in all populations studied) 
Intended for use as outcome 






76 items divided into 3 domains:  
• Symptoms  
• Activity 
• Impacts  
Telephone or face-to-face 
interview.  
10 minutes   
Weighting each item and 
dividing the summed weights by 
the maximum possible weight 
and expressing result as a 
percentage provides respondents 
score 





Reproducible, valid and 
responsive in both asthma and 
COPD populations (91-94) 
MCID found to be 4 points  (95, 
96) 
Cross cultural and linguistic 
considerations are included 
Limited coverage of 
psychological symptoms 
Most testing and development of 
questions was done in 
populations with COPD not 
asthma 
 




Questionnaire Description {Domains} 
 
Administration format, time 






68 items in 11 domains  
Items derived from 6 focus 
groups 
Major focus is psychological and 
social aspects of QOL  
 
Self-administered 
15 minutes  
3 point response option 
Higher scores indicate more 
adverse impact on QOL 
Main strength is the extensive 
qualitative research used in 
developing the questionnaire 
Correlation with generic Sickness 
Impact Profile was 0.66  
Limited range of response 
options.  
Does not measure the physical 
symptoms of asthma  
Weak to moderate correlations 





4 domains:  
• Psychological  
• Physical activity  
• Physical symptoms  
• Social.  
Self-administered 
Items are scores 0 to 1 and 
summed without weighting 
Higher scores indicate more 
adverse impact on QOL 
Internally consistent 
Highly repeatable, intra-class 
correlation for total scale =0.97 
Strongly correlated with other 
measures of QOL 
Performance as a measure of 
change has not been reported. 
Longitudinal characteristics not 
established.   
Developed in France  
Distribution skewed towards 
lower scores 
HRQOL: Health-related quality of life; QOL: Quality of life; COPD: chronic obstructive pulmonary disease; MCID: Minimal clinically important difference; 
AQLQ: Asthma Quality of Life Questionnaire.
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2.4.3 Quality of life and asthma 
From the perspective of an individual with asthma, measures of HRQOL represent 
the success of treatment in a more meaningful way than physiological end-points 
such as spirometric measures of lung function (99). Consequently, optimising 
HRQOL has become an important component of asthma management, and 
assessment of HRQOL is now regularly included as an outcome measure in clinical 
trials (54). 
Regardless of age, adults with asthma have been shown to report their health status to 
be lower than those without asthma (100). Adams and colleagues (101) showed that 
standardised SF-36 scores adjusted for age, gender and social class were significantly 
lower in subjects with asthma drawn from a representative population survey 
consisting of both hospital-based and community-based subjects when compared to 
population norms. Combined physical component and mental component scores 
were comparable to those reported by individuals with other chronic diseases such as 
diabetes and arthritis.   
Asthma has been associated with significant medical morbidity, and has also been 
reported to adversely affect an individual’s personal and social life, their 
employment, finances and relationships (102). Asthma symptoms contributing most 
to this reduction in HRQOL are dyspnoea, morning symptoms, sleep disturbances 
and recurrent hospitalisations (103, 104). In an investigation of the determinants of 
HRQOL in asthma, dyspnoea, rather than measures of lung function, was found to be 
an independent determinant of HRQOL across all levels of asthma severity (45).   
Good asthma control has been associated with improved HRQOL (52, 105). One 
study (106) showed that regardless of asthma severity, subjects with well controlled 
asthma had consistently better HRQOL (as measured with the AQLQ). This study, 
which was primarily evaluating a combination of salmaterol and fluticasone, showed 
that subjects with well controlled asthma at study entry went on to achieve greater 
improvements in their HRQOL than the subjects with poorly controlled asthma at 
study entry. However, the subjects who had poorly controlled asthma at study entry 
were able to achieve clinically meaningful improvements in their HRQOL with 
treatment (53).    
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2.4.4 Anxiety and depression in asthma 
There is evidence that anxiety and depression are more common in adults with 
asthma than in the general population (103, 104, 107-110).  The sensations that occur 
during acute episodes of asthma share many overlapping sensations to those 
associated with panic disorders. These symptoms include hyperventilation-induced 
dyspnoea, a sensation of ‘being smothered’ or choking, and increased anxiety. The 
prevalence of panic disorders in adults has been estimated to be 1-3% in community 
populations (111), but as high as 6-24% among individuals with asthma (107, 112-
118).   
Reasons postulated to explain an apparent increased risk for the development of 
panic disorder among individuals with asthma include the theory that such 
individuals generate fearful or catastrophic beliefs about their respiratory symptoms 
which in turn provoke panic attacks. Alternatively, a biological theory suggests that 
repetitive experiences of hypoxia and hypercapnia may sensitise the nervous system 
to over-react to subsequent episodes of hypoxia or hypercapnia. The fact that there is 
also an association between asthma severity and anxiety supports this notion. Figure 
2.2 is adapted from a theoretical model (108) developed to describe the potential 
adverse impacts of co-morbid anxiety or depression in adults with asthma. 
Both depression and anxiety have been associated with a decrease in the level of 
asthma control including a greater number of doctor’s visits, the inability to carry out 
usual activities and more days during which asthma symptoms are present (119). 
Further, among individuals with asthma, there appears to be a dose-response 
relationship between the severity of depression and level of physical inactivity (119). 
A prospective cohort study of 59 adults who had been hospitalised for asthma 
showed that symptoms of depression were associated with an 11.4-fold increase 
(95% confidence intervals 2.2-58.2) in the possibility of poor adherence to therapy 
on discharge from hospital (120). There is substantial evidence to suggest that poor 
adherence to therapy leads to severe asthma exacerbations (121). Lavoie and 
colleagues (122) reported an association between the presence of depression or 
anxiety and poorer HRQOL in adults with asthma. In addition, these authors found a 
significant association between depression and poor asthma control.  
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Figure 2.2 Adverse impact of anxiety/depressive disorder and asthma co-morbidity 
 
Figure adapted from Katon et al (108) 
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2.4.5   Measuring anxiety and depression in clinical trials 
The Hospital Anxiety and Depression (HAD) Scale (123) is a reliable and valid tool 
for screening clinically significant anxiety and depression in patients attending a 
general medical clinic. This scale was specifically designed for use in non-
psychiatric hospital departments and assesses an individual’s mood state through 
questions about how the individual has felt during the past week. The scale is self-
administered and takes 5 to 10 minutes to complete.  It contains 14 multiple choice 
type questions, seven of which are oriented to the detection of anxiety and seven to 
the detection of depression. All items are based on psychological symptoms.  
Questions that might also relate to physical illness, such as the presence of dizziness 
or headaches, are eliminated. A score of more than 10 on either subscale is likely to 
indicate the presence of an anxiety or depressive disorder (123).  The HAD Scale has 
been shown to reliably detect the severity of anxiety and depression and has 
demonstrated sensitivity to changes in mood state following pulmonary rehabilitation 
in subjects with COPD (124, 125). 
 
2.4.6 Dyspnoea  
Dyspnoea is the term used to describe the “subjective experience of breathing 
discomfort that consists of qualitatively distinct sensations that vary in intensity” 
(126). It has been suggested that the sensation of dyspnoea is related to the activation 
of sensory systems that are involved with respiration, which in turn relay information 
to the central nervous system where processing takes place. This information in 
conjunction with interactions from physiological, social, cognitive and 
environmental factors can induce secondary behavioural and physiological responses 
(126).  
In COPD, dyspnoea is primarily triggered by exertion due to limiting physiological 
processes and alterations in lung mechanics (126, 127), and the intensity of dyspnoea 
is shown to increase with increases in ventilation (127). In asthma, dyspnoea can be 
triggered by a number of environmental allergens or by exertion (126). The presence 
of inflammatory mediators such as those present during acute episodes of asthma can 
lead to an increased sensitivity to respiratory sensations. This in turn contributes to a 
disproportionate drive to breathe and may culminate in the presence of 
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hyperventilation syndrome (1, 126).  Dyspnoea often limits an individual’s level of 
physical activity and leads to a sedentary lifestyle which in turn decreases fitness and 
exercise tolerance (128). 
The intensity of dyspnoea in adults with asthma has been shown to loosely correlate 
with the magnitude of expiratory flow limitation as measured by a fall in FEV1 (129) 
during metacholine-induced bronchoconstriction. More importantly, dyspnoea is 
strongly and directly correlated with the development of dynamic lung hyperinflation 
that occurs because of the increase in work of breathing with this challenge (130-
132). Tidal expiratory flow limitation and dynamic hyperinflation during exercise 
have been reported in stable asthmatics without evidence of exercise-induced 
bronchoconstriction. The presence of such flow limitation and hyperinflation can 
contribute to a reduction in exercise capacity (133).   
Abnormal breathing patterns are often apparent during hyperventilation and may 
result in breathlessness, light-headedness, paresthesia and anxiety. These symptoms 
can occur in all grades of asthma severity and may be related to the increased 
incidence of anxiety and depression in asthmatic patients (134, 135). 
Some individuals with asthma, particularly those with a history of near-fatal asthma 
and chronic asthmatics whose airway pathology is characterised by inflammation and 
eosinophilia, have a blunted perception of dyspnoea and report less symptoms than 
asthmatic subjects whose obstruction is transient and more readily reversible.  Such 
individuals are considered to be poor perceivers of their symptoms (1). This 
decreased ability to perceive an increase in mechanical load or abnormal gas 
exchange may be due to temporal adaptations and physiological changes to the 
feedback mechanism.  This in turn can make an individual with asthma more 
vulnerable to a fatal attack (136-139). 
The term dyspnoea is used to characterise a range of qualitatively distinct sensations.  
Simon and co-workers (140) compiled a list of 19 descriptors of dyspnoea that were 
experienced by individuals with a variety of lung and cardiac conditions. Examples 
of some of the descriptors for dyspnoea included “My breathing requires effort”, 
“My chest feels tight”, “My chest is constricted” and “I feel out of breath”. This list 
was refined and modified to 15 descriptors and use of this list of descriptors has been 
validated and shown to have acceptable test-retest reliability (141, 142).  
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Moy and colleagues (143) showed that the qualitative descriptors of breathlessness 
changed in eight subjects with mild asthma in response to mild bronchoconstriction 
through metacholine broncho-provocation versus breathing against an external 
resistive load which provided resistance on both inspiration and expiration. For 
example, the language of chest tightness or constriction was chosen to describe 
dyspnoea in 92% of 26 trials involving a methacholine challenge causing 
bronchoconstriction, compared to only 3% of 72 trials which required breathing 
against an external resistance. When breathing against an external resistance, the 
responses chosen to describe dyspnoea related to the sensation of an increase in 
“work” and “effort”.     
 
2.4.7 The measurement of dyspnoea 
A number of instruments are available to assess dyspnoea including structured 
interviews, self-report questionnaires and visual analogue scales. However few of 
these are suitable for single point measurement during an exercise test or exercise 
training (144). The most widely used tools to measure the intensity of dyspnoea 
during exercise are the Visual Analogue Scale (VAS) and the modified Borg 
Category Ratio Scale.  The VAS requires a subject to place a mark on a 10cm 
vertical or horizontal line to indicate their level of breathlessness.  Although this 
technique has been validated (145) it lacks test-retest reliability when repeat testing 
occurs weeks apart, thus questions remain about the reliability of VAS dyspnoea 
rating across different dyspnoea-inducing exercise tasks (144). 
The Category Ratio Scale developed by Borg (1982) (146) is a scale which ranges 
from 0 (no breathlessness) to 10 (maximum breathlessness) and is a useful indicator 
of breathlessness because of its relative simplicity (146).  This scale was adapted 
from an original ordinal scale which ranged from 6 to 20 that was developed by Borg 
in 1970 (147) to measure perceived exertion.  In general, scores obtained using the 
category ratio scale are reliable over short periods of time, are easy to collect, 
sensitive to change and highly reproducible at peak exercise intensities (148). The 
recommended MCID for the Borg Dyspnoea Scale is 1-unit.  This is based on a 
retrospective review of a number of published trials which evaluated the response to 
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an exercise training program.  The MCID was calculated using a distribution-based 
approach based on the effect size (149). 
At submaximal exercise intensities (i.e. exercise below peak oxygen uptake) Belman 
and colleagues (150), assessed the reproducibility of the Borg scale ratings of 
dyspnoea in nine subjects with COPD, and found that over a 10 day period scores 
decreased significantly with successive treadmill walking tests.  These authors 
concluded that because oxygen uptake (VO2), ventilation (VE), heart rate (HR) and 
tidal volume (VT) stabilised after only one or two practise attempts, the 
proportionally greater fall in Borg ratings with repetitive testing was independent of 
a true physiological effect. Because habituation to the task of treadmill walking was 
complete by the second or third test in the study, the authors proposed that the serial 
improvement in dyspnoea scores may have resulted from desensitisation to the 
sensation of dyspnoea, and thus desensitisation may play a role in the improvement 
of individuals with COPD with exercise training (150).   
 
2.4.8 Measuring the sensation of chest tightness in asthma 
To date, a scale does not exist that quantifies the intensity of chest tightness 
experienced during physical activity in adults with asthma. In such individuals the 
sensation of chest tightness is often present, but qualitatively distinct from that of an 
increased work of breathing (151). For this reason it is important to quantify the 
separate sensations of ‘breathlessness’ and ‘chest tightness’ when assessing 
functional exercise capacity in adults with FAOA during a clinical trial.   
A review of the literature revealed one scale that has been used in an attempt to gain 
an understanding of the subjective feelings surrounding the sensation of dyspnoea in 
individuals with asthma.  This scale includes language descriptors relating to chest 
tightness used by asthmatics (140, 141). Frequency of chest tightness symptoms were 
assessed in another study conducted by Teeter and colleagues (152) with a scale that 
incorporated a 5 point whole integer scoring system (0- no symptoms, to 4- constant 
symptoms). This study rated the frequency of a number of asthma symptoms 
including chest tightness, cough, dyspnoea, wheeze, sputum production and 
nocturnal wakening in 67 adults with chronic asthma, to characterise the relationship 
between symptoms and degree of airway obstruction as determined by FEV1. The 
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time period over which the symptoms were monitored was not specified, however, 
within the study and therefore the usefulness of using this scale for individuals with 
FAOA during physical activity is not certain (152). 
To date, the only study reporting a measure of the intensity of chest tightness 
symptoms during exercise was undertaken in individuals with cystic fibrosis (153). 
This study utilised a VAS to measure the intensity of chest tightness following 
inhalation of hypertonic nebulised colistin.   
Since the Borg Category Ratio Scale (146) has shown to be reliable over short time 
periods, sensitive to change and reproducible at peak exercise intensities, it could be 
argued that this scale may be suitably adapted to measure chest tightness in 
individuals with FAOA due to the close relationship chest tightness has with 
breathlessness in those who have asthma.  The Borg Category Ratio Scale was 
utilized in the randomized controlled trial conducted in this thesis to measure chest 
tightness based on this argument (chapter 3).   
 
2.5 Functional exercise capacity in adults with asthma 
Research suggests that the risk behaviours of physical inactivity in addition to 
smoking and obesity have profound effects on asthma severity and these effects are 
compounded when multiple adverse behaviours exist (154). Several studies have 
reported lower levels of aerobic fitness in asthmatic adults in comparison to their 
healthy peers (155). A study of 44 subjects with mild to moderate asthma matched 
with 64 healthy control subjects showed that the asthmatic subjects had a 
significantly lower aerobic capacity as measured by peak oxygen uptake (VO2peak), 
anaerobic threshold and oxygen pulse compared to the healthy controls. Consistent 
with this finding, young asthmatic males conscripted to military service have been 
reported to display poorer physical fitness than those without asthma as measured by 
a 12 minute running test (156).  
Intensity of habitual exercise has also been reported to be lower in asthmatic than 
non-asthmatic subjects. In a US population-based study where, after adjusting for 
age, respondents with current asthma demonstrated on average their estimated energy 
expenditure from leisure time physical activity was 206 kilocalories lower than 
respondents with former asthma, and 91 kcal/week lower than respondents who had 
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never had asthma (p<0.001) (157). In contrast, a study which recruited 27 adults with 
stable mild to moderate asthma found levels of aerobic fitness were comparable to 
non asthmatics of average fitness levels measured with a maximal treadmill test 
(158). 
In the study conducted by Garfinkel et al (158), a self-complete questionnaire was 
also administered which was based on a revised version of the Canadian 
Standardized Test of Fitness Lifestyle Questionnaire. Results from this questionnaire 
suggested that asthmatics perceive their disease as the limiting factor to improving 
aerobic fitness. The three main reasons for not exercising more were lack of time 
(64%), breathlessness/wheezing (52%) and lack of energy (44%). In addition, factors 
which subjects thought would assist them to increase their exercise levels were better 
asthma control (64%), more time for exercise (56%), more energy (44%) and people 
to exercise with (44%).  
Potential causes of reduced exercise capacity in adults with chronic persistent asthma 
include deconditioning as a result of a sedentary lifestyle, exertional dyspnoea, 
peripheral muscle impairment arising from prolonged corticosteroid usage, decreased 
lean body mass and fatigue, low self-efficacy and fear, sleep disturbances, 
psychological impairments such as depression and anxiety and a developed aversion 
to exercise due to inappropriate restriction when young and a fear of developing 
asthma symptoms during exercise (121, 159, 160). 
 
2.5.1 Measurement of functional exercise capacity 
An objective measure of functional exercise capacity should assess the level of 
disability experienced by an individual with chronic respiratory disease. Exercise 
tests are employed in this manner to quantify exercise capacity (161, 162). The 
determination of baseline exercise capacity enables the prescription of an 
individualised rehabilitation programme aimed at improving exercise tolerance (7). 
Regular exercise testing is a useful way to monitor change in an individual’s exercise 
capacity, and such data are used as outcome measures of interventions including 
exercise training (163). 
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2.5.2 Laboratory-based exercise tests 
The gold standard for determination of exercise capacity is the measurement of peak 
oxygen uptake (VO2peak) which is usually obtained during a maximal exercise test 
conducted in a laboratory setting.  In this environment, measurements of oxygen 
saturation (SpO2), HR, work rate, VE, VO2 and expired carbon dioxide (VCO2) can 
be obtained. Arterial blood samples may also be collected and concentrations of 
inspired and expired gases can be accurately monitored by breath by breath gas 
analysis (161, 164).  
Laboratory tests are generally administered only once, due to cost and time 
constraints and because the measurement of exercise capacity through VO2peak is 
reported to be reliable after just one laboratory test (163). Testing within the 
laboratory requires sophisticated equipment and trained personnel. The equipment 
enables monitoring of the patient throughout the exercise test and the identification 
of the pathophysiological limitations to exercise (163, 164). Laboratory tests are 
commonly performed using a cycle ergometer or treadmill. Conventionally for the 
assessment of patients with known or suspected respiratory disease a cycle ergometer 
is more commonly used, but in cardiac patients a treadmill protocol is employed. 
Treadmill tests involve incremental increases in workload by progressively 
increasing a combination of speed and grade (slope). Balke’s protocol, which keeps 
speed constant at 5-6 kilometers per hour (km/hr) and progressively increases the 
slope by 1-2% per minute, is an effective and simple testing procedure; this can be 
modified by using a slower speed for individuals who are unable to tolerate such a 
high walking speed.  This method of increasing workload avoids the problem 
experienced by some individuals, for example the elderly, being unable to maintain 
fast walking speeds (164, 165). 
Exercise testing performed on a stationary cycle ergometer provides a stable platform 
for metabolic measurement. It allows easy monitoring of the patient, accurate 
determination of the workload and enables the patient’s body weight to be supported 
(166, 167). Unlike the treadmill, cycle ergometers provide easily and accurately 
quantifiable work rates, and at submaximal work rates yield VO2 values that are less 
variable than those obtained from a treadmill test (164). 
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The standard protocols used in exercise tests on a cycle ergometer to assist in the 
diagnosis of respiratory diseases involve increasing work rate by a specified amount 
each minute in a step protocol or averaging the increase in work rate over each 
minute in a ramp protocol (168, 169). Between 8 and 15 minutes of exercise is 
considered as the ideal duration for a maximal exercise test.  In normal subjects, 
exercising for less than 8 minutes or more than 15 minutes does not produce the 
typical plateau in VO2 seen when circulatory factors limit exercise capacity (164).  
2.5.3 Field-based exercise tests 
Because laboratory-based tests are expensive and often difficult to access, field 
walking tests have become an important part of the assessment of functional exercise 
capacity in adults with chronic respiratory disease (170). Field walking tests are easy 
to conduct, require little preparation and are less expensive than laboratory-based 
tests (171, 172). Distances walked during field walking tests are reliable after one 
familiarisation test (171, 173), and the outcome measures from these tests such as 
distance walked, peak dyspnoea scores and the degree of oxygen desaturation have 
been used to indicate the level of disability, to prescribe the intensity of a walking 
programme and to assess outcome following rehabilitation (6, 174, 175). The more 
common field walking tests used in older adults with respiratory disease are the 6 
minute walk test (6MWT), the 10m incremental shuttle walking test (ISWT) and the 
endurance shuttle walking test (ESWT). 
2.5.3.1   The 6 minute walk test  
The 6MWT was derived from the 12 minute walk test (12MWT) that was developed 
to estimate VO2peak in patients with chronic bronchitis (173).  The 12MWT was 
shortened to 6 minutes for disabled populations, as it was shown by Butland et al 
(177) that a test of 6 minutes duration correlated well with the 12MWT (r=0.95). Six 
minutes has become the most widely accepted length of time for this test as it is 
better tolerated by patients and usually allows multiple tests to be performed on the 
same day in the same individual (172). At present, the 6MWT is the most commonly 
used, non-externally paced field assessment of functional exercise capacity in 
individuals with COPD (6, 175). The main outcome of this test is the distance 
walked in the 6 minutes (6MWD). 
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The testing procedure for the 6MWT requires the subject to cover as much distance 
as possible in 6 minutes. Stopping to rest is permitted, and subjects must continue to 
walk again as soon as they are able. Self-selection of the pace at which a subject will 
walk may consequently result in a sub-maximal performance. The extent to which 
the subject’s cardiopulmonary system is stressed maximally is dependent on his/her 
level of motivation and whether or not they are encouraged throughout the test (171). 
Therefore, a 6MWT protocol should allow for a potential learning effect and include 
standardised instructions and encouragement with the aim of overcoming poor 
motivation as a potential source of sub-maximal performance (178-181). 
Standardised encouragement provided throughout the test has been shown to 
improve 6MWD by 30.5m in 43 subjects with COPD or chronic heart failure or both 
COPD and chronic heart failure (179).   
Comparisons between the distance walked in the 6MWT with measures of lung 
function and measures derived from a maximal exercise test (such as VO2peak and 
maximal workload) and subjective measures of functional status have been 
undertaken in patients with COPD in an attempt to validate the 6MWT. Functional 
status questionnaires have been shown to correlate more closely to the 6MWT than 
VO2peak or spirometric measurements (172).   
A moderately strong correlation has been found between the distance walked and 
values obtained from the St George’s Respiratory Questionnaire (r=0.59, p<0.0001) 
(91). Concurrent validity has also been assessed between the 6MWT and self rating 
scales such as the Oxygen Cost Diagram (r=0.68, p<0.001), structured questionnaires 
regarding patient symptoms such as the Baseline Dyspnoea Index (r=0.59), the Rand 
Instrument (r=0.31) and the Chronic Respiratory Disease Questionnaire (r=0.52, 
p=0.01) (182, 183). All of these validation studies have been undertaken in subjects 
who have COPD.  
Where coefficients of variation have been calculated for the 6MWT, excellent 
reproducibility has been demonstrated with variability of 8-9% being reported (184). 
Familiarisation with the 6MWT procedure significantly increases 6MWD, thus the 
effect of learning needs to be taken into account when measuring distance in the 
6MWT (184, 185). Knox et al (186)  showed that a 33% improvement occurred over 
12 walks of 5 minutes duration in a 3 day period.  Half of this improvement occurred 
between the first and third walk. In comparison an 8.5% improvement occurred when 
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the tests were carried out over 4 weeks. Thus it appears that one practice walk is 
necessary to achieve acceptable reproducibility in 6MWD so that changes in 
performance can be attributed to an intervention or change in disease status rather 
than to the effects of learning in subjects with COPD (173, 185).   
To quantify the magnitude of an individual’s disability, 6MWD can be expressed as 
a percentage of predicted based on reference equations that have been generated in 
healthy populations (187). Published regression equations can give a 6MWD that 
varies by up to 175m for the same individual.  Reasons for the disparity include 
variations in walking speeds of individuals from different geographical regions (188, 
189) and differences in test protocol (187). Therefore the best regression equation 
selected provide a valid estimate of the impact of a condition on 6MWD is one which 
has been generated at the same facility, using the same protocol, and in the 
population from which the patients arise (187). 
The 6MWT is considered a submaximal exercise test in individuals with COPD 
(178), although a number of studies comparing physiological parameters measured in 
a laboratory-based test and the 6MWT have shown that peak HR, dyspnoea (181) 
and VO2peak (190) are similar between tests in subjects who have moderate to severe 
COPD. Further, 6MWD has a moderate to strong correlation with VO2peak (r=0.73, 
p<0.001) (181) and maximum work rate (r=0.75, p<0.001) in individuals with 
moderate to severe COPD (191). Thus field walking tests can challenge adults with 
moderate to severe COPD to a similar level of cardiovascular and respiratory stress 
as laboratory-based tests (181, 192).  Generally the relationship between 6MWD and 
VO2peak is strongest in adults who have more severe functional limitation (187). 
In a recent study, a change of about 35m has been calculated as the change in 6MWD 
that represents an important effect following treatment for patients with moderate to 
severe COPD. This corresponds to a 10% change from a baseline 6MWD of 350m 
(193). This study involved data from nine trials which enrolled COPD subjects with 
a spectrum of disease severity and measured 6MWD at baseline and following 
participation in pulmonary rehabilitation programmes (193). A change of 54m had 
previously been widely reported as the minimal clinically important difference for 
the 6MWT (194). This minimal clinically important difference was based on one 
cross-sectional study of 112 COPD patients attending pulmonary rehabilitation. The 
methodological approach relied on patient comparisons of how they judged their own 
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walking ability relative to others and the correlations of 6MWD with self-reported 
categorical scale anchors (194).  
 
2.5.3.2 The 10m incremental and endurance shuttle walking tests 
The 10m ISWT is a standardised externally paced incremental field test developed 
for individuals with COPD. Subjects are required to walk around a 10m course and 
walking speed is regulated by pre-recorded auditory signals. There are 12 levels 
within the ISWT. The test starts with a walking speed of 0.5m/s in level one and the 
pace at which the subject walks is progressively increased by 0.17m/s each minute 
(180). 
Singh et al (195) showed a strong relationship (r=0.88) between VO2peak measured on 
a treadmill and distance walked in the ISWT in 19 subjects with moderate to severe 
COPD.  The treadmill test used a modified Balke protocol which involved increasing 
the gradient by 2.5% every two minutes while the subjects maintained a constant 
speed.  
Good reproducibility of the ISWT has been demonstrated by Singh and co-workers 
(180) in 10 subjects with COPD (mean [range] age 63 [52-74] years, FEV1 1.10 
[0.60-2.10]l) with the authors concluding reproducible results could be attained with 
one practice walk. Good reproducibility has also been demonstrated by Eiser and 
colleagues (173). In adults with moderate to severe COPD, similar peak HRs and 
dyspnoea scores were elicited in both a 6MWT using standardised encouragement 
and an ISWT, and there was a strong correlation shown between the distances 
walked on the two tests (181).  
The ESWT was developed by Revill and co-workers (196) to allow a standardised 
assessment of submaximal exercise capacity without the need for laboratory-based 
equipment. However the use of this test is limited because there is a need for the 
subject to have had a prior maximal exercise test (i.e. the ISWT) to set the workload 
for the endurance test. The workload for the ESWT is calculated at a percentage (i.e. 
85%) of the VO2peak which is estimated from the performance of a prior ISWT. 
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2.6 The effects of exercise training in adults with asthma 
There are many health benefits of exercise. Regular moderate intensity physical 
activity reduces the risk of coronary heart disease, osteoporosis, colon cancer and 
type II diabetes mellitus. It can also guard against the risks associated with being 
overweight or obese, improve mood and reduce anxiety and depression.  
Physiologically, endurance trained individuals typically demonstrate 10%-50% 
higher aerobic capacity than their sedentary peers (197, 198).   
There is evidence to suggest that regular exercise plays an important role in 
optimizing asthma management (158, 199, 200). Following an improvement in 
cardiopulmonary fitness, ventilation is reduced at low to moderate exercise 
intensities; this may increase the threshold before asthma symptoms are triggered on 
exertion (199). A study by Hallstrand and colleagues (201) showed that a 10 week 
aerobic exercise training programme improved maximal voluntary ventilation and 
decreased ventilation at a given submaximal workload and this was associated with a 
decreased dyspnoea index and ventilatory equivalent in the five subjects who had 
mild asthma and five normal control subjects enrolled in the study. Improvements in 
peripheral muscle function and neuromuscular co-ordination with regular exercise 
can also lead to an improved ability to perform activities of daily living.   
Physiological responses during exercise in an asthmatic with fully reversible lung 
function are the same as in a healthy individual without asthma. That is, the pattern 
of oxygen uptake, oxygen pulse, minute ventilation, work capacity, heart rate 
responses and blood pressure with exercise are similar between the two groups (202).  
At present, there are few published studies that have evaluated exercise training 
programmes in older adults with asthma. The majority of these studies have not 
included a control group and the frequency, intensity and modes of exercise 
evaluated have varied widely (202). A Cochrane review (203) on the efficacy and 
effectiveness of exercise training for asthma concluded that exercise training 
improved cardiopulmonary fitness, with improvements obtained in VO2peak, work 
capacity and HRmax, and this occurred in the absence of any changes in lung 
function. This review included randomised controlled trials performed in subjects 
aged 8 years or older, and training sessions that lasted at least 20 minutes, twice a 
week for a minimum of 4 weeks. Of the 13 studies included in the review, only two 
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carried out the intervention in an adult cohort.  One study included adults aged 16-40 
years who had mild to moderate asthma (200) and the other study involved subjects 
with an age range 28-33 years with asthma, recruited through media solicitation 
(204). A limitation of all 13 studies was the lack of QOL as an outcome measure 
(203).  
To date, only two studies have evaluated the effects of a supervised pulmonary 
rehabilitation programme in middle-aged and older adults with asthma. Both of these 
were carried out in Europe and involved intensive multidisciplinary programmes 
consisting of exercise, education and psychosocial interventions implemented over a 
3 month period in a mixed cohort of COPD and asthma subjects (205, 206). In both 
studies, subjects who had asthma showed improvements in exercise capacity (205, 
206).    
The study by Cox et al (206) involved 27 subjects aged 43.2±13.1 years with asthma 
randomised to a rehabilitation group and 26 subjects aged 44.3± 13.7 years with 
asthma in the control group. The rehabilitation group participated in a programme 
that incorporated team and individual sports, swimming, walking, cycling, skill 
exercises, co-ordination and relaxation exercises. Each session took 4-5 hours per 
day for a total of 38 hours per week for a period of 3 months. Results were combined 
for the asthma and COPD subjects; therefore it is not possible to determine whether 
the benefits were of a similar magnitude in the two subject cohorts, however 
improvements in oxygen uptake and endurance time in a cycle ergometer test were 
observed in the rehabilitation group.  
The intervention studied by Cambach et al (205) involved 23 subjects with asthma in 
a randomised controlled trial with a cross-over design. Rehabilitation consisted of 
pharmaceutical therapy, breathing retraining, airway clearance techniques, upper and 
lower extremity exercise training 3 times a week for 90 minutes, recreational 
activities such as swimming, cycling and hockey once a week for 45 minutes, 
education and relaxation sessions for 45 minutes once a week.  The asthmatics 
involved in this study had an FEV1 of 86±18% predicted and were aged 46±14 years.  
The study showed improved 6MWD and endurance time with cycling post 
rehabilitation. Intensive training programmes such as these two described above 
would not be feasible within clinical practice in Australia. Given the multi-
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component nature of these studies it is difficult to determine the relative benefits of 
each of the programme components. 
To date only one study has examined the long-term effectiveness of a pulmonary 
rehabilitation programme in adults with asthma.  Foglio et al (207) investigated the 
long-term effectiveness (1 year post training) of a pulmonary rehabilitation 
programme in adults with chronic asthma and COPD.  The 35 asthmatic subjects 
(age 56±10 years) had a mean FEV1 of 64±16% predicted, and FEV1/FVC of 
52±9%. These subjects participated in three sessions (each of 3 hours duration) every 
week. The sessions comprised education, a nutritional programme and an exercise 
programme for 8±10 weeks.  The study showed a significant improvement in 6MWD 
from 471±61m to 508±56m (p<0.05) immediately following the intervention and 
also at one year post-discharge (485±60m).  The total, activity, and impact scores of 
the SGRQ were also significantly improved immediately post-intervention and 1 
year later. This study showed that at baseline the asthmatic cohort had a similar 
impairment in QOL to the COPD subjects. Although the study did not have a control 
group, the aim of the study was not to assess the clinical benefits of a pulmonary 
rehabilitation programme in COPD and asthma, but rather to ascertain if long-term 
benefits could be observed in asthmatics and patients with COPD (207). 
Many health benefits can be derived from exercise in asthmatic populations.  
However, paradoxically, physical exertion can also be a potent stimulus for asthma 
symptoms if asthma control is suboptimal (159). This is because the increase in 
ventilation associated with exercise can lead to changes in airway osmolarity that 
causes smooth muscle constriction in susceptible individuals, i.e. those with 
heightened bronchial reactivity (208, 209).   
This exercise-induced asthma (EIA) is a reversible airway obstruction which can 
occur during or after exertion. Individuals may exhibit an immediate response after 6 
to 8 minutes of vigorous exercise (over and above 80% of the predicted maximum 
heart rate; HRmax) or, in about 30% of cases, a late response that occurs 6 to 8 hours 
after the onset of the exercise (210). Symptoms include cough, wheeze, dyspnoea 
and/or chest tightness.  Types of activities that are more likely to provoke EIA are 
aerobic in nature and require a high minute ventilation such as long distance running 
and soccer or activities associated with cool and dry climatic conditions such as 
cross-country skiing. Exercise which involves short bursts of intensity and lower 
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minute ventilation such as volleyball and tennis, or sports associated with warm and 
humid climatic conditions such as swimming, are less likely to precipitate EIA (211). 
The prevalence of EIA in young adults with chronic asthma has been reported to be 
between 40% and 90% (210, 211).  The prevalence of EIA in middle-aged and older 
adults has not been reported. 
 
2.7 The effects of exercise training in adults with chronic 
obstructive pulmonary disease 
Exercise training programmes are widely accepted as effective treatment strategies 
for individuals with COPD. In this population, exercise training is recognised to be 
the mandatory component of a pulmonary rehabilitation programme.  Exercise 
training alone or in combination with education has been shown to significantly 
improve exercise tolerance, decrease symptoms of dyspnoea and fatigue, reduce 
disability and handicap, improve QOL and decrease hospital utilization (6, 26, 125, 
212, 213). According to the GOLD executive summary, COPD patients at all stages 
of disease severity benefit from exercise training, with improvements seen in 
exercise tolerance, and symptoms of dyspnoea and fatigue (11). Individuals need to 
be motivated to engage in rehabilitation that is demanding in terms of their time as 
well as physical and psychological investment especially in the case of outpatient 
programmes (11, 174, 214). 
Exercise has been shown to improve fitness of patients with mild COPD, but it has 
not been shown conclusively to improve QOL or dyspnoea, or have any effect on 
long-term progression of the disease (215). A study by Babb et al (216) showed that 
in comparison to nine control subjects with normal pulmonary function, 12 subjects 
who had mild to moderate airflow limitation (FEV1 72% predicted, FEV1/FVC% 
58%) showed significantly reduced maximal exercise capacity (69% predicted 
VO2peak), versus the controls (104% predicted VO2peak). However, peak HR and the 
ratio of maximum expired minute ventilation to maximum voluntary ventilation 
(VE/MVV) were not significantly different between groups. One interesting 
observation in this study was that although resting end expiratory lung volumes 
(EELV) were similar between the groups, at maximal exercise, EELV reduced to 
45% of total lung capacity (TLC) in controls, but increased to 58% of TLC in those 
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with airflow limitation, suggesting dynamic hyperinflation played an important role 
in limiting exercise capacity even in those with mild lung impairment (216). 
In severe COPD, exercise training improves submaximal exercise tolerance in the 
absence of an increase in VO2peak, and the changes are associated with an increase in 
inspiratory capacity, improved VE and a significant reduction in breathing 
frequency, which in turn leads to a reduction in dynamic hyperinflation and 
contributes to profound improvements in submaximal exercise endurance (217).   
One review suggests that adults with asthma characterised by severe or very severe 
airflow obstruction and with poor or no reversibility should be included in 
programmes for COPD and that their rehabilitation should be similar to that 
recommended for COPD patients (202). It is reasonable, however, that those with 
chronic severe asthma, particularly those with FAOA, would benefit equally from a 
supervised exercise training programme as an individual with COPD (218).  
For adults who have FAOA, that is a fixed airways component in relation to their 
underlying diagnosis of asthma, the benefits of exercise training are less clear than in 
adults with a diagnosis of smoking-related COPD, because this patient cohort has not 
been studied in isolation. Despite the suggestion that when treated appropriately, 
patients with asthma are not ventilatory limited and therefore can tolerate high 
intensity training (218), one would assume that the permanent airways obstruction 
demonstrated in adults with FAOA would result in a comparable ventilatory 
limitation on exercise as observed in those with mild or moderate COPD.   
 
2.7.1 Factors leading to reduced exercise capacity in chronic obstructive 
pulmonary disease 
A number of mechanisms can operate in combination to bring about a reduction in 
exercise capacity in individuals with COPD. The factors which determine peripheral 
muscle function such as oxygen delivery and the presence of peripheral muscle 
weakness are just as important as variables related to lung mechanics. The 
contribution of a fall in SpO2 during exercise as a limiting factor is uncertain. 
Oxygen desaturation can worsen post-bronchodilator yet a patient may be able to 
undertake more exercise than prior to administration of the bronchodilator. Although 
supplementary oxygen decreases the magnitude of desaturation, the improvement in 
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exercise performance is more a reflection of the reduction in minute ventilation and 
reduced lactate production (219).  
Serres et al (220) have shown that skeletal muscle abnormalities are present in those 
with COPD, often a result of a sedentary lifestyle, which reduce the aerobic capacity 
of peripheral muscles. The subsequent increase in glycolytic activity at a given load 
then results in higher lactate levels and this in turn leads to excessive 
hyperventilation and dyspnoea. Malnutrition is seen in COPD, with a third or more 
individuals with the condition affected by excessive weight loss and reduced fat free 
mass, which also appear to be determinants of reduced exercise capacity (220). 
Peripheral and respiratory muscle weakness can also contribute to limited exercise 
capacity (221, 222).   
 
2.8 Components of exercise training programmes 
To be considered successful, an exercise training programme should result in 
clinically meaningful improvements. The most meaningful improvements from an 
individual’s perspective relate to functional exercise capacity and QOL (223). 
Exercise training programmes for asthma or COPD described in the literature vary 
with respect to the setting (in-patient, out-patient in either a hospital or community 
facility, or home), the frequency (number of session each week), the modalities of 
exercise (endurance, strength, upper or lower limb exercises), intensity and 
programme duration. However within the American Thoracic Society/European 
Respiratory Society official statement on pulmonary rehabilitation, there is the 
acknowledgement that ”there are no formal evidence-based guidelines regarding the 
exercise prescription or response to exercise training for patients with respiratory 
disorders other than COPD” (218).  
 
2.8.1 Safety considerations 
Safety is an important consideration in exercise prescription (218).  Potentially the 
most important safety consideration in the exercising of older adults with asthma is 
for any adult with a diagnosis of EIA to pre-medicate with short-acting beta agonists 
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or cromolyn sodium, and follow this pre-medication with an extended warm-up (199, 
224). 
 
2.8.2 Modalities of exercise 
Lower limb endurance exercise is considered a standard component of an exercise 
training programme for people with chronic lung disease, with strong evidence that 
lower extremity exercise training at high exercise intensity produces greater 
physiological benefits than low intensity training in patients with COPD (225). 
Evidence supports the addition of unsupported upper limb endurance exercise in 
adults with COPD, which both improves upper limb exercise capacity and reduces 
VE and VO2 (225).  The effects of unsupported and supported arm exercises have not 
been assessed in asthmatic subjects. 
The use of high resistance and low repetition strengthening exercise increases muscle 
strength, while a low resistance but high repetition programme increases endurance 
(226). The addition of resistance training may offer the opportunity to strengthen 
individual muscle groups in adults with asthma, and there is level 1A evidence that 
adding strength training to a programme of pulmonary rehabilitation increases 
muscle strength and muscle mass in COPD (200, 225). Whether the addition of 
resistance training translates to additional improvements in QOL and functional 
exercise capacity in adults with asthma remains unknown. 
The majority of pulmonary rehabilitation programmes are land-based.  Water-based 
exercise has specifically been recommended in asthmatic populations because EIA is 
less likely to be triggered by the moist, humid environment. The literature suggests, 
however, that even when the inspired air is dried, swimming itself causes less asthma 
symptoms than land-based endurance exercise, this finding is inexplicable because 
whole-body prone submersion in water does not seem to affect airway hyperactivity, 
and a person’s body posture on land has no meaningful effect on the severity of 
bronchoconstriction (227).  Research to date also shows that swimming itself can 
potentially worsen asthma and bronchial hyper-reactivity due to the effects of long-
term exposure to chlorine, and the possible transmission of infection through the 
water.  It is possible that these adverse effects might outweigh the benefits of 
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swimming being less likely to provoke EIA than land-based exercise once the 
disease is present (227).  
 
2.8.3 Frequency and duration of exercise programmes 
Formal exercise programmes as short as 4 weeks and as long as 18 months have 
previously been described, although most programmes range between 6 and 12 
weeks in duration. There is level 1A evidence that 6 to 12 weeks of rehabilitation 
produces benefits in several outcomes in adults with COPD which decline gradually 
over 12 to 18 months following cessation of the programme (225).  Pulmonary 
rehabilitation for individuals with COPD should involve at least an accumulation of 
30 minutes of aerobic exercise on 3 days or more a week for at least 6 to 8 weeks to 
induce meaningful improvements in functional exercise capacity and QOL (218, 
223). Most studies of exercise training in asthma have used three to five sessions 
each week as the frequency of training in their programmes (224, 228).  
 
2.8.4 Intensity of exercise 
Physiological improvements in functional exercise capacity have consistently been 
demonstrated following exercise training programmes which incorporate supervision 
of participants, prescription of moderate to high intensity training loads and the 
regular progression of exercise intensity (218). Both intensity of exercise and the 
load duration affect the magnitude of the training effect. Training at higher intensities 
generally demonstrates the greatest physiological improvements in exercise capacity 
in terms of reduced lactate, VE, HR and VO2 in COPD (225). A study by Casaburi et 
al (229) which involved COPD subjects training on cycle ergometers at either low 
[30 watts per minute, (W/min)] or high (71 W/min) intensities showed the higher 
intensity group demonstrated greater improvements in minute ventilation, oxygen 
uptake, heart rate and reduced lactate for a constant work rate test after training as 
compared with before training.  
To set the intensity of exercise variables such as external work rate, VO2, HR, 
dyspnoea and ratings of perceived exertion (RPE) have been used. For normal 
subjects, a percentage of predicted HRmax is often used and a commonly prescribed 
intensity range is between 60% - 85% of HRmax (223).  For older adults, care needs 
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to be taken when setting exercise intensity and symptoms need to be well monitored 
if intensity is increased, as often elderly patients in an exercise programme are not 
capable of exercising within the commonly prescribed ranges of intensity and 
duration. High intensity exercise in some older adults may cause musculoskeletal 
injury (223). 
The traditional approach to exercise prescription involves using a percentage of 
predicted HRmax. However, measured HR does not bear the same relationship to 
exercise intensity in COPD subjects as seen in normal subjects.  Predictions of 
maximum HRs are also subject to errors with a standard deviation of 10 beats per 
minute recognised in cohorts of subjects of the same age. Therefore using this 
method to prescribe exercise intensity may not be the most appropriate for 
individuals with chronic lung disease (223).   
The most commonly used scale for measuring perceived exertion is the Borg RPE 
scale which ranges from 6-20. Ratings on this scale increase linearly with exercise 
intensity, HR and VO2. On this scale a maximum cardiovascular response is 
associated with an RPE of 16-18 and metabolic threshold occurs around 12-14 (230).  
When this scale is to be used for targeting intensity, the desired threshold should be 
around 12 with an upper limit of 16 (230). 
 
2.8.5 Advantages of supervision and group exercise 
The advantages of supervised exercise training programmes for older adults are that 
exercises can be prescribed on an individual basis, symptoms with exercise are 
monitored and intensity is progressed within symptom tolerance. Individuals can 
benefit from the psychosocial support of exercising in a group, and the instruction 
and supervision of using asthma medications before and during exercise (231). 
Individuals can also be encouraged to recommence exercising following an 
exacerbation of asthma that enforces a degree of inactivity (199).   Potentially, older 
adults with chronic asthma may demonstrate a fear of developing asthma symptoms 
during exercise, particularly when exercising alone and at home, and thus may 
benefit from the support of a supervised exercise training programme.   
 




2.9 Burden of asthma in the community, with a focus on the 
management of respiratory disease in Western Australia 
Part 2 of this literature review describes the burden of asthma on an individual.  This 
section expands on the concept of burden to examine the disease burden on the 
community. Included in this section is a review of the health care burden in relation 
to hospital utilisation in WA, and as such a general overview on the current health 
structure for the provision of services for adults with asthma is provided. In addition, 
terms which relate to remoteness and health are introduced, given that currently a 
striking gap remains in the characterization of asthma in middle-aged and older 
adults on a regional level within WA. Investigation of the spatial distribution of 
asthma and COPD cases and patient demographics in the state could assist in the 
alignment of asthma programmes more closely with areas of need. The concept of 
GIS technology and its role in needs analyses for improved health service planning 
are also introduced. 
 
2.9.1 Health care burden of asthma 
Studies have shown that adults with asthma at the severe end of the disease spectrum 
rely more heavily on health care resources and accumulate significantly greater costs 
in the management of their disease (61, 232, 233). Costs not only arise directly, but 
also indirectly from absenteeism from work and loss of earnings.  Intangible costs 
also relate to living with an impaired QOL (234).   
In a study of emergency department (ED) visits for asthma in three countries (Italy, 
France and Spain), the likelihood of an ED visit increased with asthma severity. The  
odds ratios for individuals presenting with mild asthma, moderate asthma and severe 
persistent asthma were 1.6 (95% C.I. 1.1-2.5), 2.3 (95% CI 1.5-3.6) and 5.6 (95% CI 
3.2-9.9) respectively (235). Further, a study by Koga et al (236) found subjects who 
had multiple exacerbations of their asthma and who were at increased risk for severe 
exacerbations were characteristically those who presented with persistent irreversible 
airflow limitation. Additional risk factors were a history of chronic sinusitis and/or 
intolerance to non steroidal anti-inflammatory medication.  
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Increased resource utilisation has also been reported to be greater in those with poor 
control of their asthma when compared to those with well controlled asthma at the 
same level of severity (44). It is estimated that the cost savings would be up to 45% 
if optimal control of asthma was achieved for all asthmatics within Australia (44). 
Factors associated with a greater reliance on hospital services by people with asthma 
include socio-economic disadvantage, poor adherence to medical advice, 
psychological factors such as denial of the condition, the lack of a written asthma 
action plan, excessive use of reliever medications and inadequate use of medication 
to control symptoms (61, 237). 
 
2.9.2 Asthma in Australia 
Globally, it has been reported that asthma is less common in rural areas compared to 
urban areas (1) and that growing up on a farm may confer some protection against 
atopy and the development of allergic asthma (238). However, recent population 
surveys (2004-2005) show that the prevalence of asthma does not differ significantly 
between the metropolitan, inner regional and remote areas of Australia (18). It is 
notable, however, that death rates from asthma from 1997-2001, were significantly 
higher in outer regional and remote areas among persons aged 35 to 64 years (239). 
Death rates from asthma among females are reported to be consistently higher than in 
males in all categories of remoteness except in the outer suburbs of capital cities 
(240).   
Despite similar prevalence statistics, the rates of hospitalisation for adults with 
asthma have been shown to be significantly higher in rural or remote areas compared 
with major cities and regional areas (728 patient days versus 331 patient days per 
100 000 people). Rates of hospitalisation are also higher in more socioeconomically 
disadvantaged localities (240).   
A descriptive study by Tong and Drake (241) analysed admissions data between 
1989 and 1994, and found that hospital admission rates for asthma in New South 
Wales were 52% to 69% higher for rural residents than their urban counterparts, and 
in the period from 1983 to 1992 mortality rates were 4% to 43% higher for rural 
residents than urban dwellers. Although the authors were cautious when interpreting 
these data as the study was descriptive in nature, they suggested that the findings 
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could have significant implications for the provision and planning of asthma health 
care services in rural Australia. A key point of the authors’ discussion alluded to the 
need to investigate the potential influence that the availability of health care services 
and personnel (such as asthma educators and specialists) may have on admissions 
data (241).   
Jones and colleagues (242) showed that there was an apparent trend between health 
service accessibility and levels of mortality from asthma in the UK, and that social 
and geographical isolation contributed to the inappropriate management of asthma 
(242). This study also showed that those in lower socioeconomic classes and 
individuals without a car had a higher relative risk of dying from asthma. This is the 
only reported study that has identified geographical barriers to acute hospital services 
to be a risk factor for asthma mortality (242).  
 
2.9.3 Population demographics in Western Australia 
Western Australia comprises over one third of the land mass of Australia and is 
highly diverse in many respects: socially, economically, demographically and 
climatically.  Because of the vast land mass involved, health care planners and 
providers face unique challenges when attempting to provide equality of health 
services and to improve health outcomes. These objectives are part of the principles 
of Medicare Australia, which plays a role in delivering Australia’s universal health 
funding programmes (243).   
At the end of the June quarter, 2008, the total population of WA was estimated to be 
2,163,200 (244). This population distribution is heavily skewed to the Perth 
metropolitan area with three quarters of the population of WA living in or around 
Perth (245).  The remaining 500,000 people live in an area spanning 2.5 million 
square kilometres (246).    
The demographics of WA show that it is an ageing society, with a trend both in 
higher life expectancies but also in associated increased levels of morbidity. Eleven 
percent of the population of WA are aged 65 years and over, and this percentage is 
expected to double over the next 50 years. Areas in which the proportions of older 
adult population are greater correspond to those in which increased health services 
are required (247). The ‘sea change’ phenomenon is increasingly evident among the 
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country’s retiring population, with city dwellers moving to large rural centres for a 
‘better, healthier lifestyle’, the ‘clean country air’, reduced noise and traffic 
congestion. Contrary to general opinion however, people residing in rural and remote 
areas have many health disadvantages, as evidenced by higher disease and mortality 
rates due to poor access to health services (239).   
A trend also exists for older adults who live in the most remote parts of the State to 
shift towards larger regional centres. Among the older adult population, the 
proportion of people aged 55 years and over in remote areas is around half that of 
metropolitan and rural communities, with higher premature mortality also 
contributing to these lower proportions (248). Table 2.8 displays the population of 
West Australians in 2002 by age and gender for adults aged 45 years and over 
according to Divisions of General Practice. 
 
Table 2.8 Estimated regional residential populations for 2002 by General 
Practice Division, age and gender 
  45-64 years 65-74 years 75+ years 
































































* These figures were calibrated using local government area resident population 
figures from the 2002 census. Source: (249) 
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Australia’s indigenous population continues to have higher rates of morbidity and 
mortality than the non-indigenous Australian population. Aboriginal people make up 
3.5% of the total population of WA, and of this population, 66% live in rural and 
remote areas. Fifteen percent of indigenous people living in remote areas and 18% of 
those living in rural areas were reported to have asthma as a long-term health 
condition in the 2001 National Health Survey (250). 
 
2.9.4 The medical workforce in Western Australia 
The Australian Rural Health Institute has identified a range of problems that rural 
General Practitioners (GPs) and health workers need to overcome in order to provide 
effective asthma management for their communities. Limitations in asthma service 
provision arise from large distances and travel times to health facilities for many 
patients, a lack of facilities and medical staff, poor access to services such as 
laboratory testing, lack of funding for asthma educator positions, community apathy 
towards asthma management, and difficulties providing adequate support for 
communities that have been affected by a fatal asthma episode (251).   
To be effective in developing and delivering improved community support 
programmes for older adults with moderate to severe asthma, it is essential to: (i) 
understand current accessibility issues that patients and caregivers encounter in 
regional areas; and (ii) have a clearer understanding not only of the geographical 
distribution of asthma services, but also the prevalence and geographical distribution 
of the disease within WA.   
The GP is the key element within most rural health care delivery systems (252).  In 
terms of the medical workforce in 2002, of the estimated 2000 GPs working in WA, 
465 (2001 figures) worked in regions classified as rural or remote (249). This number 
included 16 long-term locums and 57 trainee registrars (249). Data collected at that 
time suggested a high degree of mobility was required of rural and remote patients to 
attend a GP for their illness, with only 88% of patient visits in large rural centres 
being to a doctor who lived in the region, compared to 98% in capital cities.  This 
figure progressively declined to 68% in very remote areas (253).    
It was estimated that in 2003, in rural and remote WA, there was a deficit of between 
50 and 60 GPs based on the standardised population figures, and with the trend 
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towards increased population in rural areas it was forecast that an extra 150-160 GPs 
would be needed over a ten year period to practise in rural WA. Table 2.9 
summarises the number of GPs that were working in each of the Divisions of 
General Practice throughout the State in 2002 (253). 
 
Table 2.9  General Practitioner workforce in rural and remote WA 














Central Wheat belt 35 89% 0% 0% 0% 
Goldfields 53 60% 8% 0% 13% 
Great Southern 57 86% 0% 2% 0% 
Greater Bunbury 41 90% 0% 0% 5% 
Kimberley 44 14% 0% 41% 18% 
Mid West 59 56% 0% 15% 8% 
Peel South West 129 81% 0% 1% 0% 
Pilbara 47 45% 0% 21% 11% 
Total 465 67% 2% 8% 6% 
Source: Western Australian Centre for Rural and Remote Medicine General 
Practitioner Database: November 2002, and adapted from The Analysis of Rural 
General Practice Workforce in WA (253) 
 
2.9.5 The Western Australian health system 
The WA government provides health service to the public of the State through a 
system which incorporates: 
• 5 tertiary health campuses 
• 8 public secondary campuses in the metropolitan area 
• 2 privately operated hospitals that provide service to public patients under 
contract from the Department of Health 
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• 6 regional resource centres 
• 20 district health services in rural and regional areas 
• 45 small health campuses of which a portion are multipurpose services 
• More than 300 community-based and mental health facilities 
• More than 250 non-government organisations and statutory authorities. 
There are also two privately-run hospitals in the metropolitan area and an additional 
two in regional centres (254). 
 
2.9.6 Defining remoteness in Western Australia 
The term ‘remoteness’ describes the degree of difficulty in accessing a range of 
services, whereas ‘accessibility’ describes the relative ease of accessing such 
services.  It is known that people ‘trade off’ geographic and non-geographic factors 
in making decisions about health service use (255). For example, travel for health 
care is affected by socio-demographic characteristics such as income, age and gender 
(255).     
The Accessibility/Remoteness Index of Australia (ARIA) is the commonly used 
standard classification scale for remoteness and accessibility to services.  It was 
developed in 1997 by the National Key Centre for Social Applications of Geographic 
Information Systems for the Commonwealth Department of Health and Aged Care.  
This is a scoring system which ranges from 0 to 12 that integrates information on 
physical geography and the distance from every locality in Australia to service 
centres of various sizes, with the primary aim being the measurement of remoteness 
solely on the basis of geographical accessibility excluding socioeconomic and 
population size factors. 
The Australian Bureau of Statistics further refined ARIA for the 2001 census and 
developed the Australian Standard Geographical Classification system based on this 
measure which group populated localities into one of five levels of remoteness. 
These five ASGC classifications and the ARIA index scores on which they are based 
are described in Table 2.10. The ASGC provides an objective measure of remoteness 
and attempts to distinguish remoteness in terms of accessibility alone (256). 
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Table 2.10 Australian Bureau of Statistics - classes of remoteness by ASGC 






Major cities of 
Australia 
0-0.2 Geographic distance imposes minimal restriction 
upon accessibility to goods and services 
Inner Regional 
Australia 




>2.4-5.92 Geographic distance imposes a moderate 
restriction upon accessibility 




>10.53-15 Locationally disadvantaged. Geographic 
distance imposes the highest restriction upon 
accessibility 
 
ASGC: Australian Standard Geographical Classification Areas; ARIA: Accessibility/ 
Remoteness Index of Australia 
 
2.10 Using geographic information systems in health studies 
Observations of geographical and temporal variations in health outcomes are one of 
the foundations of epidemiological analyses (257). Geographic information systems 
technology can be a powerful tool to assist health planners visualise the nature of a 
health accessibility problem. Its utility derives from the ability to explore 
relationships between geographic location and health through mapping, taking into 
account multiple sources of spatial information (258). Geographic information 
systems technology can also be used to screen and test hypotheses about disease and 
environmental factors, and assist in the generation of hypotheses relating to the 
optimal sites for health services based on areas of need (259).    
In the context of health analysis in Australia, data sources that incorporate an address 
field can be assigned a latitude and longitude, a collector’s district and also a 
statistical local area using purpose built software. It is within such spatial models that 
health attributes of interest can be incorporated for analyses and mapping (258). For 
example, hospital data codes, such as admission diagnosis of asthma or COPD can be 
attached to an ‘event’ or (de-identified) individual who was admitted to a particular 
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hospital, because the hospital has a defined latitude and longitude by which it can be 
described. This information can be accumulated and aggregated in a database 
containing other possible attributes, such as population figures for the given region 
that the hospital services. 
It is important to note that in using positional data (e.g. to assign a certain latitude or 
longitude to a hospital), errors can occur in the accuracy of the geo-referencing. This 
raises the question of how much positional error is tolerable, and the results must be 
considered in terms of the context of the purpose for which the data will be used.  
Errors can also be associated with the collection of attribute data.  For example, data 
accessed may inherently contain coding inaccuracies, not only with a change in 
coding systems over time, but also in relation to miscoding a diagnosis (260). For 
example, hospital data were initially coded with International Classification of 
Diseases (ICD) codes 9 during the period between 1988 and 1999. This changed to a 
revised coding system - ICD codes 10 from 2000 onwards. Population data sources 
include population registers, census data, electoral roll and special surveys.  The 
census is completed only every few years, and difficulties may arise in the estimation 
of data for inter-census years which must consider trends in births, deaths and 
migration factors - a particular problem in studies of small population sizes in 
specific geographic areas. In addition, geographic boundaries may change between 
censuses. 
Despite these potential flaws in the initial storing of data in a spatial database, GIS 
has a potentially important role in the creation of spatially-referenced morbidity data. 
The technology has the ability to calculate rates of disease or admissions to hospital 
in relation to the density of the underlying population, and to produce disease maps 
which allow visualisations of the spatially varying frequencies of disease within a 
region of interest (259). 
 
2.11 Conclusion 
This chapter has reviewed the pathophysiology behind FAOA and its relation to 
asthma, COPD and other respiratory diagnoses. The burden of asthma on an 
individual, at a community level and also on the government has been explored, in 
relation to the associated disability that an older adult with moderate to severe 
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disease might present as being burdened by. Exercise training as an additional 
treatment modality to the first line treatment with pharmacological agents has been 
reviewed for its effectiveness within the literature in both asthmatic and COPD 
populations. The literature review has concluded with a focus on WA, and the burden 
of disease experienced by the health system in relation to the unique challenges 
associated with servicing older adults with asthma in rural and remote areas of the 
State due to the vast land mass and low population density outside the Perth 
metropolitan area. 
  















Most studies evaluating exercise training as an intervention for chronic respiratory 
disease have focused on individuals with moderate to severe chronic obstructive 
pulmonary disease (COPD) (225). The majority of studies that have been carried out 
in subjects with asthma have been restricted to children or young adults with mild to 
moderate disease. Most of these studies have methodological limitations such as the 
lack of a control group, insufficient sample size or lack outcome measures such as 
quality of life (QOL) (202).   
Therefore it remains uncertain whether exercise training is a beneficial intervention 
in individuals with chronic moderate to severe asthma, and particularly in middle-
aged and older individuals in whom the evidence is lacking. One reason that may 
account for the lack of evidence within the asthma literature is because some of these 
individuals with asthma exhibit permanent impairments in lung function and there 
remains some controversy in the way this group is defined (10, 13, 30, 34, 261). In 
this thesis a decision was made to describe these individuals as having fixed airway 
obstruction asthma (FAOA). 
In order to address the limitations within the literature, there was a need for a 
randomised controlled trial (RCT) in a cohort of middle-aged and older adults with 
FAOA that compared outcomes in a group of subjects that participated in an exercise 
intervention with the outcomes in a control group that continued to receive standard 
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medical care only. Importantly, assessment of QOL was a necessary outcome 
measure.   
This chapter describes the methodology, results and discussion of a RCT that 
evaluated a 6 week supervised exercise training programme in a group of middle-
aged and older subjects with moderate to severe asthma who had a degree of 




Section 3.2 of this chapter describes the study hypothesis, aims and objectives.  
Subject recruitment strategies, sample size and study design are outlined, and the 
study methodology including procedures for data collection, outcome measures and 
the methods used in data reduction and analyses are described.  
 
3.2.2 Research hypothesis 
The hypothesis for this study was that adults aged 40 years and over with FAOA 
would significantly benefit from a 6 week supervised exercise training programme. 
Compared to a matched group of control subjects who received standard medical 
care only, subjects who participated in the exercise program would demonstrate 
benefits through statistical and clinically significant improvements in: 
i) QOL; 
ii) functional exercise capacity;  
iii) anxiety and depression; and 
iv) asthma control 
immediately post-intervention (6 week assessment) and at a 3 month follow-up.  
 
3.2.3 Aim  
The aim was to implement and evaluate a supervised exercise training programme in 
middle-aged and older adults (aged 40 years and over) who had moderate to severe 
asthma and a degree of fixed airways obstruction.   
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3.2.4 Objectives  
The primary research objectives were to evaluate the effects of the exercise training 
programme on: 
i)   health-related QOL (HRQOL); 
ii)   QOL; 
iii)  functional exercise capacity; 
iv)  levels of anxiety and depression; and 
v)    asthma control. 
These variables were measured immediately after the training (6 week assessment) 
and at 3 months following cessation of the intervention period.   
 
Secondary research objectives of this study were to: 
i) determine the extent of impairment in pulmonary function, peripheral muscle 
strength, functional exercise capacity and QOL in this cohort; 
ii) define any relationships between baseline measures of pulmonary function, 
functional exercise capacity, asthma control, QOL and anxiety and 
depression; 
iii) evaluate feedback from subjects regarding the exercise training programme; 
and 
iv) collect data on health care utilisation for the 12 months prior to and following 
the intervention period. 
 
3.2.5 Subjects  
3.2.5.1 Inclusion criteria 
Subjects were selected for the study on the basis that they had moderate to severe 
chronic asthma diagnosed by a respiratory physician (i.e. following investigations by 
their respiratory physician to determine disease variability, trigger factors, atopy and 
responsiveness to medications) and satisfied at least two of the following lung 
function criteria after a trial of maximum bronchodilator therapy and a trial of oral 
corticosteroids of at least 3 weeks duration:  
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i) Forced expiratory volume in one second (FEV1) <80% of the predicted 
normal value (% predicted); 
ii) FEV1/ forced vital capacity (FVC) ratio less than 80% predicted; or 
iii) residual volume (RV) >120% predicted. 
These criteria aimed to capture a population of asthmatics who had a degree of fixed 
obstruction affecting the small and/or large airways. It was conjectured that there was 
a risk that subjects with asthma affecting the small airways alone might have been 
excluded if the selection criteria defined moderate to severe asthma on the commonly 
used basis of FEV1 alone (262). 
 
In addition, subjects were required to satisfy the following criteria: 
i) aged 40 years or over; 
ii) be on stable asthma medication; 
iii) smoking history of ≤15 pack years;   
iv) demonstrate a normal or raised gas transfer (DLCO/VA >80% predicted) 
to exclude significant smoking related disease; and 
v) demonstrate a restriction in activities of daily living secondary to asthma 
determined by the subjects’ responses to the activity limitation domain of 
the Asthma Quality of Life Questionnaire (AQLQ) (70).   
 
3.2.5.2 Exclusion criteria 
Subjects were excluded from the study if any of the following criteria applied: 
i) evidence of co-existing respiratory conditions (e.g. emphysema, chronic 
bronchitis, bronchiectasis or pulmonary fibrosis);  
ii) smokers or ex-smokers who had ceased smoking within the previous 2 
years; 
iii) participation in an average of more than 30 minutes a day of moderate or 
vigorous exercise; 
iv) involvement in a pulmonary rehabilitation programme in the previous 12 
months; 
v) inability to understand written and/ or spoken English; 
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vi) co-morbid conditions limiting or likely to reduce exercise capacity (e.g. 
cardiovascular disease, neurological impairment, severe inflammatory 
joint disease, severe claudication pain, poorly controlled diabetes, or 
severe cognitive impairment); or 
vii) existence of a serious psychiatric disorder such as schizophrenia or 
bipolar disorder. 
 
3.2.5.3 Withdrawal criteria 
Subjects could be withdrawn from the study in the event of any of the following: 
i) withdrawal of consent; 
ii) two or more asthma exacerbations requiring a change in medication 
lasting more than 7 days; 
iii) development of any new medical condition which interfered with the 
subject's ability to perform the assessments or participate in the 
exercise training programme, and 
iv) for the exercise group (to reflect non-adherence) failure to attend at 
least 14 out of 18 exercise classes. 
The data from any subject who withdrew from the study was included in the 
intention-to-treat analyses.    
 
3.2.5.4 Sources for subject recruitment 
To minimise recruitment bias and variations in asthma management, recruitment was 
restricted to patients from one respiratory physician (Professor PJ Thompson [PJT]) 
at a single metropolitan hospital and one private clinic where patients were managed 
by either one of two respiratory physicians (Dr Q Summers and Dr P Bremner). The 
records of patients were screened if they were considered likely to meet the selection 
criteria and brought to the attention of the respiratory physician in charge of their 
care to determine suitability for participation in the study. The respiratory physician 
could also directly pass on the details of patients who satisfied the inclusion criteria. 
Patients who met the inclusion criteria were then sent a letter of invitation to 
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participate in the randomised controlled trial. These patients were contacted by 
telephone 1 week later.   
The aim was to recruit a study population that consisted of asthmatics who had stable 
chronic asthma and in whom fixed airways disease from other respiratory 
pathologies would have been eliminated. Full lung function measurements including 
those of patients recruited from the private clinic were reviewed by PJT to ensure 
study criteria had been met prior to study entry. This systematic approach to the 
recruitment process was aimed at reducing selection bias, and allowed accurate 
identification of the participation rate for this study. 
 
3.2.6 Study design 
A prospective RCT was carried out. Subjects were randomised using a stratified 
process matching by gender (http://www.randomizer.org) into an ‘exercise group’ 
and a ‘control group’. Two computer lists separated by gender were generated by an 
independent medical researcher (Dr J Woods) at the Lung Institute of Western 
Australia (LIWA), that consisted of random permutations of the numbers 0 (control 
group) and 1 (exercise group) for 20 subjects per group. Subjects were allocated to 
the exercise or control group at the time of informed consent, however the group 
allocation was not revealed by Dr Woods to the principal investigator or to the 
subject until after the subject had completed the 3 week run-in period and baseline 
assessment. This procedure was designed to ensure the principal investigator did not 
bias the process of recruitment of subjects into groups based on the assessment 
findings.  The subjects and investigators were, however, aware of which arm of 
treatment (exercise or control) they were allocated to from this point. 
It is acknowledged that if possible outcome assessments should be made by a 
‘blinded’ assessor in a trial such as this and double blinding is ideal. For this study, 
blinding of the investigator beyond the initial assessment was not feasible due to the 
financial restraints of the study which prevented additional staff other than the 
principal investigator being involved in the exercise training and conducting the 
assessments.  Successfully blinding participants from an intervention such as 
exercise training is also not possible. 
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The exercise group participated in a 6 week programme of supervised exercise 
training. The control group received standard medical care over this time period. 
Prior to randomisation, subjects entered a 3 week run-in period during which the 
Asthma Control Questionnaire (ACQ) (55) was completed each week. The run-in 
period was extended if a subject reported an increase in asthma symptoms as 
reflected by their responses to the ACQ, a variation in FEV1 of >10% or a change in 
their asthma medication lasting >7 days. 
Figure 3.1 illustrates the design and timeline of the study. 
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3.2.7 Procedures for data collection 
3.2.7.1 Informed consent 
Individuals who expressed interest in participating in the study following telephone 
contact were invited to a face-to-face meeting lasting approximately 45 minutes with 
the principal investigator (Sian Turner) who explained in detail the research aims, 
methods, risks and benefits and time commitment. Only subjects who gave written, 
informed consent were included in the study. 
 
3.2.7.2 Three week run-in period 
To confirm stable disease prior to commencing the intervention phase of the study 
subjects were asked to attend a weekly assessment for a minimum of 3 weeks to 
undergo spirometry and to complete the ACQ (55). All assessments of lung function 
were carried out using a portable spirometer (Vitalograph 2120, Vitalograph Ltd, 
Maids Moreton House, Buckingham, UK.) using a standard technique (260). The 
spirometer was calibrated each week by the principal investigator.  
After completion of the run-in phase, subjects were given a form to complete which 
asked for details of the respiratory medications they were currently taking, any 
unplanned hospital, emergency department (ED), respiratory physician or General 
Practitioner (GP) visits for their asthma and number of courses of oral corticosteroids 
for asthma exacerbations in the preceding year (Appendix A). 
 
3.2.7.3 Assessments  
Lung function 
Respiratory function tests were performed in the Pulmonary Physiology Department 
at Sir Charles Gairdner Hospital (SCGH). The following measures of spirometry 
were made pre- and post-bronchodilator: FVC, FEV1, FEV1/FVC.  Gas transfer 
(single breath diffusing capacity of the lung for carbon monoxide [DLCO], single 
breath diffusing capacity of the lung for carbon monoxide corrected for alveolar 
volume [DLCO/VA]) and lung volumes (total lung capacity [TLC], RV, functional 
residual capacity [FRC], and vital capacity [VC]) were also measured.  
Measurement of lung function was repeated immediately after the 6 week 
intervention period (i.e. appointments were requested for the week following the 
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intervention, and if this was not possible they were scheduled as soon as possible and 
no later than 4 weeks after the intervention ceased).  
 
Baseline and follow-up assessments 
The baseline assessment lasted approximately 2 hours and required collection of the 
following data: generic and disease-specific QOL, anxiety and depression, functional 
exercise capacity, and peripheral muscle strength. This assessment was repeated 
immediately following the intervention period (6 week assessment) and again 3 
months post-intervention (3 month assessment). Measures were taken in the 
following order: 
1. Subjective history 
2. Measurement of height, weight, and resting blood pressure 
3. Spirometry measured and completion of the ACQ 
4. First 6 minute walk test (6MWT) 
5. Completion of the AQLQ, Hospital Anxiety and Depression (HAD) Scale 
and the Medical Outcomes Study 36-Item Short-form Health Survey (SF-
36)  
6. Repeat 6MWT 
The following sections provide further detail of these measures.  
 
3.2.8 Outcome measures 
3.2.8.1  Primary outcome measures 
Health-related quality of life   
Health-related QOL was measured using the self-administered Australian-English 
individualised version of the AQLQ (69, 70). This questionnaire assessed the four 
domains of activity limitation (11 items) in which five of the questions specified 
individualised answers, asthma symptoms (12 items), emotional function (5 items) 
and environmental exposure (4 items). The activity domain requires subjects to 
identify their five most important activities that have been limited by asthma in the 
previous 2 weeks. The AQLQ was administered in written format for all three 
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assessments and took 15-20 minutes for the subject to complete. Permission to use 
this questionnaire was granted prior to the commencement of the study (Juniper, 
6.5.03). 
 
Functional exercise capacity   
Functional exercise capacity was measured using the 6MWT. This test was used 
because the test outcome [i.e. 6 minute walk distance (6MWD)] has been shown to 
be responsive to changes following exercise training and other interventions in adults 
with COPD and asthma and is considered to better reflect the ability to undertake 
physically demanding activities of daily living than performance in a laboratory-
based exercise test (175, 205, 207).  
The 6MWT was conducted in accordance with current recommendations (178). The 
test protocol was modified from the American Thoracic Society guidelines to include 
standardized instructions prior to the test and standardized verbal encouragement at 
the start of each minute throughout the test. In addition, each minute subjects were 
informed of the elapsed time, and if a subject rested, verbal encouragement “begin 
walking as soon as you are able” was provided at 15 second intervals.     
The 6MWT was performed over a straight 45m level course within an enclosed 
corridor. The 45m course was marked with two cones. A chair was located at each 
end of the course and at the mid-point for subjects to use if required. To allow for 
familiarization with the protocol at the baseline assessment, subjects completed two 
6MWTs, separated by between 20 and 60 minutes rest (264). At all follow-up 
assessments two 6MWTs were also performed (265). At each time point the greater 
of the two 6MWDs was used in the analyses. 
The 6MWT protocol is described below: 
• A heart rate (HR) monitor (Polar A1, Polar Electro Oy, Kempele, Finland) 
was applied to the subject’s chest. The polar watch was applied to the back of 
the subject’s left shoulder using a safety pin to ensure HR readings could be 
taken without interfering with test performance. Strong correlations between 
HR readings obtained from the polar monitor and electrocardiograph (ECG) 
recordings have been reported (266, 267). Throughout the test, HR was 
continuously monitored and recorded at the end of each minute.  
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• Pre-exercise blood pressure and time of test were recorded. Subjects who had 
been instructed by their respiratory physician to take prophylactic 
bronchodilators prior to exercise took their bronchodilators prior to the 
6MWT and the dose, time taken and medication were recorded. On all 
subsequent visits the subject took the same medication and dose prior to the 
6MWT.   
• The Borg (0-10) Dyspnoea Scale with standard instructions was introduced 
and pre-exercise dyspnoea was recorded (146).   
• Resting oxygen saturation (SpO2) was measured using a Tuffstat Pulse 
Oximeter and finger sensor (Datex-Ohmeda, Louisville, USA).  
• The Borg (0-10) Dyspnoea Scale was modified to also record the perception 
of chest tightness (Appendix B). This scale was developed because no 
published scale was found for recording this symptom. 
• The subject was given a description of the 6MWT course and instructed to 
turn immediately in front of the cones as if they had approached a wall. 
• This distance walked was measured to the nearest 0.5m using a metre 
measurer. 
•  The number and duration of rest periods were also recorded. 
 
End-point data  
At the end of the sixth minute, heart rate (HR), dyspnoea and chest tightness, SpO2 
and leg fatigue were recorded. Leg fatigue was measured using a modified version of 
the Borg (0-10) dyspnoea scale (Appendix C) (146). After the first test the subject 
was asked: "Was that the most you could do?  Do you think you could do better 
another time?" The Borg 6-20 Rating of Perceived Exertion (RPE) scale (147) was 
introduced, and subjects were asked to rate the level of effort or physical stress 
experienced during the test. 
  
3.2.8.2  Secondary outcome measures  
Generic quality of life  
The standardised Australian version of the SF-36 (version 1) was used to assess 
health status. Permission to use this questionnaire was granted by Quality Metric 
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following registration and licensing (Appendix D). The data obtained were compared 
with age and gender-matched Australian (77) and West Australian normative data 
(75). The SF-36 was a self-administered scale and took 10 minutes for subjects to 
complete.  
 
Peripheral muscle strength  
Quadriceps strength 
Knee extension strength was measured using a strain gauge (Falls Assessment Kit, 
Prince of Wales Medical Research Institute, NSW, Australia). The subject was 
seated on a high chair with hips and knees flexed to 90 degrees. The testing 
procedure was adapted from Andrews et al (268) to include the use of a strain gauge 
attached proximal to the subject’s ankle to a horizontal metal bar connecting the two 
rear legs of the chair via a velcro strap.   
In three separate trials, separated by a rest period of 1 minute, the subject was 
encouraged to pull against the strap assembly with maximal force, and the greatest 
force for each leg was recorded. If the highest reading was not within 10% of the 
other two readings then additional trials were carried out. Both legs were assessed 
and subjects were questioned as to their favored leg for kicking a ball. The 
measurement obtained on this leg was used in the analyses. 
This technique for measuring quadriceps strength has been described by Lord et al 
(269). Normative data using the technique and strain gauge described by Lord and 
colleagues have not been published, therefore quadriceps strength was compared to 
reference data published by Bohannon et al (270). 
Grip strength    
A hand-held Jamar 5030 J1 dynamometer (Sammons Preston Inc. Bolingbrook, 
Illinois, United States of America) was used to measure grip strength. Grip strength 
was measured with the subject seated. The subject’s arm was positioned with the 
shoulder adducted and neutrally rotated, elbow flexed at 90 degrees, and the forearm 
and wrist position were neutral. A minimum of three measures were taken with at 
least 1 minute rest between each effort. The single highest value achieved that was 
within 5% of at least two other measures was recorded  on the subjects dominant side 
and compared with normative data (271-273).  
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Anxiety and depression  
The HAD scale was used to screen for the presence of anxiety and depression and to 
assess for changes in mood states following the intervention period (124). The scale 
was self-administered and took 5-10 minutes for the subject to complete. 
This well validated scale has been shown to be a reliable tool for detecting states of 
anxiety and depression and has demonstrated responsiveness to changes in mood 
state following pulmonary rehabilitation in patients with COPD (125, 126). A score 
of >10 for either subscale was used to identify cases of anxiety or depression among 
the subjects. This threshold value is recommended when the aim is to detect cases of 
anxiety or depression with a low probability of false positives (124). Although the 
scale is reliable for detecting states of anxiety and depression, it is not recommended 
as the sole means of making a diagnosis of altered mood state (124), 
 
Asthma control 
Asthma control was assessed each week using the ACQ (55) during the run-in period 
to ensure stable asthma before the collection of baseline data and was also measured 
at all follow-up assessments to determine whether any change in asthma control 
occurred during or following the intervention period. 
  
Health care utilisation   
Data were collected on hospital admissions, length of stay, ED visits and 
unscheduled GP consultations for asthma over the previous 12 months. This was 
collected via a self-report questionnaire and validated against hospital records where 
possible (Appendix A).  
 
Subject feedback 
Subject feedback following the exercise programme was assessed using a self-
complete questionnaire. The questionnaire was developed specifically for this study 
and is provided in Appendix E. 
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3.2.8.3 Controlled measures 
Testing procedures were controlled using the following methods:  
• standardised protocols and instrumentation were used for all measurements; 
• the venue was constant and the time of day of assessments was maintained as 
constant as possible; 
• subjects were asked to refrain from eating or drinking any caffeinated 
products in the 2 hour period prior to testing to avoid any adverse effects on 
exercise performance (274);   
• subjects were requested to wear the same footwear and similar clothing on 
each testing occasion;   
• the order in which subjects performed tests and completed the questionnaires 
was kept consistent at each assessment; 
• pre-medication for exercise was administered at the same time before the 
6MWT on all assessments as the administration of a bronchodilator can affect 
6MWD (86, 275); and 
• repetitions of the 6MWT were conducted at least 20 minutes and no more that 
60 minutes apart. 
 
3.2.9 The intervention period 
3.2.9.1 Exercise group 
Subjects attended three exercise classes each week for 6 weeks. The classes lasted 
for 80-90 minutes and were supervised by a physiotherapist. Exercise was prescribed 
in accordance with the recommendations for individuals with COPD (218). An 
indoor air-conditioned corridor within SCGH and a gym in the Physiotherapy 
Department at SCGH were used for the walking programme and exercise circuit 
respectively. 
Specifically, classes commenced with a 10-15 minute warm-up period comprising a 
slow 400m walk followed by stretches (triceps, pectoralis, trunk side-flexors, 
gastrocnemius and soleus, and a hamstring stretch). 
The warm-up was immediately followed by a 20 minute walk prescribed at an initial 
intensity equivalent to 80% of the average walking speed achieved on the 6MWT 
performed at the baseline assessment (218). For example, a 6MWD of 500m would 
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be considered to have been completed at an average walking speed 5.0kph. Thus the 
prescribed walking intensity would be 4.0kph. This exercise prescription was 
provided to subjects in the format of a target distance to walk in 20 minutes within 
the 200m hospital corridor, therefore in this example the prescribed distance would 
be 1.3 to 1.4km or 1300-1400m. Subjects were encouraged to take regular rests if 
they experienced intolerable dyspnoea/chest tightness, or intolerable leg fatigue. 
Chairs were located approximately 10-15m apart throughout the hospital corridor 
(200m course).  
The walking training was followed by an exercise circuit comprising cycle ergometry 
training for 10 minutes, step-ups, wall squats and unsupported and supported upper 
limb endurance training (arm ergometry and unsupported bilateral arm elevation) for 
a total of approximately 45 minutes. Details of each of these training stations are 
provided in Appendix F.   
The target training intensity for the circuit exercises was a RPE of between 12 and 14 
(146). When subjects reported a higher RPE they continued to exercise at this 
intensity if their symptoms were tolerable. The intensity of the walking training and 
circuit exercises was increased each week within symptom tolerance (218). 
Following the circuit, the subjects repeated stretches described above and HR and 
SpO2 were re-measured at the end of the class. 
At the end of the training period each subject was provided with a home exercise 
programme based on the exercise intensities achieved during their final training week 
and instructed to exercise on at least 3 days each week. 
All subjects randomised to the exercise group continued to receive standard medical 
care for their asthma and any subjects requiring prophylactic bronchodilators prior to 
exercise were instructed to take their medication immediately prior to each class. The 
percentage of individuals with exercise induced asthma (EIA) in an older adult 
population with FAOA is unknown. However, exercise has been shown to induce 
bronchoconstriction in up to 80% of individuals with asthma (276).  The 
incorporation of a prolonged warm up, controlled temperature of the indoor facilities 
in which the exercise training took place and the encouragement to those with known 
EIA to use beta 2 agonist pre-training helped to reduce the potential for such a 
phenomenon to occur. A portable spirometer was available to measure FEV1 if 
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necessary post-training. A prolonged warm-up and the provision of pre-medication to 
help prevent a potential asthmogenic effect has also been advocated within the 
literature in exercise training programmes for adults with asthma (277). 
The period over which the exercise programme was run was extended to a maximum 
of 10 weeks for any subject who experienced an exacerbation of their asthma, or 
other problems, with the aim of subjects completing at least 14 supervised training 
sessions within a maximum of 10 weeks. 
 
3.2.9.2 Control group 
Subjects randomised to the control group were instructed to continue with their 
current daily activities and management of their asthma in the usual manner 
(standard medical care). These subjects were not supervised during the 6 week 
intervention period; however each subject attended an appointment for measurement 
of spirometry and completion of the ACQ mid-way through the 6 week period. At 
this appointment they were asked if they had changed their asthma medication due to 
illness or an exacerbation.  
 
3.2.10  Pilot study  
To determine the feasibility of conducting this study, a pilot study was performed.  
Six subjects (four females) with moderate or severe asthma completed an 8 week 
supervised exercise training programme at SCGH. The subjects were aged 65.3±4.4 
years and post-bronchodilator FEV1 was 53±6.8% predicted. Subjects attended 
classes twice a week and completed a home exercise programme on an additional 2 
days each week. Six minute walking distance and QOL (measured with the Chronic 
Respiratory Disease Questionnaire (278)) were measured prior to and immediately 
following the exercise programme (Table 3.1). This study confirmed the feasibility 
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Table 3.1 Data from six subjects pre- and post-training 
 Pre Post Significance 
6MWD (m) *n = 5 410±84 448±91 p=0.21 
Distance walked in 20 min 1333±186 1525±211 p<0.01 
QOL - total CRDQ score 86.5±8.1 109±5.7 p<0.01 
*Data are mean±SD, pre- and post data compared using paired t-tests. 
6MWD: 6 minute walk distance, m: metres; min: minutes; QOL: quality of life, 
CRDQ: Chronic Respiratory Disease Questionnaire 
 
3.2.11  Sample size  
In designing this study, consideration was given as to how many patients would need 
to be recruited to evaluate the efficacy of the treatment.  It is acknowledged that the 
answer to this question is not a simple one as it is dependent on not only the size of 
effects which are likely to be observed between the exercise and control group, the 
statistical requirements related to Type I and Type II errors (which are related to size 
and power) and on the success or failure of the types of simple comparisons which 
are to be made between the measurements made in each group.    
In this study, an anticipated clinical difference in the AQLQ and the 6MWT were 
measures chosen with an appropriate level of statistical significance to determine 
sample size. The pre-specified sample size of 32 subjects was calculated for this 
study based on detecting a clinically significant change (0.5 points per item) in the 
activity domain of the AQLQ and a 54m change in 6MWD between groups with 
80% power (α=0.05) (66, 69, 194, 207). 
 
3.2.12  Data management and statistical analyses  
Data that were not normally distributed were transformed using a natural logarithmic 
scale and non-parametric analyses performed when normality was violated. 
Baseline SF-36 data, 6MWD and muscle strength were compared with published 
norms or predicted values using paired t-tests.  
Data were analysed according to both per-protocol analyses and the intention-to-treat 
principle. For missing data, the last observation carried forward method was utilised 
(279). Baseline equivalence of the exercise group and control group for each of the 
outcome measures was tested using unpaired t-tests, Mann-Whitney U-tests and Chi-
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squared depending on the distribution of the data and its conformity with 
assumptions of normality.  
Data for the primary outcome measures were principally analysed using a 3 (time) x 
2 (group) repeated measures analysis of variance (ANOVA) and post-hoc tests. If a 
significant interaction was observed, simple contrasts were specified for differences 
between groups at the post-intervention assessment and 3 month follow-up. Main 
effects for each group were also analysed using a simple t-tests post-intervention 
compared with baseline measures if a non-significant difference was observed in the 
3 x 2 ANOVA. 
Differences between groups are expressed as mean±standard deviation (SD) or 95% 
confidence intervals (95% CIs). All statistical analyses were performed using SPSS 
software (Version 16.0) for Windows. 
The relationships between the following baseline measures for the subject cohort 
(n=34) were investigated: %predicted FEV1, magnitude of air-trapping or pulmonary 
hyperinflation at rest represented through the measurement of the ratio of residual 
volume to total lung capacity (RV/TLC), 6MWD and body mass index (BMI) with 
scores on the following questionnaires: ACQ, AQLQ, HAD and the SF-36 physical 
component summary scores (PCS) and mental component summary scores (MCS). 
 
3.2.13       Ethical considerations and safety issues 
Ethics approval for this study was obtained from the Human Research Ethics 
Committees of Curtin University of Technology (HR120/2004) and SCGH (Trial 
2003-149). Subjects gave written informed consent prior to participating in the study. 
In the event of respiratory distress occurring during any of the study assessments or 
exercise training, an emergency protocol was put in place to ensure subject safety 
throughout the study.   
Subjects were under no obligation to release their information for the study and were 
free to withdraw at any time without prejudice. Confidentiality was maintained by 
allocating each subject an identification number with the subject’s identity known 
only to the principal investigator and project supervisors. All data were stored 
electronically on a computer in LIWA and access was password protected. Hard 
copies of the data were stored in a locked filing cabinet in LIWA. Access to the 
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electronic data was via a password known only to the principal investigator, and the 
project files were accessed only by the principal investigator and project supervisors. 
Currently the data obtained for this study are stored in a secure place where it will 
remain for 5 years, after which it will be destroyed in accordance with the 





These results are divided into three parts. Part 1 describes baseline data for the 
exercise and control groups. Part 2 describes exercise training data pertaining to 
adherence with training and training loads achieved during the 6 week programme.  
Part 3 evaluates the efficacy of the exercise intervention in relation to changes in 
QOL, 6MWD, anxiety and depression and asthma control using intention-to-treat 
and per-protocol analyses as well as subject feedback regarding the exercise 
programme. Group data are presented as mean±SD unless otherwise stated.   
 
PART ONE: BASELINE DATA 
3.3.2 Subjects 
Participant recruitment took place between 23rd of August 2004 and 3rd of July 2007. 
During this period, over 1,200 medical files of adults with asthma were reviewed by 
the principal investigator. Two hundred and sixty-six patients satisfied the inclusion 
criteria and were invited to participate in the study. Of these, 40 expressed interest 
and attended an initial screening interview (Figure 3.2). The participation rate was 
14.7%, which decreased to 12.8% with subject withdrawals. Figure 3.3 describes the 
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Source D  
Private Clinic 
Mount Hospital   




5 subjects recruited  




15 subjects recruited 






11 subjects recruited 






8 subjects recruited 
27.6% participation rate 
 
Subject Source Details 
Source A (Patients managed by PJT) Patients on a respiratory database held at SCGH 
Source B (Patients managed by PJT) A systematic review of the files of all patient seen privately 
at SCGH 
Source C (Patients managed by PJT) A review of the files of all patients attending respiratory 
appointments with PJT at a public outpatient clinic between January 2005 through to August 2006 
Source D (Patients with ‘asthma diagnosis’ managed by respiratory physician) attending a single 
private clinic between 1st January 2004 to 13th April 2006 
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Figure 3.3  Study design as per CONSORT guidelines (280) 
 
35 were randomised 
2 subjects withdrew due to  
loss of interest (1) and time 
commitments (1) 
 
4 subjects withdrew due to lost interest 




40 gave informed consent and commenced baseline 
assessments 
1 subject withdrew and was lost 
to follow-up due to personal 
reasons prior to starting 
exercise classes 
1 year follow-up phone call, n= 19 
3 month data of 1 subject 
placed in intention-to-treat 
due to viral illness and 





assessments, 2 weeks 
Post-intervention phase 
assessments   
Intervention phase,  
6 weeks 
Exercise group, n=20 
0 subject withdrawals 
Control group, n=15 
Post-intervention 
assessment, n=15 
1 subject did not meet study 
criteria during assessments 
0 subject withdrawals 
3 month assessment, n=19 3 month assessment, n=12 
1 year follow-up phone call, n=9 
3 subjects withdrew as 




assessments   
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Patients who declined to participate in the study cited the following reasons for non-
participation: no interest; work commitments; too far to travel to appointments; too 
much of a time commitment, and musculoskeletal problems. Four subjects withdrew 
before the baseline assessment and one subject in the exercise group withdrew due to 
personal reasons before the intervention phase commenced but after collection of 
baseline data. Data from this subject were included only in the analysis of the effect 
of test repetition on 6MWD. Results are presented for 34 subjects (15 male) for 
baseline comparisons between groups in the intention-to-treat analyses (19 subjects 
in exercise group, 15 in control group), and with data from 31 subjects (15 male) 
included in the per-protocol analyses (19 subjects in exercise group, 12 in control 
group). 
 
3.3.3 Baseline characteristics 
Demographic, anthropometric and lung function data for the two groups were not 
significantly different (all p>0.05). These data are presented in Tables 3.2 and 3.3. 
The lung function data for both groups demonstrated moderate airflow limitation 
(mean FEV1 ≤60% predicted) with evidence of lung hyperinflation and gas trapping 
(Table 3.3). 
Twelve subjects (five of whom were ex-smokers) had a high resolution computer 
tomography (HRCT) scan in the previous year that excluded the presence of other 
pulmonary diseases. The remaining six ex-smokers had smoking histories which 
ranged from of 0.5 to 13.3 pack years (median 7 pack years).  
Subjects in both groups demonstrated a high level of functional exercise capacity 
with 6MWDs close to predicted values (88±12%) (281) and had well preserved 
peripheral muscle strength (Table 3.2). The percentage of subjects who reported 
taking regular exercise, defined as walking at a leisurely pace for 30 minutes on at 
least 3 days each week, was 53% and 60% in the exercise and control groups 
respectively.  
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Table 3.2  Anthropometrics and demographic data at baseline  






Gender (male: female) 15:19 8:11 7:8 
Age (years) 67.8±10.6 65.3±10.8 71.0±9.7 
Height (cm) 168.2±10.8 169.1±9.0 167.3±12.8 
Weight (kg) 79.0±19.2 81.7±12.7 75.8±25.3 
Smoking history (never:former) (n) 23:11 14:5 9:6 
Pack years 3.1±7.1 2.0±4.5 4.5±9.3 
CT scan (n) 12 7 5 
BMI  (kg/m2) 27.8±6.2 28.6±5.0 26.8±7.6 
BMI 18.5-24.9 (n) 12 3 9 
BMI 25-30 (n) 13 12 1 
BMI>30 (n) 9 4 5 
Quadriceps strength (N)   258±117 264±104 251±136 
% predicted  81±29 84±30 78±30 
Hand-grip strength (lb)   72±27 72±20 72±35 
% predicted  109±25 109±23 110±27 
6MWD 548±100 569±88 522±111 
% predicted 88±12 91±10 85±15 
Lived alone (n) 12 6 6 
Retired (n) 23 11 12 
Working part-time (n) 5 3 2 
Working full-time (n) 6 5 1 
Exercise Advice (n)    
No previous instructions received 
by subject (n) 
8 5 3 
General encouragement given by a 
doctor (n) 
21 10 11 
Specific instructions given by 
physiotherapist or doctor (n) 
5 4 1 
Mean±SD. BMI: Body mass index; n: number; cm: centimetres; kg: kilograms; N: newtons; %: 
percent; lb: pounds.   
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Table 3.3  Resting lung function at baseline 






Resting Lung function    
FEV1 (L) 1.6±0.6 1.7±0.6 1.6±0.7 
FEV1 % predicted 59.4±15.8 58.9±15.9 60.0±16.2 
FVC (L) 3.1±1.1 3.1±1.0 3.1±1.2 
FVC  % predicted 85.0±15.7 83.4±16.4 87.2±15.0 
FEV1/FVC % 59.7±16.1 53.8±8.3 53.1±12.9 
FEV1/FVC % predicted 53.4±10.4 71.0±9.8 71.2±16.6 
VC (L) 3.2±1.1 3.3±1.0 3.2±1.3 
VC % predicted 100.9±17.1 99.9±18.6 102.1±15.7 
FRC (L) 3.8±1.0 3.8±0.8 3.9±1.2 
FRC % predicted 159.4±56.2 161.5±58.4 157.0±55.3 
TLC (L) 6.2±1.6 6.3±1.3 6.2±1.9 
TLC % predicted 114.3±12.8 113.4±11.5 115.3±14.7 
RV (L) 3.0±0.8 3.1±0.6 3.0±1.0 
RV % predicted 142.3±26.3 144.3±22.0 139.7±31.6 
RV/TLC 49.8±8.7 49.9±8.9 49.6±8.7 
RV/TLC % predicted 124.8±19.0 127.6±19.2 121.1±18.7 
DLCO/VA (ml/min/mmHg/) 4.1±0.6 4.3±0.7 3.9±0.5 
DLCO/VA % predicted 99.5±13.7 101.6±16.1 96.9±9.6 
Mean±SD. n: number; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 
VC: vital capacity; FRC: functional residual capacity; TLC: total lung capacity; RV: residual volume; 
DLco/VA: single breath diffusing capacity for carbon monoxide corrected for alveolar volume; L: 
litres; %: percent; ml/min/mmHg: millilitres per minute per millimetre of mercury.  
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Appendices G-J illustrate physical activity levels, asthma triggers, and asthma 
management at study entry for the exercise and control groups (n=34). Specifically, 
Appendix G depicts the number of times/week, on average, subjects reported 
walking at a leisurely pace for periods of at least 30 minutes. In addition, 2 subjects 
(1 exercise group, 1 control group) played lawn bowls twice a week, and 1 subject 
(control group) played golf 3 times a week.  
Asthma triggers were grouped into one of 10 categories based on perceived triggers 
for worsening asthma symptoms listed by the subjects. These are given in Appendix 
H. Appendix I displays the asthma management profiles, specifically the number of 
subjects who owned a written asthma action plan, nebuliser, peak flow meter and the 
number of subjects who had been reviewed by a trained asthma educator in the past 
year (excluding the subject’s GP or specialist). For the group as a whole, of those 
who owned a peak flow meter, 14.7% used it daily while 41.2% never used it. These 
data are presented by group in Appendix J. 
 
3.3.4  Medications and health care utilisation in the preceding year 
Table 3.4 provides a summary of the respiratory medications taken by subjects and 
the number of hospital and ED presentations in the year preceding recruitment to the 
study for the exercise and control groups.   
For the cohort, nine subjects had visited a respiratory physician once, one subject had 
visited twice and three subjects visited three times secondary to worsening asthma 
symptoms. Seven subjects had attended an ED secondary to asthma symptoms, of 
whom five were admitted to hospital. The numbers of medical attendances with a GP 
due to an exacerbation of asthma are given in Appendix K. 
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Long-acting beta-agonists  18 (95%) 15 (100%) 
Anticholinergics  2 (11%) 3 (20%) 
Inhaled corticosteroids  18 (95%) 15 (100%) 
Maintenance oral corticosteroids  1 (5%) 1 (7%) 
Leukotriene receptor antagonists  4 (21%) 1 (7%) 
Cromoglycate  2 (11%) 2 (13%) 
Theophylline 2 (11%) 2 (13%) 
Courses of oral corticosteroids in last 12 months  8 (42%) 7 (47%) 
ED presentations in last 12 months 3 (16%) 4 (27%) 
Hospital admissions in last 12 months 2 (11%) 3 (20%) 
Data are numbers of subjects with the number in parentheses denoting the 
percentages of subjects. ED: Emergency Department; %: percent 
 
3.3.5  Asthma control  
At the start of the run-in phase, 14 subjects (73%) in the exercise group and eight 
subjects (53%) in the control group met the criteria for inadequately controlled 
asthma (ACQ score > 1.5) (56).  These data are shown in Table 3.5.   
In five subjects (4 exercise group) the run-in period was extended due to worsening 
asthma symptoms. For each of these subjects, the best three consecutive asthma 
control scores were used in analyses as that subject’s ‘first, second and third’ run-in 
data. There were no significant differences between groups in asthma control scores 
measured at the first, second or third baseline assessments (p=0.44, 0.78 and 0.99 
respectively). The last asthma control score measured in the run-in period was used 
as the baseline measure for comparison with measures of asthma control following 
the intervention period.   
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Table 3.5  Asthma control data collected during the run-in period  
 Exercise Control 
 (n=19) (n=15) 
First baseline ACQ score 2.1±0.7 (14) 1.9±1.0 (8) 
Second baseline ACQ score 2.0±0.7 (14) 1.9±1.1 (9) 
Third baseline ACQ score 1.7±0.7 (11) 1.7±1.0 (8) 
ACQ: Asthma Control Questionnaire. The number in parentheses denotes the 
number of subjects who had an ACQ score >1.5, and therefore by definition poorly 
controlled asthma (56).   
 
3.3.6 Quality of life at baseline 
There were no significant differences in the AQLQ scores between groups in any of 
the domains (all p>0.05).   
There were also no significant differences between groups in the PCS or MCS of the 
SF-36 at baseline. The PCS and MCS are calculated using data from the eight 
subscales of the SF-36 and incorporate the general population norm into the scoring 
algorithm (282). In this thesis, PCS and MCS were calculated using means, SDs and 
factor score coefficients obtained from the (unweighted) 1995 National Health 
Survey of Australia (77) (Appendix L).   
The PCS for the subject cohort at baseline was 38.1±10.0, which was significantly 
lower (p<0.05 one-sample t-test) that the normative mean value reported for both 
Australians and West Australians (49.7 reference PCS score). The MCS score 
(52.6±11.5) was not significantly different from the mean MCS scores reported for 
either the Australian (50.1, p=0.22), or WA populations (50.2 p=0.24). Figure 3.4 
illustrates the SF-36 scores for the subject cohort together with age-standardised 
population data for Australia and WA.  
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PF: physical function; RP: role-physical; BP: bodily pain; GH: general health; VT: vitality; SF: social 
functioning; RE: role-emotional; MH: mental health; PCS: physical component summary score; MCS: 
mental component summary score 
 
3.3.7 Effects of test repetition on 6 minute walk distance 
Data for the 34 subjects who performed two 6MWTs at baseline assessment showed 
an increase in 6MWD from 524±99m to 549±101m (p<0.0001) on the second 
6MWT. This equates to a 5.2±7.0% improvement. 6 minute walk distance increased 
on the second 6MWT by 22.7±29.8m in the exercise group, and by 28.5±32.8m in 
the control group, but there was no significant difference in the magnitude of 
increase between the groups (p=0.60). Data were excluded for one subject (control 
group) in this analysis due to irregularities in this subject’s HR detected using a Polar 
monitor during her second 6MWT.  
 
3.3.8 Relationships between baseline measures 
Correlations between physiological and QOL data measured at baseline for the 
subject cohort are displayed in Table 3.6. The strongest correlation was found 
between the magnitude of air trapping or pulmonary hyperinflation, as evidenced by 
RV/TLC, and 6MWD (r=-0.66). Asthma control scores were negatively and 
significantly correlated with the total score on the AQLQ. Forced expiratory volume 
in one second showed a significant negative correlation with BMI. Disease-specific 
QOL (AQLQ) was moderately and significantly correlated with SF-36 data (MCS 
and PCS) and with levels of anxiety and depression. 
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Table 3.6  Correlations (r) between physiological and QOL measurements taken at baseline for the study cohort (n=34) 
 6MWD ACQ baseline 
score 
AQLQ total score SF-36 PCS SF-36 MCS 
FEV1 (% predicted) 0.34† -0.44* 0.19 0.16 0.10 
RV/TLC -0.66# 0.23 -0.13 -0.28 -0.24 
BMI -0.15 0.50* -0.40† -0.28 -0.29 
HAD anxiety score -0.08 0.31 -0.54# 0.05 -0.57# 
HAD depression 
score 
-0.17 0.34 -0.54# -0.09 -0.74# 
AQLQ total score 0.24 -0.69# 1.0 0.37† 0.73# 
 
FEV1: forced expiratory volume in one second; %: percent; RV: residual volume; TLC: total lung capacity; BMI: body mass index; HAD: Hospital Anxiety and 
Depression scale; 6MWD: 6 minute walk distance; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; SF-36: Short-Form 36 
Health Survey; PCS: physical component score; MCS: mental component score; r: Pearson’s correlation coefficient; †p<0.05, *p<0.01, #p<0.001. 
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PART TWO: EXERCISE TRAINING PROGRAMME  
3.3.9 Training attendance 
Of the 19 subjects randomised to the exercise group, 11 attended all 18 sessions. Six 
subjects with an incomplete attendance record worked full-time. These six subjects 
attended 15 sessions (n=2) and 14 sessions (n=4).  
One subject developed knee pain on session 9 (due to the recall of the medication 
Vioxx) but attended a total of 16 sessions, and another subject developed a viral 
illness which limited full participation (15 sessions attended). No severe episodes of 
wheezing or chest tightness requiring medical intervention occurred in any of the 
subjects during the supervised training sessions.  
The intervention period was extended for five subjects in the exercise group due to 
an asthma exacerbation or viral illness (two subjects), problems attending classes 
because of work commitments (two subjects), and as a result of a foot injury 
(infection) (one subject). The intervention was extended in two subjects in the 
control group because of asthma exacerbations resulting from viral illness. 
 
3.3.10 Adverse events 
One subject randomised to the exercise group developed cervical pain from the 
unsupported bilateral upper limb exercise in the first week of training. This subject 
had a history of cervical pain. No progression of this exercise occurred and the 
subject received a course of physiotherapy treatment to relieve symptoms. 
 
3.3.11  Exercise training loads 
Twenty minute walk distance and training loads achieved during all of the exercise 
stations, with the exception of the wall squats, are presented in Figures 3.5 to 3.8.  
Over the course of the 6 week training programme, 20MWD increased by 17.8±9.6% 
from baseline (282±145m, p<0.001). Data points are displayed as the mean±2 
standard errors of the mean change from baseline at each of the time points, i.e. 
sessions 3, 6, 9, 12 etc.















































































Figures 3.5 - 3.6  Change in training load (mean±2 standard errors of the mean) over 
the 18 training sessions for 20-minute walk distance (Figure 3.5) and step-ups 
(Figure 3.6). Data points are the mean change from baseline for that session for the 
































































































Figures 3.7 - 3.8 Change in training intensity (mean±2 standard errors of the mean) 
over the 18 training sessions for arm ergometry training (Figure 3.7) and unsupported 
upper limb exercise (Figure 3.8). Data points are the mean change from baseline for 
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PART THREE: EFFICACY OF THE INTERVENTION 
 
3.3.12  Resting lung function and anthropometrics 
There were no significant changes in any measures of lung function at the 6 week 
follow-up versus baseline, nor any significant changes in BMI, handgrip and 
quadriceps strength measured at baseline, 6 week and 3 month follow-up in either 
group (Tables 3.7 and 3.8).   
 
3.3.13  Asthma control  
During the 6 week intervention period, two subjects (randomised to the control 
group) and one subject in the exercise group reported an asthma exacerbation. As 
none of these subjects experienced a change in medication lasting more than seven 
days and all reported full recovery by their 6 week follow-up, data from all of these 
subjects were included in the per-protocol analyses. Seven subjects experienced a 
clinically significant improvement in their asthma control immediately post-
intervention compared to baseline, and six of these subjects were in the exercise 
group. 
Figures 3.9 and 3.10 illustrate the mean and 95% CIs for ACQ scores recorded at 
baseline and at the 6 week and 3 month follow-up in the two groups. The change in 
ACQ scores at 6 weeks compared to baseline was -0.26±0.36 in the exercise group 
and -0.11±0.51 in the control group, and at 3 months was -0.19± 0.42 for the exercise 
group and 0.02±0.37 in the control group with per-protocol analyses. Analyses using 
intention-to-treat showed a change of -0.04±0.49 at 6 weeks and -0.07±0.37 at 3 
months in the control group. Improvements in asthma control scores therefore did not 
reach the minimal clinically significant difference of 0.5 in either group, and 
repeated measures ANOVA showed changes were also not statistically significant.   
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Table 3.7  Resting lung function at baseline and immediately post-intervention (6 weeks) 
 Exercise group (n=19) Control group (n=15) 
Resting Lung Function Baseline 6 weeks Baseline 6 weeks 
FEV1 (L) 1.7±0.6 1.8±0.6 1.6±0.7 1.5±0.6 
FEV1 % predicted 58.9±15.9 62.1±15.4 60.0±16.2 59.6±16.7 
FVC (L) 3.1±1.0 3.2±1.0 3.1±1.2 3.0±1.1 
FVC  % predicted 83.4±16.4 84.3±16.4 87.2±15.0 86.3±16.2 
FEV1/FVC % 53.8±8.3 54.5±8.1 53.1±12.9 52.3±13.2 
FEV1/FVC % predicted 71.0±9.8 72.0±10.0 71.2±16.6 70.1±17.0 
VC (L) 3.3±1.0 3.3±1.1 3.2±1.3 3.1±1.4 
VC % predicted 99.9±18.6 100.7±20.7 102.1±15.7 100.3±15.3 
FRC (L) 3.8±0.8 3.9±1.0 3.9±1.2 3.8±1.0 
FRC % predicted 161.5±58.4 166.9±63.8 157.0±55.3 156.5±66.2 
TLC (L) 6.3±1.3 6.4±1.4 6.2±1.9 6.0±1.8 
TLC % predicted 113.4±11.5 113.9±12.9 115.3±14.7 112.5±13.6 
RV (L) 3.1±0.6 3.1±0.8 3.0±1.0 2.9±0.7 
RV % predicted 144.3±22.0 142.0±32.8 139.7±31.6 137.1±24.9 
RV/TLC 49.9±8.9 48.6±10.4 49.6±8.7 50.1±8.4 
RV/TLC % predicted 127.6±19.2 124.7±22.0 121.1±18.7 122.0±15.0 
DLCO/VA (ml/min/mmHg/) 4.3±0.7 4.1±0.6 3.9±0.5 3.8±0.7 
DLCO/VA % predicted 101.6±16.1 98.2±17.6 96.9±9.6 93.7±12.4 
 
Mean±SD. n: number; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; VC: vital capacity; FRC: functional residual capacity; TLC: total 
lung capacity; RV: residual volume; DLco/VA: single breath diffusing capacity of the lung for carbon monoxide corrected for alveolar volume.  
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Table 3.8  Anthropometrics at baseline, 6 weeks and 3 months follow-up 
 Exercise Control 
 n=19 n=12 (per-protocol) n=15 (intention-to-treat) 
 Baseline 6 weeks  3 months Baseline 6 weeks  3 months Baseline 6 weeks  3 months 
Anthropometrics          
BMI  (kg/m2) 28.6±5.0 28.4±4.7 28.2±4.6 26.7±6.8 26.6±6.9 26.7±7.1 26.8±7.6 26.7±7.6 26.8±7.8 
BMI 18.5-24.9 (n) 3 4 4 7 7 7 9 9 9 
BMI 25-30 (n) 12 12 12 1 1 1 1 1 1 
BMI>30 (n) 4 3 3 4 4 4 5 5 5 
Quadriceps strength 
(N) 
264±104 279±95 293±90 283±134 269±141 285±148 251±136 240±139 253±147 
% predicted  84±30 88±24 92±23 85±29 81±33 86±34 78±30 75±32 79±33 
Hand-grip strength 
(lb)   
72±20 73±21 72±24 80±34 83±32 76±34 72±35 75±34 69±34 
% predicted  109±23 109±20 108±25 116±24 122±22 110±25 110±27 115±29 105 ±28 
Mean±SD. BMI: body mass index; n: number; N: newtons; lb: pounds 
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Figure 3.9 Mean±95% confidence intervals for asthma control scores:  











































Figure 3.10 Mean±95% confidence intervals for asthma control scores: 
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3.3.14   Quality of life, anxiety and depression 
Scores for the four domains of the AQLQ are given in Tables 3.9 (per-protocol 
analyses) and 3.10 (intention-to-treat analyses). Overall, 3x2 ANOVAs showed 
significant improvements in symptoms, activity and total scores with intention-to-
treat analyses and a significant improvement in symptom scores with per-protocol 
analyses for the exercise group. The changes in the total AQLQ score and the activity 
and symptom domains were also clinically significant immediately post-intervention 
and at the 3 month follow-up when compared to baseline scores.   
The interpretation of SF-36 data is facilitated with norm-based scoring and the use of 
summary scales.  Norm-based scoring uses general population norms which provide 
a basis for meaningful comparisons across the scales in the SF-36 profile and assist 
with the interpretation of differences.   
Eighty to 85% of the reliable variance in the eight separate SF-36 subscales are 
accounted for in the combined physical and mental component summary scores.  
These two summary measures are interpretable as the physical and mental 
dimensions of health and their use reduce the number of statistical analyses down 
from eight to two without any loss of information.  In addition, the scores obtained in 
the role-physical, bodily pain, social functioning and role-emotional domains were 
not normally distributed, therefore because of the presence of floor and ceiling 
effects on the subscales (282), statistical analyses on these subscales would not be 
easily interpretable.  Statistical analyses, therefore, were only performed on the PCS 
and MCS scores. SF-36 data are given in Tables 3.9 and 3.10.  
Overall the effect of group randomisation on PCS scores was not significant (p=0.06 
with intention-to-treat, p=0.27 with per-protocol analyses). Simple contrasts 
performed in the 3x2 ANOVA with intention-to-treat analyses showed there was a 
significant positive change in PCS scores at 6 weeks (p=0.003) in the exercise group, 
but this improvement declined at 3 months (p=0.05) such that the overall 3x2 
ANOVA was not significant.   
Mean PCS and MCS scores at baseline, 6 weeks and 3 months for both groups are 
shown in Figures 3.11-3.14. The PCS and MCS scores incorporate norm-based 
scoring. This means a linear transformation has been applied to standardise the data 
against population norms that have a mean of 50 and SD of 10. This transformation 
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enables the scores for each group to be easily interpreted as being above or below the 
norms (283).   
Anxiety and depression profiles for the exercise and control groups are reported in 
Tables 3.9 and 3.10. Only two subjects (one exercise group) recorded a score of >10 
for anxiety and one subject (control group) recorded a score of >10 for depression at 
baseline.  
Repeated measures analyses of variance showed a significant improvement in 
anxiety scores in the exercise group compared to the control group over the course of 
the study (p=0.04) in per-protocol analyses, but not in intention-to-treat analyses 
(p=0.09). There were no significant improvements in depression scores with either 
per-protocol (p= 0.13) or intention-to-treat analyses (p=0.17).  
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Table 3.9  Quality of life, anxiety and depression: per-protocol analyses 
 Exercise (n=19) Control (n=12) 
AQLQ (points per item) Baseline 6 weeks 3 months Baseline 6 weeks 3 months 
Symptoms ξ  5.2±0.9 5.9±0.7*† 5.8±0.7*† 5.7±1.3 5.8±1.1 5.7±1.4 
Activity  4.7±1.0 5.7±0.8*† 5.8±0.9*† 4.9±0.9 5.6±1.0* 5.5±1.1* 
Emotional  5.1±1.5 5.8±0.9* 5.8±0.9* 5.5±1.6 5.8±1.4 5.8±1.5 
Environmental  4.9±1.3 5.7±1.1* 5.7±0.8* 5.3±1.5 5.6±1.4 5.6±1.3 
Total score  5.0±01.0 5.8±0.7*† 5.8±0.7*† 5.3±1.1 5.7±1.1* 5.7±1.1* 
SF-36 (range 0-100) #       
Physical functioning 56.1±21.6 71.3±16.4 73.4±14.7 54.6±25.1 63.3±22.2 61.3±29.2 
Role-physical 46.1±32.6 86.8±22.6 81.6±27.4 58.3±41.7 62.5±42.0 55.6±31.4 
Bodily pain 79.4±21.9 83.4±18.5 80.6±20.8 55.6±31.5 68.0±24.5 64.8±25.5 
General health  61.0±21.5 66.3±14.9 66.8±22.2 58.2±21.4 63.3±18.3 60.2±20.1 
Vitality 60.5±18.7 69.2±14.5 67.4±16.2 59.6±16.6 68.3±10.9 64.6±14.1 
Social functioning 86.2±22.4 93.4±11.3 87.7±17.9 85.4±18.3 77.1±33.2 82.3±27.9 
Role-emotional 80.7±35.7 84.2±30.2 87.7±27.7 69.4±41.3 69.4±41.3 75.0±40.5 
Mental health 82.3±12.5 85.3±10.3 86.5±12.2 76.0±20.0 80.0±16.2 82.3±12.1 
Health transition 2.6±1.2 2.0±1.1 2.3±1.0 2.6±1.3 2.5±1.1 2.8±0.8 
Physical component summary score 39.2±9.8 47.1±6.9* 46.2±6.2* 38.0±11.4 41.8±9.2 40.0±11.8 
Mental component summary score 54.9±10.4 55.0±7.0 55.0±8.9 52.4±12.0 52.2±10.7 54.0±10.3 
HAD       
Anxiety ξ 5.2±3.5 3.4±3.2*† 3.9±3.2* 5.4±3.1 6.1±3.8 4.8±4.0 
Depression 3.3±2.8 1.8±1.8 2.2±2.8 3.8±2.6 3.6±2.6 2.8±2.7 
AQLQ: Asthma Quality of Life Questionnaire; SF-36: Short Form-36 Health Survey; HAD: Hospital Anxiety and Depression scale. *p<0.05 compared with 
baseline; †p<0.05 compared with control group; ξp<0.05 3x2 ANOVA factor*randomisation; #: statistics performed only on the physical and mental component 
scores
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Table 3.10  Quality of life, anxiety and depression: intention-to-treat analyses 
 Exercise (n=19) Control (n=15) 
AQLQ (points per item) Baseline 6 weeks 3 months Baseline 6 weeks 3 months 
Symptoms ξ  5.2±0.9 5.9±0.7*† 5.8±0.7*† 5.6±1.3 5.7±1.2 5.6±1.4 
Activity ξ  4.7±1.0 5.7±0.8*† 5.8±0.9*† 4.7±1.1 5.3±1.2* 5.3±1.3* 
Emotional  5.1±1.5 5.8±0.9* 5.8±0.9* 5.2±1.7 5.5±1.7 5.5±1.8 
Environmental  4.9±1.3 5.7±1.1* 5.7±0.8* 5.1±1.5 5.4±1.6 5.4±1.5 
Total score ξ 5.0±1.0 5.8±0.7*† 5.8±0.7*† 5.2±1.2 5.5±1.3* 5.5±1.3 
SF-36 (range 0-100) #       
Physical functioning 56.1±21.6 71.3±16.4 73.4 ±14.7 49.3±26.3 55.3±25.9 53.7±30.4 
Role-physical 46.1±32.6 86.8±22.6 81.6±27.4 53.3±39.9 50.0±45.3 50.0±46.3 
Bodily pain 79.4±21.9 83.4±18.5 80.6±20.8 54.1±28.2 66.2±23.0 63.6±23.6 
General health  61.0±21.5 66.3±14.9 66.8±22.2 54.7±21.8 57.5±20.8 54.9±21.4 
Vitality 60.5±18.7 69.2±14.5 67.4±16.2 53.0±20.9 59.3±21.4 56.3±21.5 
Social functioning 86.2±22.4 93.4±11.3 87.7±17.9 76.7±24.5 73.3±31.3 77.5±27.6 
Role-emotional 80.7±35.7 84.2±30.2 87.7±27.7 62.2±45.2 62.2±45.2 66.7±45.4 
Mental health 82.3±12.5 85.3±10.3 86.5±12.2 73.1±19.3 80.3±15.7 82.1±12.5 
Health transition 2.6±1.2 2±1.1 2.3 ±1.0 2.9±1.4 2.8±1.2 3 ±0.9 
Physical component summary score 39.2±9.8 47.1±6.9*† 46.2±6.2* 36.7±10.4 38.4±11.0 37.0±12.4 
Mental component summary score 54.9±10.4 55.0±7.0 54.9±8.9 49.6±12.5 51.1±10.8 52.4±10.6 
HAD (range 0-21)       
Anxiety  5.2±3.5 3.4±3.2*† 3.9±3.2* 5.9±3.1 6.0±3.5 4.9±3.8 
Depression 3.3±2.8 1.8±1.8 2.2±2.8 4.6±3.3 4.1±2.9 3.5±3.1 
AQLQ: Asthma Quality of Life Questionnaire; SF-36: Short Form-36 Health Survey; HAD: Hospital Anxiety and Depression scale. *p<0.05 score compared with 
baseline; †p<0.05 change between groups significant; ξp<0.05 3x2 ANOVA factor*randomisation. #: statistics performed only on the physical and mental 
component summary scores 
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Figure 3.11 Mean PCS scores at baseline, 6 weeks and 3 months:  
per-protocol analyses (n=31) 













































Figure 3.12 Mean MCS scores at baseline, 6 weeks and 3 months:  
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Figure 3.13 Mean PCS scores at baseline, 6 weeks and 3 months:  
intention-to-treat analyses (n=34)  













































Figure 3.14 Mean MCS scores at baseline, 6 weeks and 3 months:  
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3.3.15 Six minute walk distance 
Table 3.11 displays the 6MWT data at baseline, 6 week and 3 month follow-up using 
both per-protocol and intention-to-treat analyses. In the exercise group, 6MWD 
increased by 35.8±37.3m at 6 weeks (p=0.001) and 33.6±44.7m at 3 months 
(p=0.004) compared to baseline. In the control group, per-protocol analyses showed 
an increase in 6MWD of 22.0±26.6m (p=0.01) at 6 weeks and 31.2±34.9m (p=0.01) 
at 3 months. With intention-to-treat analyses, however, the mean change in the 
control group was not significant at either 6 weeks (6.3±38.3m, p=0.54) or 3 months 
(13.0±45.6m, p=0.29).   
Although the magnitudes of improvement in walk distance were significant from 
baseline in both groups at 6 weeks and 3 months, the differences between the 
exercise and control groups were not significant at either follow-up assessment 
(p>0.05, i.e. 3x2 ANOVAs not significant).   
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HR- pre (bpm) 86±12 89±12 85±13 89±12 96±14 92±10 85±13 92±15 89±11 
HR- peak (bpm) 129±16 131±20 127±20 131±20 133±19 137±18 127±20 127±20 132±21 
%pred HRmax  84 ±11 87 ±12 85±10 87 ±12 88±9 91±10 85±10 85±10 86±12 
SpO2- pre (%) 96±1.5 95.8±0.9 95.5±1.6 95.8±0.9 96.4±0.9 96.1±1.0 95.5±1.6 95.9±1.5 96.1±0.9 
SpO2- end (%) 95.6±2.0 95.0±2.2 93.8±4.7 95.0±2.2 95.3±2.1 95.2±2.7 93.8±4.7 93.7±5.3 94.7±2.8 
Mean± SD. 6MWT: 6 minute walk test; 6MWD: 6 minute walk distance; % pred: percent predicted; RPE: rating of perceived exertion; HR: heart rate; bpm: beats 
per minute; SpO2: arterial oxygen saturation; %pred HRmax: percent predicted maximum heart rate; IQR: interquartile range; * p<0.05 compared with baseline 
measures.  
Percent predicted HRmax calculated from formula 220-age. 
Predicted 6MWDs were calculated using the equation derived in healthy West Australian adults.  
Dyspnoea, chest tightness, leg fatigue and RPE are reported as medians±IQRs. Data in parentheses are ranges. 
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3.3.16  Subject feedback 
Responses to the feedback questionnaire (Appendix E) from subjects randomised to 
the exercise group are given in Table 3.12. The walking component was the most-
liked component of the training (n=16), followed by step-ups (n=14), bike and arm 
ergometry (n=13). Subjects made the following suggestions for changes to the 
training programme: increasing the duration of the classes; including an education 
component; changing the class time for people who worked; incorporating water-
based exercise and increasing the class size. 
Subjects also reported that participation in the exercise training programme:   
• reduced phlegm and nasal symptoms (n=4) 
• improved mental health (n=4) 
• increased energy (n=7) 
• improved physical fitness (n=8) 
• reduced asthma symptoms (n=4) 
• decreased the need for reliever medication, improved tone, balance, body 
posture and sleeping (n=1 for each). 
 




Agreed Unsure Disagreed Strongly 
disagreed 
More confident to 
undertake physical 
activities 
11 (58%) 7 (37%) 1 (5%)   
Improved ability to deal 
with problems caused by 
the lung disease 
7 (37%) 11 (58%) 1 (5%)   
Satisfied with the place the 
classes were held 
12 (63%) 6 (32%)   1 (5%) 
Times of classes suited 12 (63%) 5 (26%) 1 (5%) 1 (5%)  
Length of time of each 
class was right 
13 (68%) 6 (32%)    
Data denote the number of subjects  
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3.3.17  Twelve month follow-up data 
The data collected at 12 months involved a recall of unscheduled medical 
attendances due to worsening of asthma symptoms collected via self-report in the 
format of a telephone interview. Table 3.13 illustrates the health care utilisation of 
the remaining 28 subjects (19 exercise, 9 control) at 12 months. 
 
Table 3.13 Health care utilisation at 12 month follow-up 
 Exercise (n=19) Control (n=9) 
Courses of oral corticosteroids in last 
12 months 
7 (37%) 4 (44%) 
ED presentations in last 12 months 2 (11%) 2 (22%) 
Hospital admissions in last 12 months 2 (11%) 2 (22%) 
Nil RP attendances 16 (84%) 7 (78%) 
RP attendances (once) 3 (16%) 0 (0%) 
RP attendances (2 times) 0 (0%) 2 (22%) 
Nil GP attendances 10 (53%) 5 (56%) 
GP attendances (1-3 times) 8 (42%) 3 (33%) 
GP attendances (4 or more times) 1 (5%) 1 (11%) 
ED: Emergency Department; RP: Respiratory Physician; GP: General Practitioner; n: 
number; %: percent 
 





This study has demonstrated that a 6 week supervised exercise training programme 
significantly improves HRQOL and anxiety scores (per-protocol analyses) in 
individuals with FAOA. Though improvements in other outcomes measured 
(functional exercise capacity, generic QOL, asthma control and depression scores) 
were evident in the exercise group immediately post-intervention, a non-significant 
treatment effect was observed for each of these outcomes in relation to the control 
group when 3 month follow-up data were included in the analyses.   
Compared with previous studies that have investigated the effects of land-based 
exercise training in asthma, this study has a number of novel aspects and strengths: 
i) the study cohort comprised middle-aged and older adults with FAOA - a 
demographic not previously examined in the literature; 
ii) the study was rigorously designed as a RCT with an exercise and control 
group and the inclusion of a 3 week run-in period that ensured all subjects 
had stable asthma prior to randomisation and collection of baseline data; 
iii) familiarisation with the 6MWT was ensured at baseline and on all subsequent 
assessments with the aim of confirming that changes in 6MWD were not due 
to a learning effect for the test; and 
iv) the study included assessments of HRQOL, QOL and mood state, outcomes 
that have been lacking in published RCTs of exercise training in asthma. 
The following sections of this chapter discuss the major findings of the study. 
 
3.4.2 Baseline characteristics  
3.4.2.1 Subject demographics 
Thirty-four subjects participated in this study, all of whom had moderate to severe 
asthma and a degree of irreversibility in their lung function. The lung function data 
for the group demonstrated moderate airflow limitation (FEV1 ≤60%) with evidence 
of lung hyperinflation and air trapping (RV/TLC 125% and FRC 159%) but normal 
gas transfer (DLCO/VA 100%). There was a slight preponderance of females in the 
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study (19 females, versus 15 males), reflecting the gender difference noted in 
population studies of adults with asthma carried out in Australia (18). 
Fifty-six per cent of the cohort reported a diagnosis of atopic asthma that was 
identified by a positive skin prick test, a raised concentration in serum for specific 
immunoglobin E or a history of typical rhino-conjunctivitis. Although this 
information was obtained via self-report, this proportion is similar to previous studies 
(284, 285).    
Subjects randomised to the exercise and control groups were similar in all 
demographic and anthropometric measures such as age, BMI, gender and in the 
severity of lung function impairment. Both groups had well preserved peripheral 
muscle strength and a high level of functional exercise capacity with baseline 
6MWDs close (91%) to predicted 6MWDs derived from studies in healthy middle-
aged and elderly West Australians (281). More subjects in the exercise group (n=5, 
26%) were engaged in full-time work than in the control group (n=1, 7%).    
 
3.4.2.2 Body mass index 
The mean BMI for the subject cohort was 27.8±6.2. A BMI within the range of 20-
24.9 is considered normal, a BMI 25-29.9 is considered overweight, and a BMI over 
30 is equivalent to a classification of obesity, which is 20% above the upper limit of 
desirable weight (286). However, abdominal circumference is generally a better 
measure of obesity than BMI due to differences in fat distribution between men and 
women. Measurement of BMI also fails to take into consideration individuals with a 
high component of muscle mass (287). 
Although recruitment to this study did not target individuals with a high BMI , 65% 
of the subjects were classified overweight (n=13) or obese (n=9). This percentage is 
reflective of population statistics for obesity among middle-aged and older adults in 
Australia. In 2004 - 2005, more than half (54%) of adults aged >18 years were 
overweight or obese and, more specifically, in adults aged 55-64 years the proportion 
of males and females classified as overweight was 72% and 58% respectively (288).  
Guerra et al (289), in a nested case-control study from the longitudinal cohort of the 
Tuscan Epidemiologic Study of Airways Obstructive Diseases, showed that being 
overweight or obese significantly increases the risk of developing asthma in females 
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(adjusted odds ratio [OR], 3.45; 95% CI, 2.10 to 5.67) but not males (adjusted OR, 
1.69; 95% CI 0.88 to 3.27). In this study, controls comprised 1,475 subjects who 
reported no diagnoses of respiratory disease and respiratory symptoms at enrolment 
and during the study period. A large prospective study in the USA showed that an 
increased BMI was significantly associated with the risk of ‘incident’ asthma over a 
10 year period, with the strength of the association being similar in males and 
females (290). ‘Incident’ asthma was described as a new diagnosis of asthma, or the 
report of previously diagnosed asthma (i.e. diagnosed in childhood) that had 
reactivated. Because this information was gathered by self-report, it is uncertain 
whether these individuals had a diagnosis of asthma or reported respiratory 
symptoms that were misdiagnosed as asthma.    
Similar findings to these have been observed in other population studies in the USA 
(291) and Sweden (287, 292).  Further, the relationship between obesity and asthma 
in one study was almost exclusively confined to subjects with non-atopic rather than 
atopic asthma (287). 
Several studies have demonstrated a direct association between increasing BMI and 
asthma morbidity as measured by increased health care utilisation, the frequency of 
exacerbations, persistent asthma symptoms and the use of inhaled corticosteroids 
(154, 293, 294). A higher BMI has also been reported to be associated with worse 
asthma control and a greater impairment in QOL (295).  Conversely, asthma severity 
as defined by the level of bronchial hyper-reactivity (293, 296), airflow obstruction 
(297) or using the Global Initiative for Asthma (GINA) guidelines (295) does not 
appear to be associated with increasing BMI (after controlling for age and gender).   
Potential mechanisms behind the link between obesity and asthma are multifactorial 
and could relate to a sedentary lifestyle, diet, histological changes in the lung, or the 
effect of obesity on immune function (290).  It remains unclear whether obesity is a 
result of asthma rather than the cause of asthma. Regardless, there appears to be a 
direct relationship between severity of symptoms and health care utilisation and 
levels of obesity in adults with asthma. This observation is relevant to the present 
study which targeted adults with moderate to severe disease and evaluated the effects 
of an exercise intervention on measures of asthma morbidity.   
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3.4.2.3 Self-management  
Asthma Action Plans 
The National Asthma Council of Australia recommends that all individuals with 
asthma should have a written individualised plan of how to treat deteriorating 
asthma.  This should be provided in conjunction with self-management education 
and training on how to adjust medications (2). A Cochrane review showed that 
asthma self-management education programmes coupled with regular reviews by a 
health practitioner was associated with a reduction in hospital admissions, ED 
presentations, unscheduled visits to the GP, a reduction in the number of days off 
work and improved quality of life. Measures of lung function were unchanged (298). 
The provision of an asthma action plan and self-management eduction has also been 
shown to decrease the risk of asthma mortality by 70% (299).   
Forty-four per cent of the subject cohort in this study stated that they had been 
provided with an asthma action plan. This is higher than data from an Australia-wide 
study carried out in 2001 that reported between 12.9% and 16.4% adults with asthma 
had a written asthma action plan (25).  Individuals with more severe asthma and 
those with recent asthma symptoms were more likely to have an action plan, 
although there was some geographical variation in the data with a lower prevalence 
reported from WA than some other States (18). Other cross-sectional 
epidemiological studies have reported the ownership of an asthma action plan to be 
13.3% in a Melbourne study (300), 30% in a South Australian cohort (104), and 
34.7% in a New South Wales cohort (18). 
Peak Flow Meter Ownership 
The majority of subjects recruited to this study (n=24, 76%) owned a peak flow 
meter, however only eight subjects used their peak flow meter at least once a week. 
Studies carried out elsewhere in Australia report that between 10% and 15% of adults 
with asthma owned a peak flow meter, however only a minority (<1%) of individuals 
used their peak flow meter on most days (104, 300). 
Habitual exercise 
More than half of the study group (56%) reported walking at a moderate pace for 30 
minutes, or an equivalent form of exercise on three or more days a week. This 
proportion is higher than the WA data collected as part of the National Health Survey 
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(2004-2005). West Australian statistics showed that 52% of adults aged 45-64 years 
reported walking for exercise with 81% of these engaging in this activity on more 
than seven occasions during a 2 week period. The findings were similar in those aged 
over 65 years (i.e. 50% walked for exercise with 76% reporting walking on more 
than seven occasions during a 2 week period) (301). Of all individuals (all age 
groups) surveyed in the 2004-2005 National Health Survey, West Australians 
reported a slightly higher participation rate (51%) for walking compared to the 
national average (49%) (302).  
The level of habitual exercise was higher than expected in the study cohort, and this 
may have been due to the attractiveness of this type of study to individuals with a 
positive attitude towards exercise. It is also possible that since this information was 
obtained through self-report (303), the accuracy of the data may be questionable with 
a bias towards overestimation of physical activity levels (303). 
 
3.4.2.4 Peripheral muscle strength 
The subject cohort showed well preserved peripheral muscle strength at baseline 
compared to predicted values based on age and gender (268, 270). Peripheral muscle 
strength did not change in either group during the course of the study.   
Skeletal muscle dysfunction is recognised to contribute to exercise limitation in 
COPD (222) and in subjects with COPD, the presence of muscle weakness has been 
associated with a greater response to exercise training than in subjects with preserved 
muscle strength (304). In the early stages of the design of the present study, it was 
postulated that individuals with FAOA might show signs of peripheral muscle 
weakness based on long-term oral or inhaled corticosteroid usage. In the year 
preceding the commencement of this study, 42% of the exercise group and 47% of 
the control group required treatment with oral corticosteroids to treat at least one 
asthma exacerbation and two subjects (one control) were receiving maintenance oral 
corticosteroids.   
Further review of the literature suggests that long-term corticosteroid usage may not 
necessarily be associated with peripheral muscle weakness.  One study examining 
the quadriceps femoris muscles of patients with bronchial asthma on long-term 
treatment with prednisolone (mean daily dose 17.3mg) did not find clinical 
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symptoms of myopathy, significant muscle weakness or significant changes in the 
muscle histology. In the quadriceps muscles of these subjects, however, the glycogen 
concentration and activity of main regulatory enzymes of glycogen metabolism were 
modified compared with controls. The significance of these changes are unknown 
(305).   
Inhaled corticosteroid usage is also not linked to muscle myopathy in asthmatics, 
though little research has been reported in this area. The available studies appear to 
have focused on the associations between corticosteroid use and loss of bone mineral 
density and risk of fractures, two consequences which have been associated with 
long-term oral corticosteroid use (306, 307), but were not observed in individuals 
prescribed inhaled corticosteroids (308).  
 
3.4.2.5 Six minute walk distance 
Familiarisation  
In this study, 6MWD increased from 523.5±99.3m to 548.6±101.4m (p<0.0001) on 
the second 6MWT at baseline, which translated to a 5.2±7.0% improvement.  There 
are no reported data on the effects of test repetition on 6MWD in subjects with 
asthma. Six minute walk distance is influenced by the process of conducting repeat 
tests on different days (daily variability) (309) and is dependent on the testing 
protocol (178) (i.e. inclusion of encouragement) (179). Specifically, the magnitude of 
increase in 6MWD with test repetition at baseline assessment is likely to be protocol 
dependent. 
Two studies have used the identical test protocol to that used in this study and 
reported the magnitude of the increase in 6MWD with test repetition (281, 310). In 
healthy middle-aged and elderly subjects (n=109), 6MWD increased by 20±31m 
(3±5%) in males and 21±24m (4±4%) in females (both p<0.001) on the second 
6MWT (281). The other study tested 121 individuals with stable COPD referred for 
pulmonary rehabilitation (310). Subjects in this study were stratified into three 
groups according to their 6MWD (best of two tests expressed as %predicted 6MWD, 
i.e. <60%, 60-80% and >80% pred 6MWD). The increase in 6MWD in the three 
groups was 28±31m, 37±31m and 44±29m respectively which translates into 
percentage increases in 6MWD of 12%, 9% and 9% (310). Thus in the COPD cohort 
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the effect of test repetition on 6MWD was greater than in the healthy subjects and 
this may be explained by the subjects with COPD experiencing anxiety related to 
dyspnoea which is reduced with habituation on the second test. Using the same 
6MWT protocol the increase in 6MWD with test repetition in the FAOA cohort was 
greater than in the healthy subjects but less than observed in the COPD cohort. This 
might be anticipated given the FAOA cohort reported some dyspnoea but it was of a 
lower intensity to that observed in the COPD cohort (310).   
Consistent with many other studies, subjects in this study undertook a single practise 
6MWT as there is evidence that when a highly standardised 6MWT protocol is used 
and repeat testing performed on the same day, then any increases in 6MWD with a 
second practise walk are small (173, 179, 264, 311, 312). 
Best distance 
At the baseline assessment, subjects demonstrated a high level of functional exercise 
capacity with 6MWD close to predicted values (88±12%) (281). A 6MWD greater 
than 82% of predicted has been suggested to represent a normal 6MWD (312). The 
finding of a high level of functional exercise capacity at baseline was unexpected 
based on the data obtained in the pilot study. However, exercise capacity as 
measured by a maximal test such as a laboratory-based cycle or treadmill test may 
not have been within the normal range in the study cohort. One study demonstrated a 
noticeable difference in maximal exercise capacity, measured through VO2peak 
between normal subjects and patients who had mild heart failure but little variation in 
the distances covered in the 6MWT in the two groups (313).  
The baseline 6MWD recorded in the FAOA subjects (548±100m) is higher than has 
been reported in COPD subjects in studies which have used that same 6MWT 
protocol (181, 314). In subjects with COPD, Hill et al (311) reported baseline 
6MWDs of 446±112m in a group of 16 subjects (11 males, mean FEV1 37±12%), 
and 508±88m in a group of 17 subjects (11 males, mean FEV1 37±12%) prior to 
undertaking an intervention of high-intensity inspiratory muscle training or sham 
inspiratory muscle training respectively. The principal investigator in this thesis 
previously reported a study of 20 COPD subjects (15 males, mean FEV1 29±8%) in 
whom 6MWD was 475±88m (181). Both of these studies report higher baseline 
6MWD than many published studies of individuals with COPD with similar levels of 
Chapter 3: Benefits of exercise training in FAOA 
 
 -112- 
severity, which may in part be explained by the 6MWT protocol used that is aimed at 
maximising test performance (179, 187, 207, 309, 315).   
Cardiorespiratory responses 
The RPE (score of 13) at the end of the 6MWT indicated that the subjects achieved a 
submaximal but reasonable intensity of exercise. In healthy subjects, an RPE of 16-
18 is generally associated with a maximal cardiovascular response with ratings of 
between 12-14 being reported to be at the level of the anaerobic threshold (230).    
The peak HR reached by the subjects during their baseline 6MWT was 84±11% of 
predicted. This is slightly higher than attained by subjects with moderate to severe 
COPD using the same 6MWT protocol (81.6±11.4%) (181), but comparable to those 
recorded in healthy middle-aged and elderly subjects (281). One study in 12 healthy 
(six males) subjects aged 60-70 years who performed a 6MWT and a maximal 
laboratory-based treadmill test also showed comparable peak HR’s  to that recorded 
in the current study, however comprised an older subject cohort, and utilised a 
different 6MWT protocol. In this study, the intensity of the 6MWT corresponded to 
79.6±4.5% of the VO2max measured in the treadmill test (316). The authors concluded 
that in healthy older individuals the 6MWT represented submaximal exercise, but the 
intensity at which the test was performed exceeded the ventilatory threshold.   
Despite the subjects with FAOA reaching a high peak HR at the end of the 6MWT, 
the intensity of dyspnoea was lower than reported in some studies of subjects with 
moderate to severe COPD. Dyspnoea scores (3 on the Borg scale) at the end of the 
6MWT were equivalent to a mild to moderate intensity, compared to studies in 
COPD subjects performed by the principal investigator and other researchers using 
the identical 6MWT protocol, that reported dyspnoea intensities corresponding to 
severe to very severe dyspnoea (181, 191). 
The presence of dyspnoea can provide an important warning to an individual with 
asthma that there may be deterioration in their lung function (317). It has been shown 
that asthmatic subjects who frequently develop acute airflow obstruction acquire a 
degree of tolerance that reduces the perception of dyspnoea.  Asthmatics with long-
standing airflow obstruction also tend to be report less dyspnoea for any given 
reduction in FEV1 than asthmatics with complete reversibility in FEV1 (318). It is 
Chapter 3: Benefits of exercise training in FAOA 
 
 -113- 
possible that the subject cohort in the present study may have included a large 
number of individuals with a blunted perception of dyspnoea. 
Chest tightness was not a significant symptom for any of the subjects in the 6MWT 
and the well preserved SpO2 at the end of the 6MWT was anticipated given that gas 
transfer was within normal limits in all subjects (319). 
 
3.4.2.6 Asthma control 
Fourteen subjects in the exercise group (74%) and eight in the control group (53%) 
had an ACQ score above 1.5 at baseline which is indicative of poorly controlled 
asthma (56). The avoidance of environmental triggers and an overall level of good 
asthma control are considered prerequisites for assisting subjects to achieve a good 
tolerance to exercise (1).     
The international guidelines for complete asthma control recommend that patients 
should have no symptoms, no activity limitation, no rescue bronchodilator therapy 
and normal airway calibre (1). The goal of achieving normal airway calibre is not 
realistic in asthmatics that have permanent lung function irreversibility. Poor asthma 
control has been reported in up to 70-95% of asthmatics in Western Europe and the 
Asia-Pacific region (1).   
Levels of asthma control and patient adherence to asthma treatments have been 
shown to decline with age and increasing severity of asthma. One study of 5,107 
females with physician diagnosed asthma (mean age 63±7 years), found that 
adherence to medication guidelines was 57% in those with mild persistent asthma, 
55% if moderate persistent asthma was present but only 32% for those with severe 
persistent asthma (320). It has been reported that as many as 50% of asthmatics do 
not comply regularly with their medication regimen and that poor compliance 
contributes to a reduction in HRQOL (321).    
 
3.4.2.7 Quality of life 
The study cohort demonstrated impaired QOL compared to age and gender matched 
Australian and WA normative data. In particular, there were impairments in the SF-
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36 domains of physical functioning, role-physical, general health and role-emotional. 
The PCS score was significantly lower when compared to Australian norms.    
Worse QOL and HRQOL have been identified in subjects with asthma compared to 
healthy subjects in several studies (18, 68, 322), as has a trend for those with 
moderate to severe persistent asthma to have significantly worse QOL compared to 
individuals with mild asthma (285). Significant impairments in QOL were reported 
for all domains of the SF-36 in a community sample of 293 adults with asthma when 
compared to the Australian norms, with the impairments being more pronounced in 
the domains relating to physical health (101) consistent with the findings in the 
present study.   
 
3.4.2.8 Relationships between baseline measures 
This study investigated relationships between baseline measures and found that the 
magnitude of air trapping or pulmonary hyperinflation (RV/TLC) was the strongest 
correlate (r=-0.66) of functional exercise capacity (i.e. 6MWD). Post-bronchodilator 
FEV1, a measure of large airway calibre, also had a positive (but weaker) correlation 
with 6MWD (r=0.34). This differs from one study in mild to moderate asthmatics, 
which showed no association between resting measurements of FEV1 measured pre- 
and post bronchodilator and cardiovascular fitness (i.e. VO2max, maximum oxygen 
pulse or anaerobic threshold) measured by a progressive cycle ergometer test. In this 
study all subjects had well controlled asthma that was less severe than subjects in the 
present study. The authors of this study concluded that the lack of any correlation 
between airway obstruction and measures of physical fitness in the asthmatic 
subjects suggested that factors other than the severity of asthma were responsible for 
lack of fitness (323). 
A moderately strong and significant negative correlation (r=-0.69) was observed 
between asthma control and total score on the AQLQ in the current study (a higher 
ACQ score indicates poorer control, whereas a higher AQLQ score indicates better 
QOL). The magnitude of this relationship is similar to that reported in other studies 
of asthmatic subjects (84, 324).  Two other studies (52, 106) have reported 
associations between better asthma control and QOL, however in these studies 
asthma control was not measured using the ACQ. Specifically, asthma control was 
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defined using the GINA guidelines in the study by Bateman et al (106), while the 
Asthma Therapy Assessment Questionnaire was used in the study by Vollmer et al 
(52). 
There was no relationship between scores on the AQLQ and FEV1 (r=0.19), 
consistent with the findings of other studies (45, 68, 325). Ehrs et al (325) found a 
relationship between lower QOL and high usage of inhaled corticosteroids and 
suggested that corticosteroids may be more potent at normalising lung function than 
improving symptoms and QOL. Moy et al (45) also found no significant correlation 
between FEV1 and HRQOL in adults with moderate to severe asthma and that the 
strength of the association between symptom intensity and HRQOL was lower in this 
cohort when compared to subjects with mild asthma. Weaker associations between 
HRQOL and physiological measures such as FEV1 may suggest that psychosocial 
factors such as coping styles, as well as socioeconomic factors such as education or 
employment status can also influence QOL (45). Another theory is that the 
perception of airway narrowing varies greatly between patients with asthma (318), 
and this may have an influence on HRQOL (68).  
 
3.4.3 Efficacy of the intervention 
3.4.3.1 Lung function and baseline demographics  
There were no significant changes in any measures of lung function at the 6 week 
follow-up compared to baseline. This is in agreement with other studies of exercise 
training which reported no changes in lung function (200, 207, 277, 326, 327) or 
bronchial reactivity (206) following an exercise intervention. It has been suggested 
any improvements in lung function after exercise training would more likely be 
attributed to improved compliance and the optimisation of asthma treatment as a 
result of increased medical supervision provided during the intervention (202). 
No significant changes in BMI were found at the 6 week or 3 month follow-up in 
either group. Although regular exercise can contribute to weight loss, the benefits 
from short-term exercise programmes (less than 6 months duration) are minimal 
unless accompanied by strict dietary control (328). Subjects in the current study were 
instructed not to change their dietary habits throughout the intervention period to 
avoid any confounding influences on the study findings. 
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 3.4.3.2 Asthma control  
The present study did not show any statistically significant improvements in asthma 
control following exercise training. Seven subjects did, however, exhibit a clinically 
significant improvement in their ACQ scores immediately post-intervention, six of 
whom were randomised to the exercise group. The question remains as to which 
components of asthma control could be improved in response to an exercise 
intervention?  This study found no change in FEV1 following exercise training, and 
since all subjects recruited to this study had a degree of fixed obstruction this finding 
was expected. The other six items on the ACQ pertain to night waking, activity 
limitation, morning symptoms, dyspnoea, wheeze and the frequency of rescue 
medication usage. Of these, the components of asthma control most likely to change 
secondary to an exercise intervention are activity limitation and dyspnoea. It is also 
possible that any overall changes in asthma control in the study participants may 
have been a result of improved adherence to medications, as this in turn is a 
component of asthma control (18, 52).   
There is limited evidence which shows regular exercise is associated with fewer 
exacerbations, a decreased need for asthma medications and less absenteeism from 
school or work, but overall the relationship between exercise and asthma control 
remains unclear (1).  In a study by Garfinkel et al (158) more than two thirds of the 
participants held a belief that if they improved their physical fitness this would result 
in improved asthma control.   
 
3.4.3.3 Quality of life, anxiety and depression 
Both immediately post-intervention and at 3 month follow-up, statistically and 
clinically significant improvements were observed in the total score, symptoms and 
activity domains of the AQLQ in the exercise group compared to the control group.  
A significant improvement in anxiety was also observed with per-protocol analyses 
over the course of the study. These findings illustrate the positive psychological 
benefits of exercise training. The Cochrane review of exercise training in asthma 
consisted of 13 trials, however none of these trials included measures of QOL or 
anxiety and depression. The present study is the first to examine the effects of 
exercise training on QOL using both generic and disease-specific QOL measures (9).  
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An intervention programme, such as that conducted in this study can, by nature of 
the supervision and group interaction, bring about a positive change in the subject’s 
emotional well-being.   
Signficant improvements in QOL were reported by Foglio et al (207), in a mixed 
cohort of asthmatics and COPD subjects, following a 6 week exercise training 
programme. These authors showed significant improvements in the activity and 
impact scores on the St George’s Respiratory Questionnaire, however no changes in 
symptom scores were found. These improvements were maintained at the long-term 
follow-up (12 months) in the asthmatic cohort. A major limitation of this study, 
however, was the lack of a control group.  
One other study of subjects with asthma reported improvements in QOL following 
rehabilitation. In a RCT with a crossover design conducted by Cambach et al (205), 
43 subjects with COPD (FEV1 59% predicted) and 23 with asthma (FEV1 86% 
predicted) who received a 3 month pulmonary rehabilitation programme were 
compared with a control group. Significant improvements in QOL were reported 
using the Chronic Respiratory Disease Questionnaire immediately following the 
rehabilitation programme, that were still present when subjects were assessed 3 
months later. 
 
3.4.3.4 Six minute walk distance 
There were no statistically significant improvements in 6MWD in the exercise group 
compared to the control group over the course of the study. Baseline 6MWD in the 
exercise group was 569±88m and for the control group was 555±101m.  These 
distances increased to 605±89m and 528±114m respectively immediately after the 
intervention period (intention-to-treat analysis). With the per-protocol analysis these 
distances were 605±98m and 577±84m respectively. This change in 6MWD 
(35.8±37.3m) was significant compared to baseline in the exercise group, however 
the difference between the groups was not significant. The threshold for the minimal 
clinical important difference (MCID) in 6MWD has not been determined for subjects 
with asthma.  
In subjects with COPD, the first study to determine the MCID for the 6MWD 
following pulmonary rehabilitation concluded that a change of 54m was perceived by 
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subjects to be clinically important (194). However the change in 6MWD in many 
RCTs of pulmonary rehabilitation in this population fails to reach this threshold 
value (6). A recent study calculated that a change of about 35m in 6MWD, 
represented an important effect following rehabilitation for patients with moderate to 
severe COPD (193). Data were used from nine trials which enrolled COPD patients 
with a wide spectrum of severity to calculate this value of 35m.  Guyatt et al (329) 
estimated a similar MCID with an increase of 30m or more in 6MWD being 
associated with an important improvement in exertional dyspnoea.  
In subjects with asthma, there are only three studies that have used 6MWD to 
measure outcomes following an intervention that included exercise training. 
Improvements in 6MWD have been reported following exercise training both 
immediately post-intervention and at long-term follow-up in individuals with asthma 
(205, 207, 330). In the study by Foglio et al (207) which consisted of 35 subjects 
with asthma and 26 subjects diagnosed with COPD, 6MWD significantly improved 
immediately following an 8 to 10 week exercise programme, an improvement that 
was partially lost at 1 year follow-up in the asthmatic cohort (6MWD=471±61m at 
baseline, 508±56m post-intervention and 485±60m at 1 year follow-up, p<0.05). A 
major limitation of this study however was the lack of a control group.  
In the RCT with a crossover design reported by Cambach et al (205), an 
improvement of 55m occurred in 6MWD in the asthmatic subjects following the 3 
month pulmonary rehabilitation programme. The increase in 6MWD following 
rehabilitation was significant when compared to the control period which comprised 
usual care only. Emtner et al (330) used the 12 minute walk test in a study of adults 
with mild to moderate asthma who underwent an intensive 10 week programme of 
exercise training and education that commenced with a 2 week inpatient period. 
Subjects were followed up for 3 years. The authors reported an improvement in 
12MWD following the intervention and 12MWD remained above baseline when 
assessed at the 3 year follow-up. 
In the present study it is feasible that no significant changes were observed in 
6MWD post-intervention between the exercise group and control group because the 
intervention was not effective in improving functional exercise capacity in this 
cohort.  However, because signficant (p<0.05) improvements in 6MWD were seen 
immediately post-intervention in the exercise group, but not in the control group, it is 
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more likely that the lack of any intervention between the 6 week and 3 month follow-
up weakened the strength of the treatment effect calculated in the 3x2 ANOVA.  
Additionally the positive benefits observed in the activity and symptoms domain of 
the AQLQ in the exercise group strengthens the likelihood that the exercise training 
was beneficial in this group, at least in the short-term.   
Unexpectedly, a high 6MWD was measured at baseline in this FAOA cohort. This 
was not expected based on the small pilot study carried out and reported earlier in 
this chapter. The high baseline 6MWD may have limited the responsiveness of the 
6MWT to detect a meaningful change in functional exercise capacity on further 
testing due to mechanical factors that limit the ability to increase stride length (331). 
In the current study, the 6MWT was used to measure functional exercise capacity for 
several reasons. The following section discusses the rationale for choosing the 
6MWT, and other walking tests that were considered as outcome measures. 
The exercise intervention involved a large component of ground-based walking 
training. This is because walking is a very functional form of exercising, often 
avoided by people who are breathless, it is simple to undertake as it does not require 
any equipment and thus could be carried out long-term by the subjects. A further 
reason for selecting the 6MWT was to enable a comparison to be made of any 
changes in 6MWD in the FAOA cohort with the magnitude of change reported 
following exercise training in subjects with COPD. Lastly, the intent of this study 
was to develop an exercise programme that could be implemented in other centres 
within metropolitan, regional and rural WA and thus an exercise test that required no 
sophisticated equipment was necessary.  
It is possible that an alternative field walking test may have been a more responsive 
measure in this subject population. Tests to consider include the 12MWT, the 
incremental shuttle walking test (ISWT) and the modified shuttle walking test. To 
date, no studies have compared the responsiveness of these tests with that of the 
6MWT in subjects with FAOA. The 12MWT is seldom used in the current literature, 
due in part to the time consuming nature of the test. However, this test may have 
provided an indication of exercise endurance capacity and as such may have shown a 
change in the exercise group given that the distance walked in 20 minutes during the 
programme increased by 18±10%.   
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The ISWT has been tested in healthy older individuals (332). All of the subjects 
stopped the ISWT due to mobility limitations, suggesting that the inability to 
increase gait speed may have also limited the responsiveness of this test in the FAOA 
subjects such as occurred in the 6MWT. The latter stages of the modified ISWT 
(333) allow the subject to run and hence this test does not rely on the ability to 
increase stride length or walking cadence to show an improvement. A decision was 
made, however, not to use a test that involved running in this FAOA cohort due to 
safety reasons including the possibility of causing a musculoskeletal injury. 
In the COPD cohort, there is some evidence that the endurance shuttle walking test 
(ESWT) may be a more responsive measure to change following pulmonary 
rehabilitation than either the 6MWT or the ISWT (196, 334). However, 
disadvantages of the ESWT include the necessity of a prior ISWT and the difficulties 
achieving appropriate test duration at baseline to allow improvements following an 
intervention to be detected within the 20 minute time limit allowed for the ESWT. 
Further, the ESWT has not been studied in the FAOA population. 
Finally, laboratory-based tests such as a walking test using a treadmill may have 
been more responsive than the 6MWT as they allow workload to be increased by 
adding an incline and thus are not solely reliant on ability to change stride length and 
cadence.  Similarly, performance on a maximal bike test is not subject to the same 
limitations as field walking tests. However, for the reasons stated earlier, these tests 
were not considered as outcome measures. 
 
3.4.3.5  Comparison of study results to mild and moderate chronic obstructive 
pulmonary disease 
It could be proposed that literature and outcomes from exercise training in 
individuals who have mild and moderate COPD may be more appropriate to consider 
in relation to this study population who had a component of fixed obstruction, as 
opposed to studies of asthmatics with fully reversible disease. Although there is a 
large body of literature investigating the effects of exercise training in moderate to 
severe COPD, the number of studies in mild to moderate COPD are much less 
numerous and have shown some mixed results. One study has reported no effect on 
exercise tolerance, dyspnoea or QOL after a 2 month exercise programme (335), 
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another showed improved exercise tolerance but no difference in dyspnoea after an 
18 month programme (336) and another showed improvements in exercise tolerance 
after a 3 month exercise programme (337).    
A systematic review of exercise training for adults with mild to moderate COPD 
included five RCTs (215). These studies included only subjects with an FEV1 
between 47-77% predicted. Four of the studies reported an improvement in exercise 
tolerance following training. A variety of measures were used comprising the 
6MWT, maximal cycle ergometry test and an endurance walking test. The one study 
that failed to show an improvement had a low dose of supervised training (two 
sessions a week for 8 weeks) (335).  The review showed no clear effect on dyspnoea 
or QOL, which in part may have been due to the relatively low numbers of subjects 
in these studies (215). The authors concluded that exercise training improves 
exercise tolerance in mild to moderate COPD. Further, the review did not provide 
evidence of any consistent effect could be found on dyspnoea or QOL, nor could 
exercise training be shown to significantly affect long-term disease progression 
(215).   
One other study (338) stratified COPD subjects based on their impairment in FEV1 
and compared outcomes following a 12 week exercise programme. Subjects with 
mild disease (FEV1 >49% predicted) demonstrated a significant increase in 6MWD, 
endurance treadmill time and a reduction in dyspnoea assessed using the Chronic 
Respiratory Disease Questionnaire. The magnitude of change in these outcome 
variables was not significantly different from those observed in subjects with 
moderate or severe disease with the exception of treadmill endurance time which did 
not increase in those with very severe disease. Limitations of this study were the lack 
of a control group and the lack of a practice 6MWT at the baseline assessment. 
Patients in the early stages of COPD have been described as not recognising the 
presence of their disease and not considering the associated disability to be sufficient 
to necessitate rehabilitation, and this may explain why QOL and dyspnoea do not 
appear to improve in this cohort  to the same extent as seen in individuals with more 
severe COPD (225).   
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3.4.3.6 Feedback from the exercise training programme 
The feedback from the subjects who participated in the exercise training programme 
was positive, and highlighted that participation in the programme increased the 
confidence of participants to undertake physical activity. The majority of the subjects 
felt their ability to deal with problems caused by their asthma was improved, thus 
indicating an effect of the programme on self-management despite no asthma 
education being provided during the training sessions. 
 Similar benefits have been reported by Emtner et al (330) following a 10 week 
programme which incorporated education and physical training in adults with mild 
and moderate asthma (FEV1 >75% post bronchodilator).  Following the exercise 
component of the programme, all 21 subjects interviewed retrospectively as part of a 
study on long-term follow-up indicated that the training improved their ability to 
exercise to a maximal level. In addition, 19 subjects felt they had an improvement in 
their asthma status, 13 claimed to have benefited from the sense of security from 
exercising at a hospital, and 12 of the subjects believed that they had benefited from 
the use of pre-medication and a long warm-up in conjunction with the exercise. 
 
3.4.3.7 Health care utilisation and 12 month follow-up data 
Seven of the 34 subjects (20.5%) had visited an ED because of their asthma in the 12 
months prior to the study and of these five had been hospitalised. The present subject 
cohort reported a high level of utilisation of medical services for their asthma prior to 
study entry in comparison to that reported in other studies of asthmatic populations 
within Australia. A cross-sectional study carried out in Melbourne found 2% of the 
asthmatics interviewed had visited the ED because of their asthma in the preceding 
year, 28% had seen their GP and 2.3% had visited a specialist (300). In a random 
survey of a population with self-reported asthma conducted in South Australia in 
1997 (over 3,000 interviews carried out), approximately 5% of individuals reported a 
previous hospitalisation (not confined to the preceding year) (104).   
Risk factors for visits to the ED reported in asthmatics include the suboptimal use of 
preventative medication (61), the absence of a predetermined crisis plan or asthma 
action plan, previous visits to an ED and inadequate use of prophylactic medication 
during an exacerbation (339). 
Chapter 3: Benefits of exercise training in FAOA 
 
 -123- 
In a study of inner city minority populations, in which a prospective cohort of 198 
individuals was interviewed over a period of 1 year, patients who were followed by 
an asthma specialist were significantly more likely to present to an ED or have been 
hospitalized during the 6 month follow-up period (p=0.002).  Care of a specialist was 
associated with increased resource utilization and probably reflected the fact that 
sicker patients were more likely to be referred to specialists, as opposed to indicating 
differences in asthma management (340). 
One of the secondary objectives of the current study was to assess health care 
utilisation at 12 months following cessation of the intervention period. However as 
this was a secondary objective the study was not powered for this variable.  
In the current study, there was a significant attrition at 12 months and this was 
greater in the control group (20% versus 5%) and thus limited any opportunities for 
comparison between the groups for these data.  
Although exercise training in COPD patients has been associated with a reduction in 
health care utilisation (7, 341), this has not been studied in subjects with FAOA 
(207). One study in individuals with mild to moderate asthma (post-bronchodilator 
FEV1 >75%) reported that the number of ED visits decreased from 28 episodes in the 
year before participation in a 10 week pulmonary rehabilitation programme 
(exercise, education and physiotherapy) to 15 episodes during the following year 
(330). However this study lacked a control group for comparison. 
Previous studies have shown recall for hospital care and visits to respiratory 
specialists are fairly reliable, but may be unreliable for other types of health care 
utilisation, such as visits to the GP (342). Because data on health care utilisation are 
often based on self-report, it is possible that there may be recall bias, with those who 
report poorer asthma control (i.e. in response to the Asthma Therapy Assessment 
Questionnaire) also more likely to recall their health care utilisation history than 
someone who has better control over their asthma (52).   
 
3.4.4 Sample size issues and statistical power 
Forty subjects were initially recruited and randomised for the study. Based on power 
calculations it was anticipated this number would have been of sufficient size to 
detect a significant change in the primary outcome measures as the calculations prior 
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to the study showed that a sample size of 32 subjects was required to detect a 
clinically significant change (0.5 points per item) in the activity domain of the 
AQLQ and a 54m change in 6MWD between groups with 80% power (α = 0.05) (66, 
69, 194, 207). 
Only 20 subjects remained in the exercise group and 15 in the control group at the 
baseline assessment. This reduced to 19 subjects (95%) in the exercise group and 15 
in the control group at 6 weeks (100%). Two subjects in the control group withdrew 
prior to the 3 month assessment, and at 12 months, only nine of the control group 
subjects (60%) could be contacted. This level of attrition seems reasonable in 
comparison with the few published RCTs of exercise training in adults with asthma. 
For example, the attrition rate in the crossover study by Cambach et al (205) was 
33% and 20% in the two subject groups.  Although there was no attrition in the study 
by Cochrane and Clark (200), (18 subjects in the exercise group, 18 in the control), 
over the course of this study six subjects in the exercise group (33%), and three of 
the control subjects (17%) had an alteration to their asthma medication - an outcome 
which would have resulted in these subjects being included in only intention-to-treat 
analyses had they been involved in the current study.  
Reasons for the low participation rate in this study may have related to the time 
involved, which included both attendance at assessments (2 hours) at intervals 
throughout the study period and the necessity to attend classes if randomised to the 
exercise group (three times a week with each class lasting 1.5 hours and taking place 
during normal office hours, which limited participation by subjects who were 
employed). In addition to the travel time required for participants, there were also 
often problems for subjects in finding car-parking spaces at the hospital where the 
study was conducted. Attempts to overcome some of these problems included the 
provision of free parking and hospital transport if required. However, use of the 
hospital transport added greatly to the time commitment involved, as to attend a 1.5 
hour class the subject would have to be ready for pick-up at least 2 hours prior to the 
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3.4.5 Limitations of the study 
There are a number of limitations with this study. Despite being a RCT, the study 
subjects could not be blinded as to which group they were randomised to after the 
baseline assessment. This may have influenced responses to the self-complete 
questionnaires. Further, resource limitations limited the use of a blinded assessor and 
thus measurement bias was also possible since the principal investigator completed 
all assessments and also supervised the training programme. Attempts to overcome 
some of this bias involved the investigator not reviewing any of the baseline data for 
the primary and secondary outcome measures prior to any follow-up visits. 
 It was inevitable that the nature of conducting a study involving exercise was likely 
to attract subjects who are already keenly motivated to either make a change in their 
current management or were already converted to the positive benefits of exercise, 
which may have reduced the potential for a positive treatment effect in some of the 
outcomes measured. The overall effect size between groups was smaller than 
expected, therefore more subjects were needed to gain adequate study power. 
Individuals who were randomised to the control group, although instructed to 
continue with their normal management for their asthma and asked not to change 
their exercise habits, were not monitored for their exercise habits. The majority of 
those who entered the study stated that they were enthusiastic about the chance of 
participating in a supervised exercise programme, and it is likely that improvements 
seen in the control group (i.e. significant improvements in 6MWD from baseline), 
were a result of the Hawthorne effect, with some individuals in the control group 
admitting at the 6 week assessment they had increased the amount of exercise they 
were taking at home. In contrast, some individuals randomised to the control group 
seemed to lose interest in the study, and withdrew before completing the 3 month 
follow-up. This high level of attrition was not expected in this group, and limited the 
overall power of the study. 
Because exercise classes utilising the physiotherapy department facilities at SCGH 
could only be held during office hours, a number of participants in the exercise group 
had difficulties attending classes due to work commitments. The study population 
included a proportion of adults who worked either full or part-time. In the screening 
phase many of these workers were not interested in participating in the study in the 
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knowledge that if they were randomised to the exercise group they would have to 
withdraw due to work commitments. However, some subjects who were still working 
and recruited to the study attempted to change their working hours to participate in 
the study in the event of being randomised to the exercise group, and in some cases 
this resulted in an incomplete number of class attendances (<18 sessions). 
 In this study, baseline functional exercise capacity measured by the 6MWT was not 
remarkably different from normative data, nor was dyspnoea a significant factor 
limiting performance on the test. This suggests the possibility that the 6MWT was 
not as responsive as other measures for detecting change in the exercise group with 
the training, and also highlights that individuals with FAOA present differently to 
individuals with COPD in terms of their physical limitations and symptom severity. 
In retrospect, the inclusion of a maximal exercise test may have detected 
improvements following exercise that were not evident with the 6MWT. 
The literature shows that the 6MWT has been applied in many patient populations 
other than those with COPD. Examples include individuals undergoing surgical 
procedures, adults with congestive heart failure, cystic fibrosis, pulmonary 
hypertension, interstitial lung disease or peripheral vascular disease, and thus it was 
reasonable to assume that its applicability could be translated to older individuals 
who had a component of fixed obstruction as a result of asthma (311). Further 
research is necessary to evaluate its discriminative properties amongst individuals 
with conditions other than COPD (178). 
A limitation of this study arose because of the lengthy and difficult process in subject 
recruitment. Because it was such a select group of individuals, the numbers of 
subjects involved in the exercise programme at any one time were small, which 
reduced the positive benefits of peer support that may occur when subjects train in a 
group setting.  
Finally, due to the expense associated with procedural assessments, it was not 
possible to test all subjects via HRCT scans for evidence of emphysema or chronic 
bronchitis and so, although subjects had minimal or no smoking history, it is not 
possible to rule out a degree of co-existent COPD being present.  In addition, a 
recommendation for future studies of exercise training studies in this subject 
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population is that objective assessment of activity levels using a physical activity 
monitor be performed. 
 
 3.5 Implications and conclusion 
In summary, a 6 week exercise intervention produced a positive change in disease-
specific QOL and anxiety that was maintained at 3 months and was significant in 
comparison to the control group. Improvements in 6MWD, asthma control, 
depression scores and generic QOL, although significant against baseline measures 
in the exercise group, had either declined at 3 months or were not of a statistically 
significant magnitude compared with the control group.   
Although exercise training is of benefit in adults with FAOA, any improvements tend 
to decline as training ceases. Further studies are recommended to ascertain the costs 
versus benefits of providing programmes for older adults with chronic asthma and to 
assess whether improvements in functional exercise capacity translate into a 
reduction in GP attendance, ED visits or hospital stays (as is the case for COPD). 
Clinical implications of the findings of this study are that first, individuals with 
FAOA referred to pulmonary rehabilitation programmes are likely to tolerate higher 
intensities of exercise than their counterparts with COPD. A 6MWT may not be an 
appropriate measure for functional exercise capacity in this group due to a potential 
ceiling effect at baseline, and this should be taken into consideration in the 
assessment of these patients when they are referred to a pulmonary rehabilitation 
programme. 
The high baseline 6MWD in individuals who have FAOA and the low levels of 
dyspnoea experienced by these subjects during the 6MWT, particularly in relation to 
the past experience of the investigators in assessing individuals who had been 
referred to pulmonary rehabilitation with COPD, prompted the development of a 
further study which is presented in the following chapter. The study that follows 
compared outcomes measured in a group of individuals with COPD who had a 
similar level of pulmonary hyperinflation and air trapping, and were age and gender 
matched with those of obtained in a sample drawn from individuals with FAOA who 
participated in this RCT. 










Differences in resting lung function and functional 
exercise capacity in a fixed airway obstruction 




4.1  Introduction 
Older individuals with more severe asthma and an irreversible component of their 
lung function measurements (fixed airway obstruction asthma, FAOA) are more 
likely to be referred to hospital or community-based pulmonary rehabilitation 
programs than those with mild asthma. This referral trend arises because it is 
acknowledged that many of the clinical features which are associated with chronic 
obstructive pulmonary disease (COPD) and FAOA overlap, such as similarities in 
measures of airflow, symptoms of dyspnoea and reduced exercise tolerance (4, 343, 
344). 
An unexpected finding in the FAOA cohort studied in Chapter 3 was their relatively 
low level of dyspnoea at the end of the 6 minute walk test (6MWT) and high 6 
minute walk distance (6MWD). This questions the responsiveness of the 6MWT in 
these individuals and raises the possibility of a ‘ceiling effect’ with this test. The 
physiological basis for this finding is examined in the following chapter by 
comparing cardiorespiratory and dyspnoea responses to the 6MWT in a FAOA 




cohort and COPD cohort selected on the basis of the severity of their resting 
pulmonary hyperinflation, age and gender.   
The COPD cohort were obtained from a randomised controlled trial (RCT) 
investigating the benefits of inspiratory muscle training that was carried out in the 
same research facility and utilised the same protocols for the 6MWT and for 
assessments of  peripheral muscle strength, and for measurements of lung function. 
To ensure a cohort who clearly had air trapping was recruited, the resting ratio of 
residual volume to total lung capacity (RV/TLC) was the primary measure used to 
match the two groups. This was for a number of reasons: 
1) RV/TLC showed a much stronger correlation with 6MWD (r=-0.66, p<0.001) than 
forced expiratory volume in one second (FEV1) with 6MWD (r=0.34, p<0.05) in the 
RCT of exercise training in the FAOA cohort as outlined in Chapter 3 (Table 3.6); 
2) matching of the subject cohorts primarily on their FEV1 could pose problems, 
given the potential for more day-to-day variability in this measure within the FAOA 
cohort; and    
3) there is evidence that RV/TLC is more strongly correlated to exercise capacity 





The primary objective of this study was to compare functional exercise capacity (i.e. 
6MWD) and resting lung function in a cohort of subjects with FAOA matched with a 
cohort of COPD (emphysema/chronic bronchitis) subjects.   
 
4.2.2 Research hypothesis 
The study hypothesis was that the preservation of gas transfer in the FAOA subjects 
would result in better exercise performance than their matched counterparts with 
COPD, even though the cohorts have a similar magnitude of air trapping and 
hyperinflation. 





To compare, in a matched cohort of subjects with FAOA and COPD: 
• resting lung function; 
• functional exercise capacity [6MWD, peak heart rate (HR), oxygen saturation 
(SpO2) and dyspnoea post-exercise]; and 
• peripheral muscle strength (handgrip and quadriceps strength). 
 
4.2.4 Study design 




The COPD subjects were drawn from a cohort who had participated in a RCT of 
inspiratory muscle training (346) and met the following criteria: 
• a diagnosis of COPD;  
• smoking history > 20 pack years; and 
• FEV1 < 80% of the predicted normal value. 
The FAOA cohort was drawn from a group of moderate to severe asthmatics who 
had participated in the RCT of exercise training (Chapter 3) and met the following 
criteria: 
• minimal or no smoking history (<15 pack years); and 
• single-breath diffusing capacity of the lung for carbon monoxide corrected 
for alveolar volume (DLCO/VA) > 80% of the predicted normal value 
and at least two of the following: 
• FEV1 <80% of the predicted normal value;  
• FEV1/ forced vital capacity (FVC) <80% of predicted ratio; or 
• RV >120% predicted. 
These criteria aimed to capture a cohort of asthmatics who had a degree of fixed 
obstruction affecting the small and/or large airways. It was conjectured that there was 
a risk that subjects with asthma affecting the small airways alone might have been 




excluded if the selection criteria defined moderate to severe asthma on the commonly 
used basis of FEV1 alone (262). 
Subjects with FAOA were under the long-term management of a respiratory 
physician with a special interest in asthma Professor PJ Thompson (PJT) and had 
undergone detailed investigations to determine disease variability, trigger factors, 
atopy and responsiveness to medications.   
To confirm stable disease prior to commencing the intervention phase of the study 
the asthmatic subjects were asked to attend a weekly assessment for a minimum of 3 
weeks to undergo spirometry and to complete the Asthma Control Questionnaire 
(ACQ) (55).   
Both COPD and FAOA subjects were free from major musculoskeletal, 
cardiovascular and neurological conditions likely to adversely affect exercise 
performance. Ethical approval was obtained from the Human Research Ethic 
Committees of Sir Charles Gairdner Hospital (SCGH), (Ethics approval numbers: 
2003-149 and 2001-149) and Curtin University of Technology (Ethics approval 
numbers: HR120/2004, and HR 210/2002). Written, informed consent was obtained 
from all subjects.  
 
4.2.6 Matched variables in the fixed airway obstruction asthma and chronic 
obstructive disease cohorts 
Subjects within the population were evaluated and selected to ensure comparability 
of: 
• gender,  
• age (± 5 years), and 
• the severity of air trapping and pulmonary hyperinflation at rest measured by 
RV/TLC (± 0.05).   
All measurements in both groups were made within a 4 week period when subjects 
were in a stable condition. Specific details of the methodology are given in Chapter 3 
and are outlined in brief below. 
 
4.2.7 Resting lung function 




Measurements obtained were:  
• FEV1 and FVC (digital pneumotachograph, Vertek Series Hewlett-Packard, 
Palo Alto, CA, USA); 
• resting lung volumes (Medgraphics Elite Series DX plethysmograph; Medical 
Graphics Corporation, St Paul, Minnesota, USA); and  
• DLCO/VA (P.K. Morgan Ltd, Chatham, UK).   
The American Thoracic Society Guidelines (263) were followed for calibration, 
quality control and correction for haemoglobin concentration. To normalise all of the 
data, measurements were compared to predicted normal values obtained from 
published regression equations as outlined in Table 4.1.  Full details of these 
measurements are given in Section 3.2.7.3 of Chapter 3. 
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Table 4.1 Predicted normal values for resting lung function measurements: regression equations 
Gender Variable Equation 
Males TLC 8.67*height-8.49 (347) 
 VC 5.2*height-0.022*age-3.6  (348) 
 RV 2.7*height + 0.017*age-3.45 (349) 
 FRC 5.78*height+0.016*age-0.04*weight-4.24 (350) 
 FEV1 0.5536+(-0.01313*age)+(0.000172*age2)+(0.00014098*height2) (351) 
 FVC 0.1933+(0.00064*age)+(-0.000269*age2)+(0.00018642*height2) (351) 
 DLCO/VA 10.0882-2.244*height-0.0309*age for non-smoker  
9.72-2.244*height-0.0309*age for ex smokers and  
9.3214- 2.244*height-0.0309*age for current smokers  (352)  
Females TLC 7.31*height-0.016*age-6.29 (350) 
 VC 4.17*height-0.021*age-2.87 (353) 
 RV 3.2*height + 0.009*age-3.9 (349) 
 FRC 5.59*height-0.03*weight-4.91 (350) 
 FEV1 0.4333+(-0.00361*age)+(-0.000194*age2)+(0.00011496*height2) (351) 
 FVC 0.356+(0.0187*age)+(-0.000382*age2)+(0.00014815*height2) (351) 
 DLCO/VA 8.3297-1.811*height-0.0157*age for non/ex smokers  
7.5732-1.811*height-0.0157*age for smokers (352)  
TLC: total lung capacity; VC: vital capacity; RV: residual volume; FRC: functional residual capacity; FEV1: forced expiratory volume in one second; FVC: forced 
vital capacity; DLCO/VA: transfer factor for carbon monoxide corrected for alveolar volume.  Height is measured in metres in all equations apart from the FEV1 and 
FVC where it is expressed in centimetres.  




4.2.8 Six minute walk test 
The 6MWT was performed using a 45m straight course within a temperature-
controlled corridor within the hospital. Tests were supervised by one of two 
physiotherapists [Sian Turner (asthma cohort), Dr Kylie Hill (COPD cohort)]. Chairs 
were placed at both ends to enable seated rests if required. The specific instructions 
given to subjects and full details of the protocol have been described in Chapter 3, 
Section 3.2.8.1. The 6MWT was performed in accordance with current 
recommendations (178), but modified to include standardised encouragement to 
recommence walking every 15 seconds during any rest periods. Additionally, heart 
rate (HR) was recorded prior to commencing the test and was continuously 
monitored throughout the test (Polar a1 HR monitor; Polar Electro Oy, Kempele, 
Finland). The HR at the end of each minute was recorded. The peak HR achieved 
during the test was used in the analyses. Arterial SpO2 was measured prior to and 
immediately following test completion using a pulse oximeter and finger probe 
(Ohmeda 3700; GE Health care, Louisville, CO, USA or Tuffstat monitor (Datex 
Ohmeda, GE Health care, Louisville, CO, USA). The end-exercise SpO2 was 
recorded. 
Dyspnoea was measured prior to and at the end of each 6MWT using the Borg (0-10) 
dyspnoea scale (146). This same scale was used to determine the severity of leg 
fatigue at the end of the test. In the protocol followed by the COPD subjects, SpO2 
was monitored continuously throughout the test for safety reasons and dyspnoea 
scores were collected at the end of each minute. The end-exercise data for SpO2 and 
dyspnoea were used to compare the responses in the COPD cohort with those of the 
subjects with FAOA . 
Two 6MWTs were performed, separated by between 20 and 60 minutes rest. 
Supplementary oxygen was not used by any subject during the tests. Data from the 
greatest 6MWD were used in the analyses. Predicted values for the 6MWD were 









4.2.9  Peripheral muscle strength 
4.2.9.1  Quadriceps strength 
Quadriceps force was measured using a strain gauge (Fall assessment Kit, Prince of 
Wales Medical Research Institute, NSW, Australia) following a standard protocol 
with the subject seated with the hips and knees flexed to 90 degrees (269). Subjects 
were instructed to generate a maximal isometric contraction. Measurements were 
made in triplicate on both legs and the maximal value obtained was recorded. 
Measurements from the subject’s dominant leg were converted into newtons and 
expressed as a percentage of predicted values (268).  The protocol is described in 
detail in Chapter 3, Section 3.2.8.2.  
4.2.9.2  Handgrip strength 
A hand-held Jamar 5030 J1 dynamometer (Sammons Preston Inc. Bolingbrook, 
Illinois, USA) was used to measure grip strength using the protocol described by 
Mathiowetz et al (1985) (271). The subject was seated with their shoulder abducted 
and mid prone, elbow flexed at 90 degrees and the forearm and wrist position were 
neutral. A minimum of three measures were taken and the single highest value 
achieved was recorded on the subject’s dominant side.  Full details are given in 
Chapter 3, Section 3.2.8.2. 
 
4.2.10  Strategies to minimize variability during the measurement period 
To ensure subjects with FAOA had stable asthma, measurements of FEV1 were 
recorded once a week for a minimum of 3 consecutive weeks and at the same time 
subjects completed the ACQ (55). Current smokers in the COPD cohort were asked 
to refrain from smoking on each day of testing and all subjects were requested to 
refrain from ingesting food and drinks containing caffeine for 2 hours prior to the 
tests. All subjects were under the care of a respiratory physician and were receiving 
optimal medical management.  
 
4.2.11  Statistical analyses 
Data were analysed using SPSS (Version 16.0). The distributions of anthropometric, 
lung function data and 6MWD data were examined using visual plots and the 




Shapiro-Wilks test of normality, and natural log transformations applied where 
necessary.  
 Independent t-tests were then used to compare the following data between the two 
cohorts: 
• resting lung function expressed as % predicted normal value; 
• maximum 6MWD, % predicted 6MWD, pre- and peak values of HR, and pre- 
and post-exercise SpO2; and 
• peripheral muscle strength measurements expressed in absolute values for 
handgrip and %predicted normal value for quadriceps strength. 
End-exercise dyspnoea scores were categorised into binary format (0 to ≤ 3 and > 4) 
and a Chi-square test of association was employed to analyse these data (using 
McNemar’s test for significance). The same analyses were used for ratings of leg 
fatigue.   
For all comparisons the level of statistical significance was set at p≤0.05. Data are 
presented as mean±standard deviation (SD).   
Data from the 32 subjects were combined (both FAOA and COPD cohorts), for the 
analyses of relationships between exercise variables and resting lung function. 
Spearman’s rank correlation coefficients (rs) were used to examine associations 
between dyspnoea scores recorded at the end of the 6MWT with resting lung 
function measures (RV/TLC, DLCO/VA and FEV1) and post-exercise SpO2.   
Pearson-product moment correlation coefficients (r) were used to compare 6MWD 
with lung function measures (RV/TLC, DLCO/VA and FEV1) and with post-exercise 
SpO2. The relationships between post-exercise SpO2 and RV/TLC, DLCO/VA and 
FEV1 were also examined using Pearson-product moment correlation coefficients.  
For each of these relationships, the level of statistical significance was set at p≤0.05.  
 





4.3.1 Sample size 
A total of 32 subjects participated in this study; 16 with stable moderate to severe 
FAOA (10 males) and 16 subjects with moderate to severe stable COPD (10 males).   
 
4.3.2 Anthropometric and lung function data  
Anthropometric and resting lung function data for the FAOA and COPD subjects are 
summarized in Table 4.2. Compared with the FAOA group, COPD subjects had 
lower FEV1 (p<0.001), FEV1/FVC (p=0.002) and DLCO/VA (p<0.001). Twelve 
(75%) of the FAOA subjects were life-time non-smokers, and the remaining four 
subjects had a smoking history of 2, 11, 12, and 14 pack years respectively.   
 
4.3.3 Six minute walk test 
The 6MWD and cardiorespiratory and dyspnoea responses to the 6MWT are 
presented in Table 4.3. None of the subjects with FAOA rested during the 6MWT 
whereas three subjects (18.8%) in the COPD cohort rested during the tests. Total rest 
times were 22, 102 and 17 seconds respectively. The mean 6MWD was significantly 
greater in the FAOA subjects than the COPD subjects (571m ± 89m versus 488m ± 
111m respectively, p=0.005).  The mean difference (95% confidence interval) 
between the two groups in 6MWD was 84 (11.2, 155.8)m.  
There were no significant group differences in peak HR either as an absolute value or 
as % predicted HRmax (220-age).  There was also no difference in ratings for leg 
fatigue between the two subject cohorts. A significant correlation was noted between 
the 6MWD and %predicted HRmax in both groups (r=0.61, p=0.012, FAOA and 
r=0.54, p=0.03, COPD).   
Peak dyspnoea scores were significantly higher in the COPD cohort (p<0.0001) and 
the magnitude of oxygen desaturation was significantly greater in this cohort 
compared to the FAOA subjects (p<0.001) (Table 4.3). Post-exercise SpO2 was 
below 90% in all of the COPD subjects and remained above 90% in all subjects with 
FAOA (Table 4.3). 









Gender (male:female) 10:6 10:6 
Age (years) 68.7±8.2 68.0±8.3 
Height (cm)  169.9±8.6 169.1±6.5 
Weight (kg) 77.0±11.9 71.3±14.9 























































All data are mean±SD. TLC: total lung capacity; VC: vital capacity; RV: residual volume; FRC: 
functional residual capacity; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity; DLCO/VA: transfer factor for carbon monoxide corrected for alveolar volume; n: number; y: 
years; cm: centimetres; kg: kilograms; kg/m2: kilograms per metre squared;  %: percent predicted; 
mm/min/mmHg/L: millimetres per minute per millimetres of mercury per litre; ^Log transformations 
applied to these variables before t-tests performed;  
*p<0.001, # p<0.05.  
 
 









6MWD (m) 571 ± 88 488 ± 111# 
6MWD (%pred ) 95 ± 11 80 ± 16# 
Number of Subjects who rested 0 3 
 HR pre-test (bpm) 88.6 ± 14.3 90.1 ± 9.9 
Peak HR(bpm) 130.4 ± 19.7 130.4 ± 13.6 
Peak HR (%predHRmax) 86 ± 12 86 ± 10 
SpO2 pre-test (%) 95.8 ± 1.1 94.4 ± 1.2 
SpO2 post-test (%) 94.7 ± 1.9 84.3 ± 2.7* 
SpO2 < 90% post-test (n) 0 16 
SpO2 fall >4% (n) 1 16 
Dyspnoea 2.7 ± 1.8 5.9 ± 2.5* 
Leg fatigue 2.2 ± 1.6 1.9 ± 1.6 
Data are mean±SD or numbers of subjects (n). All statistical comparisons are between group 
comparisons (independent t-tests) and for dyspnoea scores McNemar’s test. 6MWT: 6 minute walk 
test; 6MWD: 6 minute walk distance; m: metres; %pred: percent predicted; bpm: beats per minute; 
HR: heart rate; %predHRmax: percent predicted maximum heart rate; SpO2: oxygen saturation; n: 
number; % percent. +p=0.018, #p≤0.005, *p≤0.001  
 
4.3.4 Peripheral muscle strength  
Hand grip strength and quadriceps strength were not significantly different between 
the two cohorts (Table 4.4). 
 









77 ± 24 
40 - 116 
74 ± 20 




256.0 ± 91.3 
125 - 500 
246.2 ± 88.4 




76 ± 16 
50 –  113 
80 ± 27 
40 – 135 
p=0.63 
Data are mean±SD. N: number; COPD: chronic obstructive pulmonary disease; FAOA: fixed airway 
obstruction asthma; Lb: pounds; N: newtons %: percent  
 




4.3.5 Relationships between exercise variables and measures of lung function 
Table 4.5 provides the correlations between post-exercise dyspnoea, 6MWD and 
post-exercise SpO2 with RV/TLC, DLCO/VA and FEV1 in the 32 subjects. 
Moderately strong and significant relationships were found between DLCO/VA with 
both dyspnoea and SpO2.  There was a significant inverse relationship between 
6MWD and RV/TLC. Six minute walk distance was also significantly related to 
FEV1. The relationship between post-exercise SpO2 and dyspnoea was inversely and 
moderately strong (rs=-0.61, p<0.001), and was significant (r=0.44, p<0.05) between 
6MWD and post-exercise SpO2. 
 
Table 4.5  Correlations between dyspnoea, 6MWD and post-exercise SpO2 
with measures of resting lung function in the 32 subjects  
 Dyspnoea 6MWD Post-exercise SpO2 
RV/TLC 0.05  -0.39# -0.09 
DLCO/VA -0.60*  0.30 0.75* 
FEV1 0.22  0.51# 0.59* 
RV/TLC: residual volume on total lung capacity, DLCO/VA: transfer factor for carbon monoxide 
corrected for alveolar volume, FEV1: forced expiratory volume in one second, 6MWD: 6 minute walk 
distance, SpO2: oxygen saturation, *p<0.001, #p<0.05 
 
 





The main findings of this study were that, despite having comparable baseline 
pulmonary hyperinflation, compared to subjects with COPD, those with FAOA were 
characterized as having: (i) a significantly greater 6MWD; (ii) less dyspnoea during 
the 6MWT; and (iii) preservation of oxygen saturation during the 6MWT. It is most 
likely that these findings can be attributed to the well-preserved gas transfer in the 
FAOA group, although it is also possible that differences in the degree of dynamic 
hyperinflation (DH) between groups, which were not measured in the present study, 
could also contribute to the different responses. 
 
4.4.1 Demographic variables  
The two cohorts participating in this study were matched for gender and comparable 
with respect to age, weight and height. For each of the lung function variables 
measured, comparisons between groups were also made after normalising these 
values using reference equations which took into consideration demographic 
variables such as age, weight and height. Increased age results in decreased lung 
recoil due to changes in the connective tissue matrix of the lung. At rest, RV/TLC is 
increased with age, inspiratory capacity is reduced, and elderly subjects can 
experience DH at a high intensity of exercise in a manner similar to, but of a lesser 
magnitude than that seen in subjects with COPD (354). In individuals with airflow 
limitation, a higher ventilatory demand due to these mechanical derangements 
contributes to higher levels of dyspnoea in an older individual compared to a younger 
individual (354). Age, weight and short stature have also been shown to be 
associated with a decreased 6MWD (178, 187, 355).  .   
 
4.4.2 Gas exchange and oxygen desaturation 
In the present study, a significantly lower DLCO/VA was observed in the COPD 
subjects when compared with the FAOA subjects. This measurement represents the 
ability of the lungs to exchange respiratory gases between the alveoli and pulmonary 
circulation (356). Since the gas transfer is corrected for alveolar volume it is more 
sensitive to the level of appropriately matched perfusion and any inhibition of gas 




diffusion across the alveolar capillary membrane. It is expected that in a progressive 
condition such as emphysema, a reduction in DLCO/VA will occur due to the 
pathological destruction of air spaces distal to the terminal bronchioles, causing both 
reduced diffusion of gas and poor perfusion per se (357). In asthma, DLCO/VA 
remains relatively well preserved (356) despite the repetitive inflammation that can 
cause permanent airway obstruction in chronic severe asthma (262). This presumably 
occurs because of an intact alveolar-capillary membrane and, if anything, increased 
perfusion.  
In earlier studies, DLCO has been shown to be a significant predictor of functional 
performance and oxygen uptake (319, 343). A lower DLCO/VA constrains oxygen 
transport to the metabolically active cells, and this can lead to an early shift in energy 
pathways from aerobic to anaerobic pathways during exercise, with the net result of 
the early production of lactic acid (192, 358). Lactic acidosis occurring during low 
intensity exercise provides an additional ventilatory stimulus and can accentuate the 
symptom of dyspnoea and lead to a premature cessation of exercise (354). 
The level of ventilation required to provide adequate alveolar ventilation for 
homeostatic acid-base regulation in an individual with FAOA is likely to be lower 
than for individuals with emphysematous changes given that hypoxia does not play a 
significant role in FAOA and that these individuals will have a lower level of lactic 
acid production. 
In the present study, significant oxygen desaturation did not occur in the FAOA 
cohort at the end of the 6MWT in contrast to the finding of marked desaturation in 
the COPD subjects. A normal SpO2 is likely to reflect preserved oxygen transfer 
(DLCO/VA), as DLCO has been shown to be a predictor of arterial oxygen 
desaturation during exercise (319).   
To date, there is little evidence that the severity of oxygen desaturation per se has a 
major impact on exercise performance (219, 359).  However, in single laboratory-
based assessments of exercise, supplementary oxygen (short-term) has been 
demonstrated to increase endurance exercise capacity, reduce dyspnoea (at iso-time) 
and improve oxygen saturation (360-363). This was the conclusion of a Cochrane 
review which included 31 studies comparing an exercise test breathing oxygen or air 
in subjects with moderate to severe COPD (360). A Cochrane review (364) 




investigating the use of ambulatory oxygen during exercise training in individuals 
with COPD who did not meet the criteria for long-term oxygen therapy, concluded 
that the evidence for the benefits of this therapy (i.e. effect on symptom alleviation, 
HRQOL or ambulation) was uncertain due to the availability of only a small number 
of included studies, which could not allow a conclusion to be drawn. There is a need 
for studies with larger numbers of participants and a strong design.   
In COPD subjects, the proposed mechanisms by which supplementary oxygen  
improves exercise tolerance, is by lowering the ventilatory requirement as a result of 
direct peripheral chemoreceptor inhibition, which in turn slows breathing frequency 
and thus decreases dynamic lung hyperinflation (365). Supplementary oxygen may 
also have an effect on reducing skeletal muscle lactate production (366).   
 
4.4.3 Relationship between resting lung function and functional exercise 
capacity 
It is well recognised that the ability to predict exercise capacity using anthropometric 
or physiological variables alone in individuals with COPD and asthma is low, 
however the severity of respiratory impairment measured through resting lung 
function measurements does partially contribute to the limitation in exercise capacity 
(183, 345, 367, 368). The present study demonstrated a significant relationship 
between resting pulmonary hyperinflation (RV/TLC) and 6MWD (rs=-0.39, p<0.05). 
A similar finding was also observed by Marin et al (343) who reported a correlation 
of 0.38 (p<0.001) between mean 6MWD and resting pulmonary hyperinflation 
(RV/TLC) in 72 males with COPD (FEV1 45±13.3% pred).   
Another study (369) in 27 males with severe COPD (FEV1 40±2.6%pred) reported a 
significant correlation (r=0.46, p<0.01) between the degree of resting pulmonary 
hyperinflation and the tolerability (or time to end) of an interval exercise test 
performed on a cycle ergometer at 100% of peak work capacity which alternated 30 
seconds of pedalling with 30 seconds of rest.   
In the present study, the level of large airway obstruction (%pred FEV1) at rest 
explained a small but significant part of the variability in 6MWD (r=0.51, p=0.003).  
Normalising FEV1, by expressing this variable as a percentage of predicted 
ultimately removes the effects of age and height to this relationship and thus tends to 




lower the correlation coefficient (345). This may account somewhat for conflicting 
results in the degree to which FEV1 contributes to exercise intolerance in COPD 
(176, 367, 370) and asthma (345, 368). An interesting trend observed by Lo Russo et 
al (371) is that the more severely disabled a group of patients are, the better the 
prediction between FEV1 and exercise capacity. The correlation between FEV1 and 
peak oxygen uptake (VO2peak) for a group of patients with mild COPD (FEV1 2.78 
±0.77l) was 0.69 compared to a correlation of 0.87 for a group of patients with 
severe COPD (FEV1 1.06± 0.47l). These authors did note, however, that although the 
correlations between resting pulmonary function tests and measures of maximal 
exercise capacity were significant, a large variance precluded the use of resting lung 
function tests such as FEV1 to accurately predict exercise cpacity in individual 
patients. 
In studies which have included asthmatic populations that do not have a component 
of fixed airways obstruction, FEV1 is likely to account for a lower percentage of the 
variability in exercise capacity that occurs in COPD because of the reversibility 
demonstrated in this lung function measure post-bronchodilator. The study by Foglio 
et al (345) evaluated the physiological and symptom determinants of exercise 
performance as measured by 6MWD and VO2peak from a symptom limited cycle 
ergometer test in a group of 44 subjects with COPD (age 63±7yrs, FEV1 
48±19%pred) and 55 subjects with asthma (age 55±10yrs, FEV1  65±17%pred). The 
authors showed that RV/TLC, age and Baseline Dyspnoea Index were the strongest 
and most consistent correlates of exercise performance whilst FEV1 was not a 
significant predictor of exercise performance (6MWD or VO2peak). This may have 
been because all of the asthmatics were receiving inhaled bronchodilators and all had 
variable airflow limitation with reversible obstruction, which is likely to have 
weakened the significance between the degree of airflow obstruction and exercise 
performance.    
In the present study, the FAOA and COPD groups were not comparable with respect 
to FEV1, as our hypothesis of similar responses occurring during the 6MWT in the 
FAOA and COPD cohorts was based on resting pulmonary hyperinflation rather than 
large airways obstruction being matched. 
 




4.4.4 Dynamic hyperinflation with exercise 
End-expiratory lung volumes typically increase during strenuous exercise in 
individuals with mild to moderate airflow limitation, in contrast to healthy controls in 
whom end-expiratory lung volume decreases during exercise (217, 372). In the 
present study, it was hypothesised that because subjects with FAOA and COPD had 
similar resting pulmonary hyperinflation, a similar degree of DH would develop in 
both cohorts during the 6MWT. This is because the presence of air trapping at rest 
increases the work of breathing and causes a higher ventilatory demand with activity 
(343) which may lead to further hyperinflation with exercise in both individuals with 
FAOA (133, 136) and those with COPD (373).   
One of the characteristic pathological changes that has occurred in an individual who 
presents with low diffusing capacity is an irreversible destruction of one of the major 
connective tissue components in the lung called elastin (374).  This loss of elastin, 
which is mediated by proteases, results in a loss of alveolar attachments which 
contributes to early peripheral airway closure (375).  Early airway closure leads to 
further DH with exercise and results in greater inefficiency of the lung and chest wall 
contributing to dyspnea and impaired exercise tolerance (374). 
Dynamic hyperinflation has been shown to be inversely related to the level of resting 
lung hyperinflation in individuals with COPD (376), but it is not currently known 
whether this also applies to individuals with FAOA. The present study did not 
measure the development of DH during the 6MWT and therefore it is not possible to 
comment on whether the magnitude of exercise-induced DH differed between the 
two groups.   
The development (or absence) of DH during exercise is generally measured in a 
laboratory by taking serial measurements of inspiratory capacity, first practicing the 
measurement protocol at rest before the exercise begins (130, 373). Errors in the 
measurement of inspiratory capacity can occur if inspiration begins before the 
patient’s normal end-expiratory lung volume is reached (130). It is assumed that TLC 
is constant during exercise therefore the change in inspiratory capacity reflects the 
degree of DH (130, 377). Pre- and post- measures of inspiratory capacity recorded 
with calibrated pneumotachography have also been used to measure DH during a 




6MWT in individuals with COPD to indicate the development of DH during a 
6MWT in this population (343). 
One study (133) which measured DH during exercise in 20 stable asthmatics, of 
whom only three exhibited an FEV1 below normal limits at rest, reported that 13 of 
these subjects developed DH in a symptom-limited cycle ergometer test, and exercise 
capacity was significantly reduced in these subjects (maximum exercise work rate 
75±9% pred) compared to those who did not develop DH (maximum exercise work 
rate 95±13% pred). It is possible, however,  that during short bouts of exercise (i.e. 
an exercise test of short duration such as the 6MWT) or submaximal exercise tests, 
the development of DH is less of a contributor to exercise limitation and dyspnoea 
intensity in asthmatic populations (136, 378).   
Several studies have reported the presence of DH in asthmatic subjects during 
metacholine-induced bronchoconstriction (131, 379-381). The DH that develops 
during a metacholine challenge is likely to be attributed to increased expiratory 
resistance as a result of persistent activity of the inspiratory muscles (130). In a study 
of 21 subjects with mild stable asthma, Lougheed et al (379) showed that an increase 
in end-expiratory lung volume was the single most important contributor to dyspnoea 
occurring during a methacholine challenge. Furthermore, airway obstruction and 
hyperinflation have been found to be the best predictors of dyspnoea in individuals 
with asthma during a methacholine challenge (381). 
In the present study, the reduced DLCO/VA in the COPD cohort may have 
accelerated the rise in breathing frequency at an earlier time point during the 6MWT, 
leading to a greater ventilatory demand in this cohort compared to the FAOA 
subjects. If so, the magnitude of DH would be greater in the COPD subjects than 
would occur in the individuals with FAOA with normal gas transfer (376). If DH is 
exacerbated during exercise in an individual with COPD to a greater degree than in 
an individual with FAOA, the end result will be a greater limitation in functional 
exercise capacity and a higher intensity of dyspnoea (382). 
 
4.4.5 Expiratory flow limitation 
Also related to the physiological concept of DH is expiratory flow limitation, ‘the 
maximum expiratory flow achievable by an individual during tidal breathing’ (130). 




The gold standard for the measurement of expiratory flow limitation is by the 
determination of iso-volume relationships between flow and transpulmonary pressure 
using the passage of an oesophageal balloon, but more commonly, is detected by 
superimposing a flow-volume loop of a tidal breath with a maximal flow-volume 
curve (130). The presence of expiratory flow limitation promotes DH and may 
contribute to dyspnoea, with the rate of development of DH being reported to be 
greatest in subjects with the most severe expiratory flow limitation, the lowest 
DLCO/VA and the highest ventilatory demand (376).   
Although the presence of expiratory flow limitation has been observed in stable 
asthmatics with normal spirometry, potentially contributing to reduced exercise 
capacity in these individuals (133), its occurrence has been reported more frequently 
in COPD populations than asthmatic populations (130).   
 
4.4.6 Relationship between dyspnoea and resting lung function 
In the present study dyspnoea scores recorded at the end of the 6MWT were 
significantly correlated with DLCO/VA, but not with FEV1. A study by Marin et al 
(383), showed that exertional dyspnoea measured by a visual analogue scale during a 
symptom-limited cycle ergometer test was not correlated with any resting 
spirometric or plethysmographic measurements (including FEV1), nor with measures 
of anthropometry or respiratory muscle function in 26 patients with severe COPD 
(FEV1 27.1±10.7% predicted). These authors instead found a significant relationship 
between exertional dyspnoea and the subject’s resting respiratory drive and the 
response of the central output to increased carbon dioxide stimuli. These authors did 
not measure resting levels of DLCO/VA, however it is possible their findings might 
also be reflective of impaired gas transfer, particularly as this may impact on 
respiratory drive as alluded to earlier in this discussion.  
The present study also found no significant correlation between dyspnoea and 
RV/TLC, and as has previously been highlighted, it is possible that RV/TLC does not 
necessarily reflect the degree of DH that develops during exercise. This may explain 
the reason for this poor relationship between these two variables.   
 




4.4.7 Dyspnoea on exertion in individuals with chronic obstructive pulmonary 
disease and asthma 
The present study showed significantly greater dyspnoea at the end of the 6MWT in 
subjects with COPD when compared to the cohort with FAOA. The pathophysiology 
of dyspnoea is multifactorial (126), and to date, the exact mechanisms which 
underlie this sensation in individuals with asthma are not fully understood (139, 
381). The sensation of dyspnoea is most often triggered by exertion in an individual 
with stable COPD (219), but in asthma, other stimuli which give rise to 
bronchoconstriction can be the cause of dyspnoea (384). It has been reported that a 
given ventilatory threshold needs to be reached before both asthmatics and COPD 
subjects perceive dyspnoea (138). 
A study by Laveneziana et al (2006) (381) which involved 22 subjects (19 with mild 
asthma, two with moderate asthma (FEV1 60-80% pred) and one with severe asthma 
(FEV1 ≤60%pred) showed the descriptors of dyspnoea that subjects chose varied for 
the two tasks, one being an incremental (6-8 minute) cardiopulmonary exercise test 
and the other a methacholine challenge. Specifically, chest tightness was more often 
reported during the metacholine challenge, whereas an increase in effort was the 
method by which the individuals described their dyspnoea during the exercise test.  
As such the underlying mechanisms of dyspnoea are likely to be different depending 
on the task (381).  This finding has also been reflected in two other studies (143, 
385). 
 
4.4.8 Blunted dyspnoea response 
All of the subjects with asthma who participated in this study had evidence of airway 
obstruction, as measured by resting lung function. Asthmatics with airway 
obstruction at rest have been reported to have an impaired perception of external 
resistive loads which is not observed asthmatics with normal airway calibre (386).  
Barriero et al  (136) showed subjects with severe and long standing asthma tended to 
have a poor recognition of their symptoms and perception of the severity of their 
disease.  
It has previously been mentioned in the discussion of study 1 (Chapter 3, Section 
3.4.2.5), that some individuals with chronic asthma, who in the past have had a near 




fatal asthma attack, suffer from significantly more hospitalisations, asthma 
exacerbations and deaths as a result of this reduced perception of dyspnoea (387, 
388). Another study showed less dyspnoea measured using a category scaling 
technique occurred during histamine challenge in a subset of subjects with asthma 
who had airflow obstruction present at the start of the challenge compared to subjects 
with normal lung function prior to the challenge.  This study also showed a 
significant relationship between the degree of bronchial hyper-responsiveness and 
the level of dyspnoea (318).    
It is difficult to estimate how many subjects in the FAOA cohort had experienced a 
near fatal asthma attack, given that information on such a history was not collected.  
A future study that investigates the prevalence and effect of this condition on 
dyspnoea in individuals who have FAOA would be of interest. Because all of the 
asthmatics in this study had fixed obstruction at rest, it is possible that a blunted 
dyspnoea response with exercise may have (at least in part) accounted for the lower 
intensities of dyspnoea at the end of the 6MWT compared to the COPD subjects, 
however this was not demonstrated through clinical signs of disproportionate level of 
work of breathing in relation to their dyspnoea scores in these subjects at the end of 
the 6MWT. Further research is required to better understand the differences in 
dyspnoea in individuals with FAOA versus COPD.   
 
4.4.9  Systemic differences between COPD and asthma: peripheral muscles 
and BMI 
In this study, both cohorts showed similar levels of quadriceps strength and handgrip 
strength, though the cohort size was relatively small for making such comparisons.  
Peripheral muscle strength has been shown to be reduced in individuals with COPD 
and contributes to impaired exercise tolerance (221, 222).  The proximal arm 
muscles are more affected by peripheral muscle weakness and wasting than distal 
hand muscles in individuals with moderate to severe COPD, although the 
impairments in upper limb muscle strength are of a lesser magnitude than the 
changes in quadriceps strength (389).   
Associated with the disease process in COPD are the mediators of hypoxaemia and 
oxidative stress which contribute to the pathophysiology of skeletal muscle 




dysfunction in these individuals (390). In COPD, shifts in fibre type distribution of 
the vastus lateralis muscles (391) and a reduction in fibre size (392) have been 
documented, as well as impairment in the oxidative metabolism of these muscles 
with a reported increase in glycolytic enzymes and a reduction in aerobic metabolism 
(393).  This presence of a reduction in skeletal muscle strength and a loss of muscle 
mass in individuals with advanced COPD is one of the systemic consequences of 
COPD (374).  The increased concentration of inflammatory mediators such as TNFα 
and IL6 and presence of oxygen derived free radicals may also contribute to the 
development of osteoporosis, chronic anemia, depression and an increased risk of 
cardiovascular disease (374). 
Reduced physical activity in individuals with moderate to severe COPD can also lead 
to muscle atrophy through disuse (390) and steroid-induced myopathy from the 
prolonged treatment with corticosteroids in individuals with COPD has been 
documented, which again leads to reduced peripheral muscle strength (394). As 
alluded to in the discussion of Chapter 3, long-term corticosteroid usage may not 
necessarily be associated with peripheral muscle weakness in individuals who have 
asthma, with one study demonstrating normal muscle strength and function of the 
quadriceps femoris muscle in individuals with bronchial asthma on chronic treatment 
with prednisolone (mean daily dose 17.3mg) (305).   
Two other factors which have been shown to have a negative effect on muscle 
strength and aerobic capacity are reduced body mass, which is often a co-morbidity 
associated with advanced COPD (395), and ageing (390).  Malnutrition and weight 
loss can reduce muscle strength and endurance by reducing respiratory muscle mass 
and the strength of the remaining respiratory muscles (374). The BMI of the FAOA 
cohort and the COPD cohort in the present study were similar however one limitation 




The most important findings of this study were that, despite a similar magnitude of 
air trapping and hyperinflation at rest, the FAOA subjects achieved a significantly 
higher 6MWD and experienced less dyspnoea and desaturation than the subjects with 




COPD.  Overall therefore, adults with FAOA are likely to tolerate much higher 
exercise intensities than their counterparts with COPD, regardless of their resting 
pulmonary hyperinflation. This is explained at least in part by their well preserved 
gas transfer, which is reflected in normal SpO2 levels during the 6MWT. This study 
lead to a discussion which illustrated that, regardless of the similar resting pulmonary 
hyperinflation between the cohort of subjects with FAOA and those with COPD, the 
structural abnormalities behind these two conditions lead to different mechanical 
derangements (such as lower DLCO/VA in the COPD cohort) which limit maximal 
ventilation and hence functional exercise capacity to a different degree in these two 
disease cohorts. 









Respiratory services and hospital admissions for 





In order to develop improved community support programmes for middle-aged and 
older adults with asthma and chronic obstructive pulmonary disease (COPD) in 
Western Australia (WA), it is important to define the current geographical 
distribution of health services throughout the State and highlight areas which 
experience a greater burden of hospital admissions secondary to these conditions. 
Geographic information systems (GIS) technology is able to manage spatially 
referenced data that describe human health outcomes and can assist in the 
visualisation of issues relating to health accessibility. This chapter utilises GIS 
technology to explore the current distribution of respiratory health services in WA, 
and hospital admissions secondary to asthma or COPD from 2000-2004 in adults 
aged 40 years and over.   
 
5.2 Methods  
5.2.1 Research aims 
The aims of this section of the thesis were to: (a) determine accessibility to 
respiratory health services in WA, (b) spatially represent and analyse the distribution 
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of hospital admissions for asthma and COPD, and (c) investigate trends in hospital 
admissions over a 5 year time period (2000-2004). 
 
5.2.2 Objectives  
Using GIS, the objectives were to: 
1. Map the current distribution of the following respiratory health services in 
WA: 
• hospitals; 
• emergency departments (EDs); 
• respiratory physician clinics; 
• pulmonary rehabilitation programmes; and 
• asthma educators. 
2. Determine the proportion of admissions to hospital (2000-2004) for adults 
aged 40 years and over with asthma or COPD within each health service 
relative to the population size within that health service by thematic mapping. 
Thematic maps would show:   
• admissions with a primary diagnosis of asthma; 
• admissions with a primary diagnosis of COPD; and  
• admissions with a primary diagnosis of both asthma and COPD.  
3. Define trends in admissions data for both asthma and COPD for each health 
service area over the time period 2000-2004, by gender and by age groups. 
 
5.2.3 Study design  
A record-linked prevalence study was undertaken to obtain prevalence, demographic 
characteristics and regional distribution of asthma and COPD admissions for adults 
aged 40 years and over in relation to respiratory services in WA. The following steps 
were followed: 
1. obtain data on: 
a) all hospital services (HOSPITAL DATASET); 
b) respiratory physician services (SPECIALIST DATASET); 
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c) pulmonary rehabilitation programmes (REHAB DATASET); and 
d) practising asthma educators (EDUCATOR DATASET). 
2.  Extract population data of adults aged over 40 years from the 2001 census 
using CDATA 2001, a CD Rom released by the Australian Bureau of 
Statistics (POPULATION DATASET). 
3. For each hospital admission during the time period 2000-2004, sort and geo-
code the data for asthma and COPD. These data were accessed from the 
Health Department of WA in a de-identified format (ADMISSIONS 
DATASET). 
4. Build a geo-database linking each of these datasets using GIS software.   
Detailed information on these data sets is provided in Section 5.2.6 (page 157).   
A geo-database refers to an object-orientated data model produced with GIS 
technology which removes redundant data and provides a means of understanding 
the organisation of the data in a systematic structure. Figure 5.1 outlines the geo-
database data input required to visualise hospitals, asthma educators, respiratory 
physicians, pulmonary rehabilitation programmes and asthma and COPD admissions 
of adults aged 40 years and over for regional and remote WA. 
 

















Obtain and complete datasets containing locations of pulmonary rehabilitation programmes, 
asthma educators, respiratory physicians and hospital admissions (asthma/COPD) in WA 
 
Sort admissions data of individuals 40+yrs with a primary 
diagnosis of asthma or COPD according to place of 
residence  
 
Geo-code admissions data to 
health service boundaries 
 
Aggregate population data to 
health services 
Extract from total population data, adults aged 
40+yrs living within each postcode boundary   
 
Build a spatial geo-database (Arc GIS 9) containing health 
information, health service boundaries and population data 
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5.2.4 Selection of geographic information systems software and data model 
The programmes ArcMap, Arc Catalogue and Arc Info were chosen to develop the 
GIS database. These ArcGIS programmes allow the discovery of patterns, 
relationships, and trends in data through their management and integration in a visual 
format, i.e. displayed as points on a map.   
MapInfo Professional8, a GIS programme, was also accessed within the framework 
of a customised application called CDATA 2001. CDATA is a CD-ROM that is 
released conjointly by the Australian Bureau of Statistics and MapInfo Australia and 
which allows manipulation of census data within a GIS environment. CDATA with 
MapInfo include a range of digital maps such as postcode boundaries, census 
boundaries and the Australian Standard Geographical Classification (ASGC) Areas 
for WA. The population data contained in the CD-ROM were collected during the 
2001 census. Digital maps of the study area, postcodes, and ASGC Areas as well as 
attribute data from the census, were imported into the Arc GIS programme in the 
form of shape-files as part of the process of building the geo-database.   
A vector data model was used to store and manipulate the spatial data. Geographic 
entities that are encoded in this type of model are referred to as features and 
represented by ‘polygons’, ‘lines’ and ‘points’. For the current study, polygons 
represented the study area of WA, postcode boundaries, and health service catchment 
areas and point data comprised the positions of hospitals, asthma educators, 
pulmonary rehabilitation programmes, and respiratory physician clinics.   
 
5.2.5 Identification of the study area 
The state of WA was chosen as the study area boundary. Western Australia spans 
2.525 million km2 and covers one third of the Australian continent. Latitudes range 
from 14° to 35° south.  This study area was divided initially into postcodes and then 
merged (or ‘dissolved’, to use the Arc GIS terminology) into 30 larger health service 
areas for the basic spatial unit for analysis. Initially it was anticipated that data would 
be coded according to the individual residential postcodes of each asthma and COPD 
admission that occurred during the time period 2000-2004. However, Health 
Department data did not allow this level of identification to be released for research 
purposes due to ethical issues. Further, post office box addresses, ‘lot’ numbers and 
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‘care-of’ addresses could potentially have been given as address details for asthma 
and COPD admissions that lived in rural and remote areas. Such addresses are not 
easily able to be geo-coded and this would have resulted in a high percentage of 
missing data in rural areas, and have led to inaccurate estimates of the extent of 
COPD and asthma within the area. In addition, in more remote parts of WA, the use 
of postcodes and census districts as the areal unit would have generated very small 
catchments, and may have led in some instances to the admission of an individual 
being able to be identified based on the area of residence. Therefore the larger, but 
more clinically relevant health service boundaries were chosen as the areal unit on 
which to carry out mapping. 
The WA public health system has multiple levels of administration including the 
Health Department of WA, metropolitan and country health services and individual 
health units and hospitals. In 2004, Dr Jim Coddee within the public health division 
of the Health Department of WA was approached to provide information on the 
administrative boundaries for the provision of health services in WA for this study. 
Appendix M lists the spatial relationships between health services, to health districts, 
local government areas and statistical local areas for WA.   
 The digital map of postcode areas supplied in the CDATA programme was imported 
into the Arc GIS programme in the form of a shape-file. Using a computer software 
programme command called ‘dissolve’ which is located within the Arc GIS toolbox, 
the postcodes that corresponded to each health service boundary could be 
amalgamated together into the larger boundary areas of health services (Figure 5.2). 
‘Dissolve’ is a command that is used to create a simplified coverage from one that is 
more complex. Although the input coverage may contain information concerning 
many feature attributes, the output coverage contains information only about the 
‘dissolve’ item. The merging of polygons with Dissolve is the counterpart of 
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Figure 5.2  The ‘dissolve’ command used to change the postcode coverage to 
health service boundary areas 
 
‘Dissolve’ creates a new coverage by merging adjacent polygons, lines or regions that have the 
same value for a specific item 
 
Meta-data provided from the Health Department of WA for the point locations of 
hospitals used the following co-ordinate systems:  Australian GDA 1994 Spheroid, 
GCS_GDA_1994, D_GDA_1994 and Prime meridian was Greenwich 0. These 
coordinate systems were used to reference all other point and polygon data which 
were imported into the geodatabase.   
Maps which contained the attributes of health services for middle-aged and older 
adults with asthma and COPD were overlayed onto the base study area using the 
‘Overlay’ command that is located within the Arc Toolbox of Arc GIS-9. Overlay 
operations (Figure 5.3) merge spatial features on separate data layers to create a new 
feature class. 
Figure 5.3  Illustration of the ‘spatial overlay’ command in Arc GIS-9 
 
The three separate layers in this figure which are illustrated by two separate 
rectangles and circle become combined in the input so that all three layers are visual 
in the output simultaneously 
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Trends in admissions data were analysed by importing the data sets into SPSS 
version 16.0 and separating the data using a cross tabulation technique. 
 
5.2.6 Data sources 
5.2.6.1    Hospitals 
Attributes of hospitals throughout WA were imported into the health geo-database.  
The original source document supplied from the Health Department of WA 
contained the following attributes relevant to the study: hospital ID number, name of 
hospital, address of hospital, poscode, town, whether the hospital was a public or 
private hospital, the presence of an ED at the hospital, whether the hospital was 
located in a regional or metropolitan area, and the grid references to spatially locate 
the hospitals within a GIS setting. 
The 102 hospitals which admit adults with respiratory symptoms (i.e. asthma and 
COPD cases) are provided in Table 5.1. Hospitals which do not provide this type of 
care (i.e. children’s hospitals or hospitals which provide only maternity care, dental 
treatment or specialist eye hospitals) were excluded from the original list provided by 
the Health Department before importing into the geo-database. Table 5.2 provides a 
list of the 29 hospitals which were excluded. 
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Table 5.1 Attributes of the 102 hospitals in WA providing care for adults with respiratory disease 
 
ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Perth or Surrounding Metro Area         
203 Armadale/Kelmscott District Memorial Albany Highway ARMADALE 6112 PUBLIC E20 -32.13316800 116.01945900 
623 Attadale Hospital 21 Hislop Road ATTADALE 6156 PRIVATE D20 -32.02957400 115.81077600 
255 Bentley Hospital 33 Mills Street BENTLEY 6102 PUBLIC D20 -32.00688100 115.92730700 
602 Bethesda Hospital 25 Queenslea Drive CLAREMONT 6010 PRIVATE D19 -31.98761800 115.77903600 
632 Cambridge Private Hospital 187 Cambridge Street WEMBLEY 6014 PRIVATE D19 -31.94097500 115.82417000 
102 Fremantle Hospital Alma Street FREMANTLE 6160 PUBLIC D20 -32.05776600 115.75485800 
630 Fremantle Kaleeya Hospital Staton Road EAST FREMANTLE 6158 PRIVATE D20 -32.03632800 115.76636900 
647 Galliers Private Hospital 3056 Albany Highway ARMADALE 6112 PRIVATE E20 -32.15019500 116.02309700 
633 Glengarry Hospital 53 Arnisdale Road DUNCRAIG 6023 PRIVATE D19 -31.83424900 115.78458800 
641 Hollywood Private Hospital Monash Avenue NEDLANDS 6009 PRIVATE D19 -31.97022100 115.80898500 
642 Joondalup Health Campus Shenton Ave. JOONDALUP 6027 PRIVATE D19 -31.73898300 115.77128400 
454 Kalamunda District Community Hospital Elizabeth Street KALAMUNDA 6076 PUBLIC E19 -31.96850000 116.06139000 
629 Mercy Hospital Thirlmere Road MOUNT LAWLEY 6050 PRIVATE D19 -31.93652400 115.88396100 
608 Mount Hospital 150 Mounts Bay Road PERTH 6000 PRIVATE D19 -31.95847800 115.84575900 
607 Mount Lawley Private Hospital 14 Alvan Street MOUNT LAWLEY 6050 PRIVATE D19 -31.93432100 115.87419100 
626 Niola Private Hospital 61-69 Cambridge Street WEST LEEDERVILLE 6007 PRIVATE D19 -31.94037800 115.83683600 
239 Osborne Park Hospital Osborne Place STIRLING 6021 PUBLIC D19 -31.88538400 115.80477500 
639 Rockingham Family Hospital 221 Willmott Drive WAIKIKI 6169 PRIVATE D20 -32.31033200 115.76342900 
277 Rockingham - Kwinana District Hospital Elanora Drive ROCKINGHAM 6168 PUBLIC D20 -32.29205800 115.77048800 
101 Royal Perth Hospital Wellington Street PERTH 6000 PUBLIC D19 -31.95482400 115.86648700 
616 St John of God Health care Subiaco 175 Cambridge Street SUBIACO 6008 PRIVATE D19 -31.94124900 115.82538600 
640 St John of God Health care Murdoch 100 Murdoch Drive MURDOCH 6150 PRIVATE D20 -32.06805300 115.84481400 
105 Sir Charles Gairdner Hospital Verdun Street NEDLANDS 6009 PUBLIC D19 -31.96822500 115.81652800 
618 South Perth Community Hospital 76 South Terrace COMO 6152 PRIVATE D19 -31.98799400 115.86700400 
244 Swan District Hospital Eveline Road MIDDLE SWAN 6056 PUBLIC E19 -31.87655700 116.00600300 
         




ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Rural or Remote WA        
201 Albany Regional Hospital Warden Ave. ALBANY 6330 PUBLIC F23 -35.00417200 117.90475600 
204 Augusta District Hospital Donovan Street AUGUSTA 6290 PUBLIC D22 -34.30593700 115.15816100 
401 Beverley District Hospital Sewell St. BEVERLEY 6304 PUBLIC E20 -32.10288900 116.92247000 
402 Boddington District Hospital Hotham Avenue BODDINGTON 6390 PUBLIC E20 -32.80358100 116.47562400 
432 Boyup Brook Hospital [Upper Blackwood] Hospital Drive BOYUP BROOK 6244 PUBLIC E21 -33.83900300 116.39135000 
444 Bridgetown District Hospital Peninsula Road BRIDGETOWN 6255 PUBLIC E21 -33.95180300 116.13183800 
206 Broome District Hospital Robinson St. BROOME 6725 PUBLIC K5 -17.96060900 122.23669200 
403 Bruce Rock Memorial Hospital Dunstal St. BRUCE ROCK 6418 PUBLIC G19 -31.87352000 118.14655300 
208 Bunbury Regional Hospital Bussell Hwy. BUNBURY 6230 PUBLIC D21 -33.36678500 115.64759400 
209 Busselton District Hospital Mill Road BUSSELTON 6280 PUBLIC D21 -33.65390600 115.31961000 
210 Carnarvon Regional Hospital Cleaver Street CARNARVON 6701 PUBLIC B12 -24.88654400 113.65932800 
211 Collie District Hospital Deakin Street COLLIE 6225 PUBLIC E21 -33.35153000 116.16258000 
404 Corrigin District Hospital Kirkwood St. CORRIGIN 6375 PUBLIC F20 -32.32450400 117.87846100 
405 Cunderdin District Hospital Cubbine street CUNDERDIN 6407 PUBLIC F19 -31.65510600 117.24460000 
406 Dalwallinu District Hospital Myers St. DALWALLINU 6609 PUBLIC E18 -30.27678600 0.00000000 
214 Denmark District Hospital Strickland Street DENMARK 6333 PUBLIC F22 -34.95918200 117.35362100 
215 Derby Regional Hospital Loch Street DERBY 6728 PUBLIC L5 -17.30594300 123.63321900 
476 Dongara Health Service 48 Blenhein Street DONGARA 6525 PUBLIC C17 -29.26501600 -29.26501600 
271 Donnybrook District Hospital Bentley Street DONNYBROOK 6239 PUBLIC D21 -33.57508100 115.81890100 
408 Dumbleyung District Memorial Hospital McIntyre St DUMBLEYUNG 6350 PUBLIC F21 -33.31029100 117.74045400 
218 Esperance District Hospital Hicks Street ESPERANCE 6450 PUBLIC J21 -33.85650400 121.89215000 
219 Exmouth District Hospital LEFROY Street EXMOUTH 6707 PUBLIC C9 -21.93363500 114.12600700 
127 Fitzroy Crossing Hospital Fallon Road FITZROY CROSSING 6765 PUBLIC N6 -18.19139200 125.56265900 
220 Geraldton Regional Hospital Shenton Street GERALDTON 6530 PUBLIC C16 -28.78293500 114.61069600 
410 Gnowangerup District Hospital Yougenup Road GNOWANGERUP 6335 PUBLIC G21 -33.93060000 118.00319400 
411 Goomalling District Hospital Forrest Street GOOMALLING 6460 PUBLIC E19 -31.30369200 116.83109800 
128 Halls Creek Hospital 70 Roberta Avenue HALLS CREEK 6770 PUBLIC P6 -18.22590200 127.66655900 
412 Harvey District Hospital 45 Hayward St. HARVEY 6220 PUBLIC D21 -33.07777800 115.89711400 
475 Kalbarri Health Service Kaiber Street KALBARRI 6536 PUBLIC C15 -27.71287800 114.16140400 




ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Rural or Remote WA        
226 Kalgoorlie Regional Hospital Piccadilly Street KALGOORLIE 6430 PUBLIC J18 -30.74046500 121.47006300 
227 Katanning District Hospital Clive Street KATANNING 6317 PUBLIC F21 -33.68294200 117.56372400 
409 Kellerberrin Memorial Hospital 51-63 Gregory St. KELLERBERRIN 6410 PUBLIC F19 -31.62904400 117.71739900 
445 Kojonup District Hospital Spring Street KOJONUP 6395 PUBLIC F21 -33.82920900 117.15343500 
413 Kondinin District Hospital Graham St. KONDININ 6367 PUBLIC G20 -32.48905200 118.26547600 
257 Kununurra District Hospital 96 Coolibah Drive KUNUNURRA 6743 PUBLIC Q3 -15.77538800 128.73473200 
414 Kununoppin District Hospital Leake St. KUNUNOPPIN 6489 PUBLIC F19 -31.10988400 117.92268100 
230 Lake Grace District Hospital Stubbs Street LAKE GRACE 6353 PUBLIC G21 -33.10206800 118.45310600 
272 Laverton District Hospital Beria Road LAVERTON 6440 PUBLIC K16 -28.62395500 122.39624500 
273 Leonora District Hospital Sadie Canning Drive LEONORA 6438 PUBLIC J16 -28.89436600 121.33730100 
233 Margaret River District Hospital Farrelly Street MARGARET RIVER 6285 PUBLIC D21 -33.95233700 115.07097900 
234 Meekatharra District Hospital Savage Street MEEKATHARRA 6642 PUBLIC G14 -26.59118600 118.49144500 
235 Merredin District Hospital Kitchener Road MERREDIN 6415 PUBLIC G19 -31.48500600 118.27660000 
417 Moora District Hospital Dandaragan Road MOORA 6510 PUBLIC E18 -30.63955300 116.00103200 
418 Morawa District Hospital Caufield rdt. MORAWA 6623 PUBLIC E17 -29.21318000 116.00320600 
419 Mullewa District Hospital Elder St. MULLEWA 6630 PUBLIC D16 -28.53625600 115.51036200 
420 Murray District Hospital [Pinjarra] McKay St. PINJARRA 6208 PUBLIC D20 -32.63933300 115.87146500 
422 Nannup District Hospital Carey Street NANNUP 6275 PUBLIC D21 -33.98291500 115.76693500 
423 Narembeen District Hospital Ada Street NAREMBEEN 6369 PUBLIC G20 -32.06156100 118.39127400 
236 Narrogin Regional Hospital Williams Road NARROGIN 6312 PUBLIC F20 -32.93646900 117.16883500 
260 Newman District Hospital Mindarra Drive NEWMAN 6753 PUBLIC H11 -23.35500100 119.73614600 
460 Nickol Bay Hospital [Karratha] Millstream Road KARRATHA 6714 PUBLIC E8 -20.73639400 116.84893600 
424 Norseman District Hospital Talbot St. NORSEMAN 6443 PUBLIC J20 -32.19973400 121.77077800 
237 Northam Regional Hospital Robinson Street NORTHAM 6401 PUBLIC E19 -31.64924400 116.65829400 
425 Northampton District Hospital Stephen St. NORTHAMPTON 6535 PUBLIC C16 -28.35142300 114.63521600 
426 North Midlands District Hospital [Three Springs] Station Street THREE SPRINGS 6519 PUBLIC D17 -29.53450600 115.75927800 
238 Onslow District Hospital Second Avenue ONSLOW 6710 PUBLIC D9 -21.64313000 115.11549100 
267 Paraburdoo District Hospital Rocklea Road PARABURDOO 6754 PUBLIC F11 -23.20356500 117.67188300 
645 Peel Health Campus 110 Lakes Road MANDURAH 6210 PRIVATE D20 -32.53253600 115.76322000 




ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Rural or Remote WA        
427 Pemberton District Hospital Hospital Avenue PEMBERTON 6260 PUBLIC E22 -34.44462900 116.03250900 
428 Pingelly District Hospital Stratford Street PINGELLY 6308 PUBLIC F20 -32.53208100 117.08675300 
429 Plantagenet District Hospital [Mt Barker] Langton Road MOUNT BARKER 6324 PUBLIC F22 -34.62595900 117.65443400 
240 Port Hedland Regional Hospital Kingsmill Street PORT HEDLAND 6721 PUBLIC G8 -20.30993100 118.58113200 
446 Quairading District Hospital Harris Street QUAIRADING 6383 PUBLIC F20 -32.01413600 117.40251500 
430 Ravensthorpe District Hospital Martin Street RAVENSTHORPE 6346 PUBLIC I21 -33.58500600 120.04541100 
243 Roebourne District Hospital 42-44 Hampton Street ROEBOURNE 6718 PUBLIC F8 -20.77618500 117.14352900 
612 St John of God Health care Bunbury Lot 800 Bussell Highway BUNBURY 6230 PRIVATE D21 -33.36648700 115.64753500 
613 St John of God Health care Geraldton Hermitage Street GERALDTON 6530 PRIVATE C16 -28.78419400 114.61604800 
431 Southern Cross District Hospital Coolgardie Road SOUTHERN CROSS 6426 PUBLIC H19 -31.23044100 119.33764500 
256 Tom Price District Hospital Mine Road TOM PRICE 6751 PUBLIC F10 -22.72581700 117.77650700 
245 Wagin District Hospital Warwick Street WAGIN 6315 PUBLIC F21 -33.30497900 117.34731300 
433 Warren District Hospital [Manjimup] Hospital Avenue MANJIMUP 6258 PUBLIC E22 -34.24028900 116.15372500 
266 Wickham District Hospital Mulga Way WICKHAM 6720 PUBLIC F8 -20.67531800 117.14233200 
437 Wongan Hills District Hospital Ackland Street WONGAN HILLS 6603 PUBLIC E18 -30.89409400 116.72459700 
438 Wyalkatchem - Koorda District Hospital Honour Avenue WYALKATCHEM 6485 PUBLIC F19 -31.17600300 117.38607600 
249 Wyndham District Hospital 
Lot 1270 Minderoo 
Street WYNDHAM 6740 PUBLIC Q3 -15.47896500 128.12706600 
439 Yarloop District Hospital Barrington-Knight Road YARLOOP 6218 PUBLIC D20 -32.95556400 115.90243700 
251 York District Hospital Trews Road YORK 6302 PUBLIC E19 -31.89408500 116.75765600 
 
Footnote;  WA_GRID refers to the Western Australian Grid reference identity for each hospital, GDA_lat and GDA_long refer to the global latitudes and longitudes of each hospital defining their location 
on the earth’s surface with respect to the Royal Observatory at Greenwich (United Kingdom), the centre of mass for the earth and the axis of rotation of the earth with a reference radius of -9.
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Table 5.2 Attributes of the 29 hospitals in WA which do not provide care for adults with respiratory disease 
ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Perth or Surrounding Metro Area         
459 Central Drug Unit [Next Step] 32 Moore Street EAST PERTH 6004 PUBLIC D19 -31.95318500 115.86896000 
691 Colin Street Day Surgery 51 Colin Street WEST PERTH 6005 PRIVATE D19 -31.94941400 115.84172500 
638 Concept Fertility Centre 374 Bagot Road SUBIACO 6008 PRIVATE D19 -31.95052600 115.82007400 
695 Cottage Hospice 15 Bedbrook Place SHENTON PARK 6008 PRIVATE D19 -31.95275000 115.79993900 
694 Eye Surgery Foundation 42 Ord Street WEST PERTH 6005 PRIVATE D19 -31.95013400 115.83976500 
648 General Practice Divisions of WA [Home Ward] 130 Royal Street EAST PERTH 6004 PRIVATE D19 -31.95311300 115.87692900 
698 GI Clinic 20 Fortune Street SOUTH PERTH 6151 PRIVATE D19 -31.98787700 115.86375100 
935 Graylands Hospital (MHS) Brockway Road MT CLAREMONT 6010 PUBLIC D19 -31.96220300 115.79106800 
699 Harborne Dental Clinic 286 Harborne Street GLENDALOUGH 6016 PRIVATE D19 -31.92114900 115.82035400 
686 Ian Rosenberg Oral Surgery 235 Wanneroo Road TUART HILL 6060 PRIVATE D19 -31.88698900 115.83667000 
104 King Edward Memorial Hospital For Women 374 Bagot Road SUBIACO 6008 PUBLIC D19 -31.94989500 115.81897100 
685 Lions Eye Institute Day Surgery 2 Verdun Street NEDLANDS 6009 PRIVATE D19 -31.96731900 115.81416100 
682 McCourt Street Day Surgery 28 McCourt St. WEST LEEDERVILLE 6007 PRIVATE D19 -31.94139500 115.82784000 
696 Marie Stopes Midland 8 Sayer Street MIDLAND 6056 PRIVATE E19 -31.89192100 116.01043200 
644 Midland Dialysis Centre 46 Helena St. MIDLAND 6056 PRIVATE E19 -31.88914400 116.00291000 
684 Murdoch Community Hospice 100 Murdoch Drive MURDOCH 6150 PRIVATE D20 -32.06804900 115.84484700 
681 Murdoch Surgicentre 100 Murdoch Drive MURDOCH 6150 PRIVATE D20 -32.06804900 115.84484700 
631 Ngala Family Resource Centre 9 George Street KENSINGTON 6151 PRIVATE D19 -31.98495200 115.88629400 
643 Perth Clinic 29 Havelock St. WEST PERTH 6005 PRIVATE D19 -31.95121500 115.84402000 
103 Princess Margaret Hospital For Children Roberts Road SUBIACO 6008 PUBLIC D19 -31.94582100 115.83760700 
100 Royal Perth Rehabilitation Hospital Selby Street SHENTON PARK 6008 PUBLIC D19 -31.95438600 115.80430700 
158 Selby Authorised Lodge (MHS) 2 Selby Street SHENTON PARK 6008 PUBLIC D19 -31.95829400 115.80279400 
692 Serapis Day Hospital 57 Burroughs Road KARRINYUP 6018 PRIVATE D19 -31.87632300 115.77516400 
690 Southbank Clinic 38 Meadowvale Avenue SOUTH PERTH 6151 PRIVATE D19 -31.97589200 115.87176500 
689 Westminster Day Surgery 476 Wanneroo Road WESTMINSTER 6061 PRIVATE D19 -31.86364900 115.82818600 
247 Woodside Maternity Hospital 18 Dalgety Street EAST FREMANTLE 6158 PUBLIC D20 -32.04126700 115.77174700 
697 Woodvale Private Hospital for Women 231 Timberlane Drive WOODVALE 6026 PRIVATE D19 -31.78313800 115.78801400 




ID NAME ADDRESS TOWN POSTCODE CLASS WA_GRID GDA_LAT GDA_LONG 
 Hospitals in Regional or Remote WA         
687 Albany Hospice Diprose Crescent ALBANY 6330 PRIVATE F23 -35.00426700 117.90485800 
680 Busselton Hospice Mill Road BUSSELTON 6280 PUBLIC D21 -33.65390600 115.31961000 
 
Footnote;  WA_GRID refers to the Western Australian Grid reference identity for each hospital, GDA_lat and GDA_long refer to the global latitudes and longitudes of each hospital defining their location 
on the earth’s surface with respect to the Royal Observatory at Greenwich (United Kingdom), the centre of mass for the earth and the axis of rotation of the earth with a reference radius of -9.
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5.2.6.2    Respiratory physicians 
The medical specialist outreach assistance programme was accessed from the 
Western Australian Centre for Rural and Remote Medicine (WACRRM) to identify 
all respiratory physicians working in areas outside of the metropolitan area. In 
addition, the Medical and Surgical Specialist Referral Directory of WA, (2004) 
compiled and published by Dr Stephen Hobdy and the St John of God Clinical 
Services Directory, a referral guide for General Practitioners (2005) were also 
sourced to identify specialists working in the private system who may not have been 
included in the WACRRM database. 
 
5.2.6.3 Pulmonary rehabilitation programmes 
For the purpose of this study, a pulmonary rehabilitation programme was defined as 
a supervised group exercise training programme provided specifically for individuals 
with chronic respiratory disease. Data sources used to create a comprehensive picture 
of the location of pulmonary rehabilitation programmes across the state were:  
(1) telephone survey of the Physiotherapy Departments within public and private 
hospitals conducted from June 2005-Sept 2005;  
(2) data from a project carried out by a physiotherapist at Fremantle Hospital in 
2005;  
(3) The Australian Lung Foundation website (http://www.lungfoundation.com); and  
(4) the Australian Physiotherapy Association.   
Physiotherapists have the knowledge and skills to provide education and one-on-one 
rehabilitation for individuals with a chronic disease, and it must be acknowledged 
that any private physiotherapy practice is able to offer this service, and many do offer 
an informal type of service to individuals with chronic respiratory disease. However, 
the added benefits of a supervised exercise programme in a group setting have been 
discussed in Chapter 2 (section 2.8.5) of this thesis. 
 
5.2.6.4 Asthma educators 
To complete the asthma-educators dataset, the Asthma Foundation of WA provided 
the postcodes of all practising asthma educators within metropolitan and rural areas 
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who had given their consent to have their details on a database held by the Asthma 
Foundation in 2005. It was estimated that this database included one third of all 
educators in WA. In addition, hospitals and nursing posts around WA were contacted 
by phone over a 3 week period in August 2005 and contact was made with any 
individual at that hospital or post who was trained as an asthma educator or provided 
formal asthma education to patients.  Through this contact it was ascertained if the 
individual was employed in part, or full as an asthma educator. Asthma educators in 
regional areas were then asked if they outsourced and provided this service to other 
parts of the district.    
 
5.2.6.5 Hospital admissions data 
Hospital admissions data from patient discharge summaries are coded by 
professional coders within the Health Department of WA. It is notable that hospital 
admissions represent only a small percentage of all cases of asthma and COPD. Only 
the most severe exacerbations are included in hospital admissions data. From 2000, 
the 10th Edition of the International Classification of Diseases Coding System (ICD-
10) were used to code diagnoses during hospital admissions across WA. This was an 
update to the previous ICD-9- CM coding system in use prior to 2000.   Therefore for 
the purpose of this study, a five year period (2000-2004) was selected as the time 
period in which to study hospital admissions, because it was the most up-to-date 
dataset available and the older ICD-9 coding system was no longer in use from 2000. 
The Health Department of WA holds the State’s Hospital Morbidity Data System 
(HMDS) which contains discharge data for every admission to acute hospitals in 
WA. Information accessible from the HMDS includes age, gender, race and clinical 
information such as primary diagnoses, length of stay and complications from the 
admission. Table 5.3 lists the attributes of the data that were retrieved with 
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Table 5.3  Attributes of hospital admissions data  
Abbreviation Definition 
EVE ID Unique identifier 
FIN YEAR 2000/2001, 2001/2002, 2002/2003, 2003/2004 financial years 
HSRES Health service of residence: patient admitted to 
AGE GROUP five year age strata groups 40 years and over 
SEX  Male or Female 
ETHNICITY Aboriginal or Torres Strait Islander or other 
ASTHMA Asthma flags showing either as a principal diagnosis, additional 
diagnosis, or no asthma 
ASTHMA_CODE ICD 10 codes: J45 Asthma and or J46 status asthmaticus 
COPD Flagging those with a principle diagnosis, additional diagnoses or no 
diagnosis of COPD 
COPD_CODE ICD 10 codes J40-44.9 codes as follows: J40 Bronchitis not specified as 
acute or chronic, J41 simple and mucopurulent chronic bronchitis, J41.0 
Simple chronic bronchitis, J41.1 Mucopurulent chronic bronchitis, J41.8 
Mixed simple and mucopurulent chronic bronchitis, J42 unspecified 
chronic bronchitis, J43 Emphysema, J43.0 MacLeod’s syndrome, J43.1 
Panlobar emphysema, J43.2 Centrilobar emphysema, J43.8 Other 
emphysema, J43.9 Emphysema unspecified, J44 Other Chronic 
obstructive pulmonary disease, J44.0 Chronic obstructive pulmonary 
disease with acute lower respiratory infection, J44.1 Chronic obstructive 
pulmonary disease with acute exacerbation, unspecified, J44.8 Other 
specified chronic obstructive pulmonary disease, J44.9 Chronic 
obstructive pulmonary disease unspecified. 
 
The hospital admissions data obtained from the Health Department of WA were 
provided in a spreadsheet generated in Excel, which was converted into a database 
file to allow import into Arc GIS. The source file contained 46,356 records for either 
a principle or additional diagnosis of asthma or COPD. 
 
5.2.6.6 Baseline population data 
MapInfo for Windows is a compatible programme for CDATA 2001 to access 
census data and digital boundaries. Before the census information could be used, 
relevant MapInfo coverages were converted into shape-files using the Map-Info 
toolbox and these were imported into the health geo-database for this study. 
Data obtained included population data (males and females) for each health service 
area and for the ASGC Remoteness Areas. This latter dataset refers to the five 
classification areas (major cities, inner regional, outer regional, remote and very 
remote) that census districts are allocated to, around Australia, based on road 
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distance from a locality to the closest service centre in each of the five classes of 
population size.   
 
5.2.7 Ethical considerations 
Ethics approval was granted from the Human Research Ethics Committee of Curtin 
University of Technology (HR120/2004) prior to the commencement of this study.  
 
5.3  Results 
5.3.1 Overview 
This section describes the location of health services in WA for asthma and COPD 
and illustrates the distribution of the asthma and COPD admissions data between 
2000 and 2004. These data are presented in a graphical format, to aid the 
visualisation of service and admissions data. The objective of this study was to use 
the tools within GIS to provide information that could be further tested through 
epidemiological studies, hence no further analyses have been conducted on these 
results. The results are divided into two main parts, the first part, (5.3.2) focuses on 
services and the second (5.3.3) on admissions data. 
 
5.3.2  Health services 
5.3.2.1  Hospitals and their selective attributes  
Maps illustrating the distribution of hospitals, EDs, respiratory physicians, 
pulmonary rehabilitation programmes and asthma educators are located in Figures 
5.4 through to 5.8. 
Health services without a visiting respiratory physician included the Pilbara, 
Northern Goldfields and Vasse-Leeuwin. The Midwest-Murchison Regions and 
Kimberley were among those without access to pulmonary rehabilitation. Asthma 
educators could be contacted within almost all health service boundaries. Table 5.4 
illustrates the location and frequency of respiratory physician visits to regional areas 
within WA and Table 5.5 illustrates the location of pulmonary rehabilitation 
programmes in regional WA. 
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Figure 5.6       Hospitals with pulmonary rehabilitation programmes within WA 
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Figure 5.8  Distribution of asthma educators in relation to Australian 
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Table 5.4   Location and frequency of respiratory physician visits within 
regional WA  
Location Number of physicians Frequency of clinics 
Broome 1 Full-time 
Bunbury 2 Once a month, once every 2 
months 
Busselton 1 Once a month 
Geraldton 2 Both clinics once every 3 
months 
Mandurah 2 Once a fortnight, once a month 
Narrogin 1 Once a month 
Northam 1 Once a month 
Rockingham 1 Full-time 
 
Table 5.5  Location of pulmonary rehabilitation programmes within 
regional WA  
Location Number of classes per week when a block 
programme is held 
Albany 2 
Bunbury 2 





Port Hedland 3 
 
5.3.3   Hospital admissions data 
5.3.3.1   Distribution of admissions across Western Australia 
A total of 23,049 admissions were recorded with a primary diagnosis of asthma or 
COPD (4,159 asthma and 18,890 COPD) in adults aged over 40 years between 2000 
and 2004. Individuals of Aboriginal or Torres Strait Islander descent comprised 
1,262 of the COPD admissions (6.7%), and 670 of the asthma admissions (16.1%). 
In 2001, indigenous individuals, however, represented only 3.2% of the total 
population of WA (396). Across the State, 55% of asthma admissions and 41% of 
COPD admissions were in adults residing in health services outside the metropolitan 
area.   
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Figure 5.9 illustrates the health service boundaries in WA used to analyse the 
distribution of asthma and COPD cases relative to baseline population data (40 years 
and over) within each catchment area. Figure 5.10 shows the percentage of 
admissions in adults aged 40 years and over recorded between 2000-2004 with a 
diagnosis of asthma by health service boundary. Figure 5.11 illustrates these 
percentages relative to the number of adults aged 40 years and over counted in the 
2001 Australian Bureau of Statistics census for each health service boundary.  
Figures 5.12 and 5.13 illustrate the data for COPD admissions in each health service 
and figure 5.14 combines the number of asthma and COPD cases and presents these 
data relative to baseline population data for each health service boundary. In Figure 
5.11, it is evident that Geraldton and the Wheatbelt recorded the highest number of 
admissions for asthma in relation to baseline population data between 2000 and 
2004. In Figure 5.13, Geraldton, the Eastern Pilbara health service, Kalgoorlie-
Boulder and the Wheatbelt show the greatest percentage of COPD admissions in 
relation to baseline population data. Table 5.6 depicts the relationship between the 
number of respiratory physician clinics per year outside the metropolitan area and 
pulmonary rehabilitation programmes, to the average number of combined asthma 
and COPD admissions from 2000-2004, the population of adults aged 40 years and 
over within each health service and the health service area size. 
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*‘Health services’ in the legend correspond to the 31 administrative boundaries, both regional and 
metropolitan, that the Health Department of WA has defined in 2005 to provide the State with 
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Figure 5.10 Percentage of admissions with a primary diagnosis of asthma 
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Figure 5.11 Asthma admissions (2000-2004) relative to baseline population 
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Figure 5.12 Percentage of admissions with a primary diagnosis of COPD (2000-
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Figure 5.13 Chronic obstructive pulmonary disease admissions (2000-2004) 




























COPD admissions % 
population 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 181 
Figure 5.14 Asthma and COPD admissions (2000-2004) combined in relation 
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Table 5.6 Respiratory physician clinics and pulmonary rehabilitation programmes in relation to numbers of admissions for asthma and COPD in 
adults aged 40 years and over, the population (40 years and over) and size of each of the rural health service boundaries within WA  
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5, 255 241.2 1.6 2.3 0 0 0 








623 149.4 1.0 28.9 8.3 0.1 1.6 
Central Great 
Southern 




18, 114 0 0 0 0 0 0 




12, 771 0 0 0 0 0 0 




396, 559 0 0 0 11.4 0.1 0.0 




59, 103 0 0 0 0 0 0 




136, 288 0 0 0 32 0.1 0.0 








1, 796 90.0 1.2 8.9 5.6 0.1 0.6 
Harvey/ 
Yarloop 




2, 258 0 0 0 0 0 0 




421, 451 1590.2 16.2 0.6 0 0 0 
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20, 863 0 0 0 3.0 0.1 0.0 




95, 444 0 0 0 0 0 0 




373, 409 0 0 0 0 0 0 
Northern 
Goldfields 




637, 218 0 0 0 7.3 0.1 0.0 








2, 716 138.3 1.3 14.0 3.6 0.0 0.4 




151, 507 0 0 0 0 0 0 
Upper Great 
Southern 
1 RP visits 
monthly 




43, 724 124.0 1.5 0.3 0 0 0 
Vasse Leeuwin 1RPvisits 
1/month 




2, 242 119.7 0.9 5.3 0 0 0 




14, 231 0 0 0 0 0 0 




116, 276 0 0 0 0 0 0 




31, 753 0 0 0 0 0 0 
RP: respiratory physician, PR: pulmonary rehabilitation programmes, COPD: chronic obstructive pulmonary disease, km2: kilometeres squared, 40+yrs: adults aged 
40 years and over 
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5.3.3.2 Data analyses of hospital admissions with a diagnosis of asthma o 
chronic obstructive pulmonary disease as a co-morbidity 
The data provided in Section 5.3.3.1 excluded any admissions for which a primary 
diagnosis of asthma was recorded as the reason for admission but for which (i) the 
hospital stay was further complicated by a secondary or additional diagnosis of 
COPD as a co-morbidity, or (ii) the admissions in which a primary diagnosis of 
COPD was recorded along with a secondary or additional diagnosis of asthma as a 
co-morbidity which complicated the hospital admission. These data were analysed 
separately as they provide an indication of the degree of overlap or cross-over 
between these two conditions in adults aged 40 years and over.   
Between 2000 and 2004 there were 152 admissions recorded that had a primary 
diagnosis of asthma with the additional diagnosis of COPD, and 102 admissions 
reported with a primary diagnosis of COPD along with an additional diagnosis of 
asthma. These data are presented in relation to health service boundary area in Table 
5.7, together with data on the numbers of admissions for individuals that had either 
asthma or COPD as an additional diagnosis, but the primary reason for the hospital 
stay was for an unrelated condition (e.g. diabetes, fracture). 
Aboriginal and Torres Strait Islanders made up 16 of the 152 admissions (10.5%) 
that occurred with a primary diagnosis of asthma along with complicating additional 
diagnosis of COPD, and 17 of the 102 admissions (16.7%) with a primary diagnosis 
of COPD along with the complicating additional diagnosis of asthma. 
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Table 5.7 Admissions with asthma and/or COPD as a co-morbidity (2000-
2004) by health service boundaries in WA, for adults 40 years and 
over 
Health Service Asthma as primary 
diagnosis + COPD as 
additional diagnosis 
(n) 
COPD as primary 
diagnosis + asthma as 
additional diagnosis (n) 
Other condition as  
primary diagnosis + 
Asthma as additional 
diagnosis only (n) 
Other condition as  
primary diagnosis + 
COPD as additional 
diagnosis only (n) 
Perth metropolitan area and 
surrounding suburbs 
    
Armadale/ Kelmscott 3 1 165 965 
Bentley 9 6 347 22181 
Fremantle 7 15 324 1724 
Inner City 16 2 104 726 
Kalamunda - 4 110 450 
North Metropolitan 14 8 741 4355 
Rockingham/Kwinana 2 3 115 820 
Swan 8 3 422 1997 
Wellington - - 52 169 
Regional and Remote     
Avon 3  44 319 
Bunbury 3 2 186 527 
Central Great Southern 7 4 39 82 
Central Wheatbelt - - 14 79 
East Pilbara 2 - 33 121 
Eastern Wheatbelt 3 5 61 201 
Gascoyne 2 - 58 150 
Geraldton 6 6 204 540 
Harvey/Yarloop 3 - 44 177 
Kimberley - 10 115 264 
Lower Great Southern 21 2 266 543 
Midwest 2 - 64 153 
Murchison - - 9 45 
Northern Goldfields 1 9 85 302 
Peel 9 4 159 824 
South East Coastal 4 11 96 190 
Upper Great Southern 18 3 52 244 
Vasse Leeuwin - 1 77 484 
Warren/Blackwood 7 - 45 276 
West Pilbara 2 1 36 116 
Western - - 42 183 
Other     
Unknown WA - 2 42 89 
Metro Post Box - - 1 3 
Total 152 102 4152 19399 
(n): number, COPD: chronic obstructive pulmonary disease 
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5.3.3.3 Asthma and chronic obstructive pulmonary disease admissions by 
gender within each health service boundary in Western Australia (40 
years and over) 
Data concerning the proportions of asthma and COPD admissions across each health 
service by gender are interrogated in Figures 5.15 and 5.16.  In these figures the 
yellow bars represent the cumulative number of females admitted with a primary 
diagnosis of asthma (Figure 5.15) or a primary diagnosis of COPD (Figure 5.16) in 
each health service from 2000-2004, while the blue bars represent the number of 
males admitted with asthma or COPD in this time period. The names of each health 
service that correspond to the number Id ‘1 through to 33’ are located within the 
legend of each figure. 
 
Figure 5.15  Total numbers of asthma admissions by gender in each health 
service (40 years and over) 




















1: Armadale/Kelmscott, 2: Avon, 3: Bentley, 4: Bunbury, 5: Central Great Southern, 6: Central 
Wheatbelt, 7: East Pilbara, 8: Eastern Wheatbelt, 9: Fremantle, 10: Gascoyne, 11: Geraldton, 12: 
Harvey-Yarloop, 13: Inner-city, 14: Kalamunda, 15: Kimberley, 16: Lower Great Southern, 17: 
Midwest, 18: Murchison, 19: North metro, 20: Northern Goldfields, 21: Peel, 22: 
Rockingham/Kwinana, 23: South East Coastal, 24: Swan, 25: Upper Great Southern, 26: Vasse 
Leeuwin, 27: Warren/Blackwood, 28: Wellington, 29: West Pilbara, 30: Western health service 
 = Males = Females  
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Figure 5.16  Total numbers of COPD admissions by gender in each health 
service (40 years and over) 
 


















1: Armadale/Kelmscott, 2: Avon, 3: Bentley, 4: Bunbury, 5: Central Great Southern, 6: Central 
Wheatbelt, 7: East Pilbara, 8: Eastern Wheatbelt, 9: Fremantle, 10: Gascoyne, 11: Geraldton, 12: 
Harvey-Yarloop, 13: Inner-city, 14: Kalamunda, 15: Kimberley, 16: Lower Great Southern, 17: 
Midwest, 18: Murchison, 19: North metro, 20: Northern Goldfields, 21: Peel, 22: 
Rockingham/Kwinana, 23: South East Coastal, 24: Swan, 25: Upper Great Southern, 26: Vasse 
Leeuwin, 27: Warren/Blackwood, 28: Wellington, 29: West Pilbara, 30: Western health sevice 
 
 
5.3.3.4  Age distribution of asthma and chronic obstructive pulmonary disease 
admissions (2000-2004) 
When admissions were analysed in relation to the ages of the patients, there was an 
increase in the number of admissions with a primary diagnosis of COPD with 
increasing age. In contrast there was a trend towards a decline in asthma admissions 
with increasing age (Figure 5.17). 
 = Males = Females  




























5.3.3.5  Time trends in asthma and chronic obstructive pulmonary disease 
admissions (2000-2004) 
A gradual decline in the total number of asthma admissions was observed across the 
2000-2004 time period (Figure 5.18), with 1,129 admissions reported in 2000-2001 
and 934 admissions in 2003-2004. This equates to a 17.3% fall in admissions over this 
time period. In contrast, a large increase in the number of COPD admissions was 
recorded between 2000 and 2004 (Figure 5.19). There were 4,594 admissions in 
2000-2001, while 4,971 admissions were recorded in 2003-2004.  This equates to an 
8.2% rise in the total number of admissions.   
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Figure 5.18  Total number of asthma admissions for adults aged 40 






















Figure 5.19  Total number of COPD admissions for adults aged 40 years and 
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5.3.4 Summary of results 
These analyses have illustrated the distribution of services and admissions data for 
asthma and COPD in adults aged 40 years and over in WA. The maps provided 
illustrate a disproportionate number of hospital admissions in rural and remote areas 
comparative to baseline population data within this age group. In addition, many parts 
of the state are without a respiratory physician, pulmonary rehabilitation programme 
and ED for the management of acute and chronic asthma and COPD. The trends in 
admissions data show a gradual decline in asthma admissions over the 2000-2004 
time period. This was in marked contrast to COPD admissions which increased over 
the period. Differences in trends within the admissions data when analysed according 
to age and gender were also observed for asthma and COPD. For example, there was 
an increase in the number of admissions for COPD as age increased, with more males 
than females admitted with this diagnosis. Conversely the number of admissions for 
asthma was fairly steady or declined slightly as age increased and occurred more 
frequently in females. 




The purpose of this study was to provide descriptive data to allow the spatial 
representation of respiratory services for middle-aged and older adults with chronic 
asthma and COPD throughout WA, and also to provide a visual comparison of 
hospitalisation data in relation to health service boundaries for this group of 
individuals. To achieve these aims, GIS technology was implemented to map hospital 
admissions data and health services. The findings of this study identified that: i) 
access for individuals in rural and remote regions of WA to respiratory physicians, 
pulmonary rehabilitation programmes and an ED was limited in many parts of 
regional WA; ii) there was a disproportionate number of hospital admissions due to 
asthma and COPD in regional areas compared to the Perth metropolitan area for 
adults aged 40 years and over  relative to baseline population data for these areas; iii) 
hospital separations for Aboriginal and Torres Strait Islander adults aged 40 years and 
over were high comparative to the percentage of total population that this group 
represented; iv) the number of admissions for females with asthma was consistently 
higher than for males across all health services, and this pattern was reversed when 
looking at the numbers of admissions with a primary diagnosis of COPD; and v) there 
has been a gradual decline in asthma admissions, and a rise in COPD admissions over 
the time period 2000-2004, with the proportion of individuals admitted with COPD 
increasing with age. The study was observational and descriptive in its nature and 
therefore it is not possible to test specific epidemiological hypotheses without further 
data collection and analyses.   
 
5.4.1 Services for asthma and chronic obstructive pulmonary disease in 
Western Australia 
The GP is the key element in most rural health care delivery systems as it is this 
person who controls referral to higher levels of care and allied support services (252). 
Because of limited access to specialist services in regional areas and  the constraint of 
patients not willing or able to travel long distances to Perth for appointments, the GP 
is often required to provide a higher level of care in addition to basic care. From a 
review of the literature (Chapter 1), it is apparent that the availability of GPs in 
regional and remote WA has not kept pace with the size and thus health demands of 
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the population. Hence there is an increasing need for individuals in these areas to 
access other specialist and support services. 
Optimal access to health care involves providing the right service at the right time and 
in the right place (397). The locations of hospitals, EDs, respiratory specialist 
services, pulmonary rehabilitation programmes and asthma educators in WA were 
identified in this study. The population distribution of WA is such that the majority of 
people live in Perth and surrounding areas, and therefore in relation to the land mass 
that regional and remote WA encompasses there is low overall population density. 
Due to such demographic characteristics, it is often not feasible for the level of 
services provided for individuals with asthma and COPD to be equivalent in all parts 
of the State. There are many areas outside the Perth metropolitan area that do have 
sufficient population density, and also based on the numbers of hospital admissions 
for asthma and COPD, enough of the population affected by respiratory disease to 
warrant at least an outreach service by a specialist if a full-time service is not feasible.  
 
The four largest towns without access to a respiratory physician, pulmonary 
rehabilitation programme or an ED at the time of data collection (2005) were:  
• *Albany in the Lower Great Southern Health Service which did not have a 
respiratory physician or a dedicated pulmonary rehabilitation programme (only 
a combined exercise programme for patients with cardiovascular and other 
conditions was available). The town had a resident population of 22,256 in 
2001.  
• Port Hedland in the Pilbara Health Service, with a resident population of 12,697 
in 2001, did not have access to a respiratory physician.   
• Esperance with a resident population of 9,365 in 2001 in the South East Coastal 
Health Service did not have access to a respiratory physician, pulmonary 
rehabilitation programme or ED.  
• Carnarvon with a resident population of 7,189 in the Gascoyne Health Service 
did not have an emergency department, respiratory physician and only provided 
pulmonary rehabilitation ‘on demand’. 
Research, policy making and practical implementations have been made at both a 
community and State level to improve access to health services in rural areas (398). 
Poor accessibility to medical services can lead to reduced use of services and possibly 
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poorer health outcomes (399). One study in the United States (US) reported the 
pattern of ED use in a rural area and showed that although many ED patients may 
travel long distances for medical care, the majority come from nearby areas, with 
larger hospitals drawing more inpatients from afar than smaller hospitals (400). This 
pattern was also observed in a study performed in the United Kingdom (UK) where 
standardised episode ratios decreased as distance increased for acute emergency 
admissions (401). Another study conducted in New Zealand showed that individuals 
with asthma who lived in close proximity to an acute district hospital were three times 
more likely to use the ED and be admitted than those living distant (402).  
Health needs increase and the social conditions become increasingly poorer for 
inhabitants in geographical areas that are more remote and less accessible to health 
services, according to a study carried out in the UK (399). Jones and colleagues (242) 
observed an apparent association between health service accessibility and levels of 
mortality from asthma in the UK. Social and geographical isolation played a part in 
suboptimal management of asthma (242).   
The lack of respiratory specialists in regional and remote areas in WA may reflect an 
increasing urban orientation of this specialist training and the attractiveness of 
metropolitan medical practices with support facilities and personnel which are lacking 
in regional areas (252). An alternative to having a respiratory specialist providing a 
full-time clinic within a smaller township is to have a structured and organised 
outreach programme. In rural and remote areas to date, outreach services have most 
often been organised ad-hoc and without a systematic approach to determine the 
needs of the towns or current availability of services (403). For outreach to be 
effective, visits need to be regular and predictable, and patients need to have prior 
notification (403). 
Outreach services can be demanding for specialists as they entail early departures, late 
return, overnight stays and often combine travel over large distances with days of 
consulting (403), therefore significant remuneration or other type of incentive would 
most likely need to be provided to make the provision of an outreach service attractive 
to the respiratory physician providing the service. A study in rural New South Wales 
showed that the provision of health and community services in small rural towns was 
more likely to be provided secondary to funding allocations based on historical 
funding rather than identified community needs. This study highlighted the need for a 
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holistic approach to service delivery and better co-ordination which was not focused 
on one particular professional group, as well as an improved understanding of the 
context and culture of individual towns (404).   
Utilisation of a specialist in the management of chronic disease often results in 
improved patient care and satisfaction, as well as a greater likelihood of discharge 
from care (403). One study which specifically investigated the care of COPD patients 
in an inner city hospital studied a random sample of 80 medical records and showed 
that the involvement of a respiratory specialist in the patient’s care resulted in 
management that was more consistent with the Global Initiative for Chronic 
Obstructive Disease (GOLD) guidelines than if the patient had treatment from only a 
generalist during their hospital admission (405). 
Access to pulmonary rehabilitation was also limited in many parts of regional WA. If 
a service was provided it was not necessarily operational throughout the year and was 
dependent on staff availability, funding and numbers of referrals. The ‘Pulmonary 
Rehabilitation Toolkit’ is an online information resource designed to help health 
professionals establish pulmonary rehabilitation programmes with or without an 
education component in metropolitan, regional and rural settings throughout 
Australia. An initiative of The Australian Lung Foundation and Australian 
Physiotherapy Association, the toolkit states that the minimum requirement for staff 
for a pulmonary rehabilitation programme is a health professional that has the 
expertise to run an exercise training programme and has been trained in 
cardiopulmonary resuscitation (406).  
Community-based pulmonary rehabilitation programmes are usually implemented in 
areas of population density large enough to support a group exercise programme, thus 
it is unrealistic to suggest that all small town centres should have this service in 
operation. For example the Murchison Health Service, which spans 373,409 km2, has 
a population of 2,142 adults aged 40 years and over and had a combined average 
number of only 16.75 asthma and COPD admissions during the 2000-2004 period, 
would not be able to recruit sufficient numbers to effectively provide a group 
pulmonary rehabilitation programme (Table 5.5). Allied health services such as 
physiotherapy which run pulmonary rehabilitation programmes in rural and remote 
areas of Australia are faced with chronic workforce shortages as a result of high staff 
turnover, a mobile workforce, and an increased demand for  services (407). This 
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reduces the time commitment these services are able to allocate to providing the 
regular classes needed for a supervised rehabilitation programme.   
One study conducted by Grimmer et al (1998) looked at eight public hospitals in 
South Australia, Queensland and Tasmania and compared the allied health services in 
metropolitan areas compared to country areas. The authors reported that small 
numbers of therapists, usually only one or two, provided the service in rural areas 
compared to up to 20 therapists working together in city sites. The standardised rates 
of through-put were similar for country and metropolitan allied health services despite 
the smaller numbers of staff in country areas providing services to larger geographical 
areas. The patients seen by allied health staff in country areas were older than their 
metropolitan counterparts and were more reliant on government support for income. 
Fewer patients were eligible for private health rebates for their treatment. There was 
also a tendency to greater chronicity of a condition, possibly related to the older age 
of the patients (408). This study provided an argument for similar funding 
opportunities for country and metropolitan ambulatory health services. 
At a world wide level, it has clearly been shown that regardless of the region in which 
one lives, the cost of primary care for asthma is less expensive than hospital care, 
emergency treatment is more expensive than planned treatment, and the cost of 
managing acute attacks is far greater than the cost of providing preventative 
management (1). The breakdown of the direct medical expenditure for asthma in 
Australia in 2001 showed that out-of-hospital medical expenses - which included GPs, 
specialists and imaging and pathology services – comprised only a small fraction of 
the total medical costs for the disease (16% combined). Pharmaceuticals accounted 
for 54% of the budget and 24% was allocated to hospital expenses (inpatient, 
emergency and outpatient care) (409). A Dutch study in 1993 investigating the burden 
and cost of illness of asthma and COPD, illustrated that the smallest component of the 
overall direct medical costs for asthma was taken up by physicians (which included 
GPs and specialists). This equated to 7% of the total breakdown of asthma costs for 
GPs and 6% for respiratory specialists. The largest cost components were 
medications, which accounted for 45% of the total costs, and hospitalisations 
accounting for 27% of the costs. For COPD, inpatient hospital care costs accounted 
for 57% of the total direct medical costs for the disease, medications accounted for 
23%, GP’s 3% and respiratory specialists 4% of the total medical costs (410). 




5.4.2 Regional variations in hospital separation rates 
The present study identified a disproportionate number of hospital admissions for 
both asthma and COPD in regional and remote health services compared to health 
services situated in metropolitan areas.   
Fifty-five percent of asthma admissions and 41% of COPD admissions resided in 
health services outside the metropolitan area, despite 75% of the population of WA 
residing within this metropolitan area, so a much smaller percentage of admissions in 
rural and remote WA were expected.   
Reasons for differing hospital admission rates in rural areas are multi-factorial and, as 
this study was descriptive, one can only postulate on reasons for this. These 
preliminary findings for WA are not isolated, as a study conducted in country Victoria 
(Australia)  showed that four local government areas in the Loddon Mallee Region 
had close to double the state average number of hospital admission rates for asthma 
(398). In New South Wales, Tong and Drake (241) showed hospital admission rates 
for asthma were 52% - 69% higher for rural residents than their urban counterparts.   
Hospital admissions are a consequence of a complex relationship between disease 
severity, illness behaviour and utilisation of health care services (257). Admissions 
over time can be influenced by factors independent of disease status.  These could be 
differences in diagnostic practices, management practices in the ED, alterations in the 
access patients have to services, different financing of health care, and diversity in 
admission policies (411).  There are a number of reasons which might also explain 
why length of stay, or separation rates, are higher for rural and remote patients. These 
may include the necessity of keeping patients who are returning to very remote areas 
longer because of a lack of support services in the region. In contrast, access to some 
services (such as nursing care provided in a patient’s residence) may lead to earlier 
discharge for patients who live in metropolitan areas while these services may not be 
available in regional areas, so there is a greater need to ensure the patient is clinically 
stable and unlikely to require immediate medical attention on return to the community 
due to lack of a tertiary hospital in the region. 
The demographic make-up of residents within one region compared to another region 
may also vary, for example socio-economic factors, lifestyle characteristics, genetic 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 197 
or ethnic factors. A study of participants, aged 18-70 years, attending a public hospital 
ED for asthma showed many patients did their own “cost-benefit analyses” by altering 
the dosage of their medications, not adhering to specific guidelines or not take 
medication to save on cost (102). Some stated they would reduce the use of 
preventative medications based on their cost and this was likely to have precipitated 
the hospital presentation in a number of the participants. For 63% of the participants 
(38/61), cost was an issue determining adherence to asthma management guidelines 
(102). 
A WA study (412) investigating the relationship between socio-economic status 
measured using the socio-economic indices for areas (SEIFA), and hospital utilisation 
at a census district level, showed that higher rate ratios of hospital admission occurred 
in more disadvantaged quintiles based on socio-economic status. The study showed 
individuals in census districts with lower SEIFA indices were higher users of hospital 
services but had worse outcomes following hospitalisation, which was consistent with 
their worse health status.  The SEIFA values for census districts are determined 
through population censuses conducted by the Australian Bureau of Statistics.  Other 
studies have shown that potentially avoidable hospitalisations and adverse outcomes 
were more frequent in individuals who had a lower income or lacked private health 
insurance (413-415) 
The number of individuals living in remote areas is relatively small but these 
individuals represent the most disadvantaged groups, both in terms of location and in 
terms of socio-demographic characteristics. Therefore, in rural and regional areas 
there is an over-representation of people living in less advantaged areas due to small 
population numbers. The majority of people, however, who are living in 
disadvantaged areas reside in major urban centres. Western Australia has 10 of the 64 
‘most disadvantaged’ statistical local areas (SLAs) in Australia- these are 
Ngaanyatjarraku, Laverton and Menzies in the Northern Goldfields Health Service, 
Halls Creek and Derby in the Kimberley Health Service, Upper Gascoyne in the 
Gascoyne Health Service, Cue and Murchison in the Murchison Health Service, 
Kwinana in the Rockingham/Kwinana Health Service and Nannup in the Warren-
Blackwood health service (416).   
The boundary areas for rural health services in WA as a whole do not, however, have 
a significant percentage of their population in either the highest or lowest SLAs of 
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socio-economic disadvantage. The exception to this is the Kimberley region, which 
has considerably lower than average SEIFA index. The average indices of relative 
social disadvantage for rural regions in 2001 were as follows: Kimberley 905.8, 
Peel/Southwest 958.7, Central Wheat-belt 978.2, Eastern Goldfields 978.7, Great 
Southern 986.6 and Greater Bunbury 979.1 (246). The national average for the index 
of relative disadvantage in 2001 was 999.0, and for Western Australia was 977.0 
(417). 
The highest average number of combined admissions for adults aged 40 years and 
over with asthma and COPD over the years 2000-2004 occurred in the Lower Great 
Southern Health Service (329 admissions), followed by Peel with 275 admissions and 
then Geraldton (178 admissions on average each year). The presence of 
environmental variations, in the form of climatic differences or the use of agricultural 
or other industrial aerosols, which might precipitate exacerbations of asthma or COPD 
in these rural health services relative to other areas, are potential mechanisms that 
could be explored further in future research.   
For patients with chronic respiratory disease, hospitalisations often indicate a decline 
in health status as a result of deterioration in quality of life and accelerated disease 
progression (418). Hospitalisation usually represents the largest component of health 
care costs and is a reflection of advanced disease, increased frequency and severity of 
exacerbations for both COPD and asthma, and poor disease control (61, 418, 419).   
A US study showed that the prognosis for COPD patients (aged 50-54 years) who 
required a hospital admission was poor, with only 50% surviving to retirement age.  
The estimated cumulative survival after 10 years was much higher for those patients 
admitted with a diagnosis of asthma. Survival after 10 years for men and women 
admitted with asthma was 83.5% and 93.2% respectively, but in contrast only 60.1% 
for men and 78% for women with COPD. Women had a better prognosis than men for 
both asthma and COPD in all age groups (420). This study indicated a need for active 
prevention and treatment following a first admission to hospital, particularly for 
COPD (420). Within Australia, approximately two-thirds of deaths that were 
attributed to asthma in 2003 occurred among people aged 65 years and over (421).  
 
It has also been shown that a small proportion of patients with asthma account for a 
disproportionate number of acute health service events. In a study by Adams et al 
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(232) in which 293 patients with moderate to severe asthma were surveyed, only 23% 
of these patients had a single admission to hospital over a 12 month period whereas 
16% had two or more admissions over this time frame. Hospital admissions data 
appear to represent less than 1.5% of asthmatics as most with mild disease self-
manage and only the most severe exacerbations are reflected through hospitalisation 
data. Geelhoed et al (418) also showed that more than 50% of hospital admissions 
with a primary diagnosis of COPD lead to a readmission within a year.   
One strategy that has been suggested to improve asthma management in regional 
areas is a regional asthma management model that is based on a uniform approach to 
asthma management. This model includes formal ED protocols and written 
instructions that are provided to patients to follow for the ensuing 24-48 hours after 
presenting to an ED with an asthma attack (422). It is widely acknowledged that 
improved management leads to reduced severity and frequency of asthma 
exacerbations. 
 
5.4.3 Aboriginal and Torres Strait Islanders 
In the present study, individuals of Aboriginal or Torres Strait Islander descent 
comprised 1,262 of the 18,890 (6.7%) COPD admissions for adults aged 40 years and 
over, and 670 of the 4,159 (16.1%) asthma admissions. This was despite indigenous 
individuals representing only 3.2% of the total population of WA in 2001 (396). 
The 2004-2005 National Aboriginal and Torres Strait Islander Health Survey which 
involved approximately 1/45th of Australia’s total indigenous population (10,439 
people) showed that indigenous individuals were 1.6 times more likely to report 
asthma as a long-term condition than individuals who were non-indigenous. Asthma 
was more prevalent in older indigenous adults (19%) than younger individuals (12-
16%) (396). After adjusting for age differences, indigenous individuals were 1.3 times 
more likely to be hospitalised in the 12 months prior to the survey than non-
indigenous people and hospital admissions were more common in indigenous adults 
55 years and over (396). 
In a retrospective analysis of hospitalisations for Aboriginal and non-Aboriginal 
patients for respiratory tract diseases between 1988 and 1993 in WA, Williams et al 
(423) showed indigenous people were admitted to hospital two to 16 times more 
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frequently for a respiratory complaint than non-Aboriginals of the same age. Asthma 
was a frequent cause of admission among Aboriginal children and hospitalisation 
rates were much higher in non-metropolitan than metropolitan areas. Asthma was the 
second leading cause of admissions in young adults, and amongst Aboriginals, 
comprised 19% of respiratory admissions.  
In WA, most of the State’s indigenous people live in the Kimberley region with 
34.1% of the population of this health service area being indigenous. In regional and 
remote WA, 8% of the population is indigenous compared with only 3.2% of the State 
as a whole (249). 
The causes of poor health among indigenous people are multifactorial. In addition to 
problems of poor education, poverty, harsh environments and crowded households, 
they participate more frequently in risk-taking behaviours such as smoking and the 
under-use of medications. Barriers which lead to the misuse or under-use of 
medications include the distance required to travel to services, lack of ownership of a 
car, the cost of the medication and culturally inappropriate services (424). 
In 1999, in an attempt to improve access to pharmaceuticals (including those which 
are required for asthma) in designated remote areas, the Aboriginal Medical Services 
was given the authority to order pharmaceuticals from benefit scheme items and 
distribute them directly as needed to patients. This led to an improvement in health 
outcomes in locations where the scheme was in place (425). This legislation only 
applies to remote areas. Indigenous individuals who live in regional and urban areas 
still need to obtain their medications through the standard delivery systems such as 
visiting the GP and then the pharmacist. It has been suggested that widening the 
legislation to apply to indigenous people in regional and urban areas would provide a 
benefit to a much larger proportion of indigenous people (425). 
A study involving an interview of 17 remote health practitioners, three indigenous 
patients, five specialists and five regional health administrators highlighted that the 
barriers faced by remote indigenous people in accessing hospital-based specialist 
services (403). These barriers included geographical remoteness which resulted in 
transport and accommodation issues, disorientation and fear in urban centres, and 
dislocation from the family. In addition, specialist services are often culturally 
inappropriate and there is often poor doctor-patient communication due to limited 
proficiency in English and insufficient or no access to an interpreter. Other barriers 
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highlighted were the lack of family in attendance at consultations, poverty, the 
inflexibility of the health service structure in terms of appointment times, rushed 
consultations, and inadequate communication between the hospital and the remote 
clinic (403).  
 
5.4.4 Trends in admissions for asthma and chronic obstructive pulmonary 
disease 
A gradual decline in the number of asthma admissions was seen across the 2000-2004 
time period in WA (Figure 5.17), with a 17.3% fall in admissions over this period.  A 
population health survey carried out between 1994 and 1997 involving 3,000 
interviews with individuals residing in metropolitan Adelaide and major country areas 
in South Australia with populations >1,000 also observed a downward trend in 
hospitalisation rates for asthma (104). Since the 1980s in the US there has been a 
decrease in hospital rates for asthma in older adults but a modest increase in children 
and young adults (426). It has been suggested that changes in health care practice 
influences the rate of hospital admissions and may influence the decline in rates. 
Reduced rates may also be attributed to the increased use of inhaled glucocorticoids 
and other anti-inflammatory medication (1). Hospital separations and average length 
of stay have been decreasing since the late 1990s (1999-2003) for asthma (427). 
In the present study, in contrast to the fall in asthma admissions, an increase in the 
total number of COPD admissions was recorded between 2000 and 2004, which 
equated to an 8.2% rise in the total number of admissions. On a national level, the age 
standardised rate of hospitalisations for COPD as a principal diagnosis remained 
stable from 1999-2004 for adults aged 55 years and over (427).  
The trends in increased numbers of admissions for COPD observed in the present 
study are consistent with an ageing demographic profile and an increasing population 
in WA. However, the data reflect overall numbers of admissions rather than age- 
standardised rates and therefore the figures do not take into consideration the overall 
change in the baseline population. The estimated residential population of Perth in 
2001 was 1,393,002; this had increased to 1,478,039 by 2005, whilst the rest of the 
State had an estimated population of 508,157 in 2001, which had increased to 532,925 
in 2005. If standardised rates were calculated it is possible that the increase in 
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admissions observed may be explained by the growth in population over this time 
period.   
In a recent WA study examining the long-term trends in COPD admissions using data 
from the WA data linkage system, the rate of hospital admissions with a primary 
diagnosis of COPD declined between 1980-1998 except in elderly women, and the 
decrease in the rate of hospitalisations was particularly evident for men and women 
under 70 years (418). The rate/100,000 in 1980 was 435.3 for males aged 40-69 years 
and 2698.3 for males aged 70 years and over, and in 1998 was 208.3 for males aged 
40-69 years and 2406.9 for males aged 70 years and over. The rate/100,000 in 1980 
for females aged 40-69 years was 227.8 and 642.2 for females aged 70 years and over 
and in 1998 was 146.2 for females aged 40-69 years and 440.6 for females aged 70 
years and over. However, consistent with an ageing population, the total annual 
number of admissions increased by 50% over the same time period. The authors 
postulated that reduced trends in COPD admissions within WA may be a reflection of 
a lower smoking prevalence as disease trends for COPD are largely a result of tobacco 
exposure (418).   
The data obtained in the current study illustrated that there was a clear trend for the 
number of admissions to increase with age for COPD, but not with asthma, and that a 
greater number of males were admitted with COPD than females across all health 
services. However, this pattern was reversed when considering the data for asthma.  
The US ‘NHANES’ study showed an increase in hospitalisation rates between 1990-
1999, and this was higher for males than for females in the years prior to 1995. From 
1995-200 the rate of hospitalisation for COPD in the US was similar with respect to 
gender. Since 1990 the largest increase in hospitalisation rates for COPD has been 
observed in people aged 65 years and over (426).  Another study reporting trends in 
hospital admissions for asthma and COPD in the Netherlands showed that the number 
of admissions and length of stay increased with age for those with COPD, while both 
the number of admissions and length of stay decreased with age for asthma (410). 
A limitation of the present study is that it failed to analyse length of stay. One study 
carried out in the US which analysed data from 1991-1997 showed that a decline in 
length of stay from an average (± standard deviation) of 7.5±6.6 days to 5.4±5.6 days 
for individuals diagnosed with COPD (428). For individuals with COPD who were 
given an early ‘do not resuscitate’ order (i.e. within the first couple of days of 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 203 
admission), post discharge mortality was higher, while for the individuals who were 
not given a ‘do not resuscitate’ order, the reduced length of stay was not associated 
with worse post-discharge outcomes (428). 
 
5.4.5 Overlap between asthma and chronic obstructive pulmonary disease 
In the current study, there were 152 admissions registered with a primary diagnosis of 
asthma that also had an additional diagnosis of COPD, and 102 admissions with a 
primary diagnosis of COPD that also had an additional diagnosis of asthma. As 
previously discussed, in older people with either asthma or COPD, it is often difficult 
to distinguish the two conditions and there can be substantial overlap in both the 
clinical manifestation of the diseases and the approaches to disease management. The 
potential for diagnostic misclassifications between asthma and COPD has been 
estimated to be about 10% based on the long-term data analyses of hospital 
admissions collected by Geelhoed et al (418). 
National statistics for Australia showed that in the year 2003-2004 there were 283 
admissions registered with asthma as the primary diagnosis in conjunction with 
COPD as an additional diagnosis, and 480 admissions with asthma as the additional 
diagnosis and COPD the primary diagnosis for hospitalised people aged 55 years and 
over (421). One discussion point this report highlighted was that since COPD is 
overwhelmingly the more common condition, misclassification of asthma as COPD 
only has a small impact on COPD statistics but has a substantial impact on asthma 
statistics even if potentially a small proportion of COPD is miscoded. The authors 
reasoned however that the overall decreasing trend in the number of asthma 
admissions over the time period of data collection was unlikely to be a result of 
misclassification issues because this trend had also been seen among younger age 





5.4.6  Limitations in the methodology and data 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 204 
5.4.6.1  Health outcome data 
The Western Australian HMDS consists of discharge extracts from all admissions to 
public and private hospitals in WA since 1970. Data includes demographic details for 
each patient, medical and clinical information and referral and discharge destinations. 
For the HMDS there are 21 separate quality checks in place to maintain data quality 
and periodic audits of hospital assigned codes.  Hospitals are encouraged to provide 
accurate and timely data through financial incentives (429). The data collected in the 
current study through the HMDS did not have the capacity to distinguish between 
admissions that were repeat admissions. 
The next logical step in the analysis of this data would be to take advantage of the 
WA Health Services Research Linked Database. This allows amalgamation of 
information from two or more admissions that are believed to be attributable to the 
same individual (260), and thus can enhance the information gained in the current 
study by tracking individuals and obtaining data related to readmission rates for 
asthma and COPD. This would assist in defining the percentage of individuals who 
account for this burden on the health system through recurrent hospitalisations. It 
would also allow the identification of individuals who might have been diagnosed 
with asthma during one admission, but then diagnosed with COPD on a subsequent 
admission, as there is a potential for diagnostic misclassification to occur on 
admission by the reviewing doctor and thence at the subsequent review by the 
medical coders. In terms of utilising data linkage methods, the study design would 
need to have the following desirable criteria: the population being relatively stable, of 
adequate size (i.e. greater than 1 million) and with adequate longitudinal coverage (10 
years or longer) (260). 
For the present study, it was decided the analyses of trends in the data pertaining to 
additional diagnoses of asthma or COPD may not be valid given the alteration in 
coding practices of additional diagnoses around the time the data were collected (this 
arose from the release of new guidelines for the coding system). From the 1st of 
January 1998, diseases were classified according to the ICD- 10-AM. For this coding 
system, a revised set of guidelines was released in July 2000 which clarified the 
details regarding when a condition should be recorded as an additional diagnosis.  
These guidelines emphasised that an additional diagnosis should only be included if 
that second diagnosis was a significant factor for that particular hospital stay (430). 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 205 
These guidelines had an impact on the coding of an additional diagnoses, particularly 
immediately following the release of the guidelines, although further decreases in the 
recording of additional diagnoses occurred in subsequent years. It was identified that 
among the conditions for which additional diagnoses substantially declined were the 
codes J45, J46 for asthma and J44 for COPD only. For example, the number of 
asthma diagnoses as a secondary condition fell by 68% between 1999-2000 and 2002-
2003 within Australia and for COPD decreased by 47%. This change was consistent 
across most States (421).   
5.4.6.2  Boundary effects 
The original postcode boundaries used to create the maps in this study were digitised 
postcode boundaries current to the year 2001. These postcode boundaries were 
acquired from the CDATA programme, and were originally boundaries that were 
captured by the Australian Surveying and Land Information Group. Because the 
hospital admissions data were collected between 2000 and 2004, there may be a slight 
spatial mismatch in the overall position of the health service boundaries during this 
time period as postcode boundaries have since changed with the expansion of WA’s 
population and the creation of new suburbs. Changes to existing suburb boundaries 
may have also resulted in changes to postcode boundaries even when these changes 
may not result in the creation of new postcodes. As this study was descriptive in 
nature and did not involve further spatial analyses, any small positional changes that 
may have occurred to the boundaries from the reference map of 2001 to 2004 were 
not considered a major limitation.   
Since completion of this study, these 30 health service boundaries have since been 
aggregated by the Department of Health for WA into seven larger regional Health 
Services which are all under control of the WA Country Health Service (Goldfields, 
Great Southern, Kimberley, Midwest, Pilbara, South West and Wheatbelt regions) and 
three larger Health Services servicing the metropolitan area (North Metropolitan 
Health service, South Metropolitan Health service and the Princess Margaret Hospital 
for children). In the current study, the original 30 Health Service boundaries that were 
in operation at the time that the hospital admissions data were collected were used to 
display the admissions data for this study as they were temporally relevant. 
Furthermore, it was considered that the much larger amalgamated seven regional 
areas and three metropolitan areas (of which only two are relevant to asthma and 
Chapter 5: Respiratory services and hospital admissions for asthma and COPD in WA 
 
 206 
COPD admissions of older adults) would potentially conceal any spatial patterns in 
the data and that the geographical (areal) unit might become too broad for meaningful 
interpretation of the data. 
5.4.6.3 Baseline population estimates 
In terms of population fluxes in various SLAs, Rockingham recorded one of the 
highest increases in population growth with a 3.9% increase from 2001-2005. Moora, 
Coolgardie, Manjimup, Narrogin and Northam all experienced declines in population 
of between 1.4 to 1.7%. Over this time period, in general, the growth rate of the city 
of Perth was 1.4%, inner regional areas in WA grew by 4%, outer regional areas grew 
by 0.2%, remote areas decreased their population size by 0.4% and very remote areas 
increased their number of residents by 0.8% (431). The 2001 census data was used to 
reference the baseline population data in the maps generated in the current study and 
thus do not illustrate the change in the size of the baseline population within each 
Health Service in subsequent years.  
5.4.6.4  Identification of health services and providers 
The positions of hospitals, pulmonary rehabilitation programmes, respiratory 
physicians and asthma educators were all point data located through geocoded 
addresses. Although sources of error can exist in the positional accuracy for geocoded 
addresses, geocoding for the most part is very accurate (i.e. within 100m). For this 
study, it was considered that any slight positional errors, potentially resulting in errors 
of spatial resolution, were negligible (432).   
The original asthma educator data set is likely to have been incomplete due to the 
inability of tracking and geocoding asthma educators who were working only in 
individual private practice clinics in both rural and metropolitan areas. This was due 
to the difficulty of accessing these professionals through The Asthma Foundation of 
WA due to confidentiality issues, and also the impracticality of contacting every 
existing medical practice in WA to identify educators.  This study did not take into 
consideration health professionals who may have completed additional training, such 
as GPs who had developed an interest in respiratory medicine and were therefore 
more qualified to provide specialist care. In addition, the study did not incorporate 
other important components of the holistic care for older adults with respiratory 
disease such as locations of pharmacies, pathology services, and laboratories for lung 
function testing. 





The changing epidemiology associated with respiratory disease and the consequences 
that this places on public health policy has increased the need for studies monitoring 
health outcomes (433).  By locating current resources for middle-aged and older 
adults with asthma and COPD in WA, the present study provides spatial information 
which could assist in identifying opportunities for improved patient outcomes and 
optimisation of resource planning in WA. The analyses provide an overview of the 
distribution of admissions to hospital for adults with asthma and COPD across the 
State, and thus the burden placed on health services in both regional and metropolitan 
WA.   









Recommendations and Conclusions 
 
 
The studies in this thesis have improved our understanding of the characterization of 
fixed airway obstruction resulting from chronic asthma and management issues which 
confront middle-aged and older adults with this condition. Three studies were 
conducted. Firstly, a randomised controlled trial (RCT) investigated the efficacy of 
exercise training on quality of life (QOL), functional exercise capacity, anxiety and 
depression, asthma control and peripheral muscle strength in individuals with fixed 
airway obstruction asthma (FAOA). Secondly, a comparative study contrasted resting 
lung function, functional exercise capacity and peripheral muscle strength in 
individuals with FAOA with individuals with chronic obstructive pulmonary disease 
(COPD). Finally, a spatial study mapped and analysed hospital admissions data of 
middle-aged and older adults with asthma and COPD in Western Australia (WA) and 
the distribution of support services for respiratory disease. This chapter summarises 
the novel findings presented in this thesis and discusses the implications of these 
findings for clinical practice and future research. 
 
6.1 Summary of the first and second studies 
A major finding of this thesis is that a 6 week supervised exercise programme in 
subjects with FAOA improves health-related quality of life (HRQOL) (intention-to-
treat and per-protocol analyses) and anxiety (per-protocol analyses) when measured 
immediately following the exercise programme and when measured again at 3 months 
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after cessation of the programme. A strength of this study was the inclusion of a well 
matched control group who did not participate in the exercise programme. Following 
training, the improvements in all domains of the Asthma Quality of Life 
Questionnaire (AQLQ) exceeded the threshold for a clinically important change, 
highlighting the fact that exercise training improved not only symptoms and activity 
limitation but also was associated with improved emotional function and a reduction 
in asthma symptoms in response to environmental stimuli.  Improvements in both 
anxiety levels and QOL indicate that an intervention programme, such as that 
conducted in this study can, by nature of the supervision and group interaction, bring 
about a positive change in the subject’s emotional well-being. To date, there are no 
other RCTs in adults with asthma that have used the AQLQ to assess the outcomes of 
an exercise training programme.    
For all outcomes measured in the RCT, any benefits observed in the exercise group 
tended to decline in the 3 month period following cessation of the exercise training 
programme, despite subjects being provided with a home exercise programme at the 
end of the supervised training period. It is possible that the tendency for outcome 
measures to return to baseline levels following training could have been avoided had 
subjects been offered a formal maintenance programme. At present the role and 
recommended format of such maintenance programmes in patients with chronic lung 
disease is unclear (225). The control group was not given any exercise advice. 
However, by participating in a study of exercise training, these subjects may have 
increased their activity levels or experienced improved well-being (i.e. Hawthorne 
effect). Indeed, this effect may account for the improvement seen in the activity 
limitation domain of the AQLQ in this group at the 6 week follow-up assessment.   
In the RCT, it was found that the baseline functional exercise capacity in the FAOA 
cohort as measured using the 6 minute walk test (6MWT) was not different from 
normative data and while an increase was observed in 6 minute walk distance 
(6MWD) immediately post-intervention, this improvement was not statistically 
significant compared to the control group.   These findings suggest the possibility that 
the 6MWT may not be the most responsive measure for detecting change in 
functional exercise capacity following exercise training in this patient cohort and this 
should be taken into consideration in the assessment of patients with FAOA if they 
are referred to a pulmonary rehabilitation programme.   
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A high 6MWD in individuals with FAOA was again emphasised in the second study 
of this thesis which compared resting lung function and 6MWT data in a cohort of 
subjects with FAOA and a cohort of subjects with COPD. This study showed 
significantly higher 6MWDs in the FAOA cohort compared to distances achieved in 
the COPD cohort despite comparable levels of baseline pulmonary hyperinflation and 
subjects being matched for age and gender. 
Dyspnoea is one of the most disabling symptoms in COPD and has been shown to 
improve with exercise training (434), yet for the subjects with FAOA involved in the 
first two studies in this thesis, this symptom was not a significant factor limiting their 
performance on the 6MWT. Though the symptom of dyspnoea has been reported as a 
common complaint in individuals with chronic asthma, it may in fact be more of an 
issue to these individuals during exacerbations rather than when their disease is stable.   
A number of potential mechanisms may have been responsible for the high 6MWDs 
and relatively low dyspnoea reported by the subjects with FAOA, and these 
mechanisms were explored in the second study in this thesis. Transfer factor is 
inversely related to 6MWD in COPD subjects (319, 343) and thus in part the well-
preserved single breath diffusing capacity for carbon monoxide corrected for alveolar 
volume (DLCO/VA) may have explained the high 6MWDs seen in the subjects with 
FAOA. The development of dynamic hyperinflation (DH) has been shown to correlate 
with the increased perception of dyspnoea during the 6MWT in COPD subjects and, 
together with DLCO and Medical Research Council Dyspnoea Grade, explained 51% 
of the variance in 6MWD (343). The addition of forced expiratory volume in one 
second (FEV1) to this regression model was associated with very little increase in the 
amount of variance explained (343). Although the subjects involved in this study had 
evidence of hyperinflation at rest, inspiratory capacity was not measured and thus the 
magnitude of DH and its contribution to the sensation of dyspnoea on exercise is 
unknown.   
There is accumulating evidence that deconditioning and muscle weakness are 
important elements in the functional deficit displayed during activities of daily living 
in individuals with COPD (435, 436). Exercise training addresses this functional 
deficit, yet these impairments are not necessarily such an important factor for 
individuals with FAOA since well preserved peripheral muscle strength was observed 
in these subjects. In addition, the systemic consequences of COPD which are 
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important in the morbidity and prognosis of this condition (390) may not necessarily 
occur to the same effect (if at all) in individuals who have FAOA, and hence this 
preserved function influences the ability of these individuals to exercise. 
 
6.2  Clinical implications and recommendations of the first and 
second studies 
In clinical practice, adults with moderate to severe asthma are sometimes referred to 
pulmonary rehabilitation programmes, with the assumption that the training protocol 
and benefits provided for patients with COPD can be extrapolated to individuals with 
asthma, due to the similarities in the symptoms and impairments in these patient 
groups (4, 8). The findings from the studies in this thesis demonstrate that this may 
not necessarily be an appropriate assumption as individuals with FAOA are likely to 
be able to tolerate higher intensities of exercise than their counterparts with moderate 
to severe COPD and will require less supervision during exercise than many patients 
who currently attend such programmes. 
Managing individuals with FAOA in a mixed pulmonary rehabilitation programme 
with adults with COPD therefore does pose a number of problems. Strategies which 
are taught and practised to manage moderate to severe dyspnoea and oxygen 
desaturation in individuals with COPD are not always relevant for those with FAOA, 
and whilst some individuals with COPD require oxygen for training, this is rare for 
patients with stable asthma. For individuals with bronchiectasis who are involved in 
pulmonary rehabilitation, there is an emphasis on airway clearance, again an issue 
which is not relevant for subjects with FAOA. Some components of exercise training 
for COPD such as inspiratory muscle training in individuals with COPD who are 
unable to take part in whole-body exercise training (314), or unsupported upper limb 
training which can improve upper limb endurance, reduce ventilation and oxygen 
uptake cost during arm activity (225) and has shown a trend towards improvements in 
dyspnoea in individuals with COPD (437), are less likely to be of benefit to 
individuals with FAOA because these individuals rely less on accessory muscles for 
respiration and thus are likely to experience less dyspnoea during upper limb 
activities.  
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For individuals with asthma, there is a prolonged warm-up and an emphasis on pre-
medication prior to exercise to prevent worsening asthma symptoms, yet for those 
with COPD a ‘prolonged warm-up’ may be all they can manage for a walking session. 
Patients with COPD are encouraged not to reach for their reliever medication when 
dyspnoeic on exercise but instead to take a short rest and adopt recovery positions. In 
addition, if education sessions that focus on self management are formal components 
to pulmonary rehabilitation, there needs to be specifically tailored sessions for 
individuals who are required to manage their asthma and exacerbations of their 
condition.   
In many countries there is a shortage of pulmonary rehabilitation programmes (438-
440). The subjects with FAOA involved in the RCT reported activity limitations due 
to their asthma and therefore met the criteria for referral for pulmonary rehabilitation 
(218). One suggestion arising from these study findings is that the role of pulmonary 
rehabilitation specialists for patients with FAOA is to screen for complicating factors, 
provide reassurance to these subjects that exercise is safe and effective when their 
condition is stable and, if available, offer referral to community-based exercise 
programmes such as those which may exist for middle-aged and older individuals 
with arthritis and diabetes. 
Long-term adherence remains a significant issue for pulmonary rehabilitation 
programmes provided for individuals with COPD (441). The declines in benefits 
observed from the exercise training programme at the 3 month follow-up in the RCT 
highlight adherence is also likely to be an issue in individuals with FAOA.  
Supervised programmes of at least 3-6 months in duration tend to have more success 
in reporting extended benefits (442), however these are costly to provide. Further, 
given the limited access to pulmonary rehabilitation within Australia (438-440), 
programmes of longer duration will result in a restriction of the numbers of patients 
who can receive rehabilitation. For older adults with asthma, further studies are 
recommended to ascertain the costs versus benefits of providing short term exercise 
programmes and to assess whether improvements in functional exercise capacity 
translate into a reduction in General Practitioner (GP) attendances, emergency 
department (ED) visits or hospital stays (as is the case for COPD) (218, 225). 
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6.3 Summary of the third study and its implications  
The prevalence study undertaken as part of this programme of research clearly 
indicated the disproportionate numbers of admissions from both asthma and COPD in 
regional WA compared to the metropolitan area. Many factors may account for this 
finding, including different thresholds for hospital admission versus discharge from 
the ED due to greater isolation or distances traveled by rural patients and potential 
consequences if such an individual was discharged back to the community early 
without adequate follow-up, different hospital practices, and potentially a greater 
community reliance on hospital services due to a lack of or poor access to other 
resources and professionals that provide care for these individuals in rural areas.   
Western Australia has a population that is heavily skewed towards Perth city, and 
hence the provision of services such as pulmonary rehabilitation, respiratory 
physicians, and asthma educators are often not feasible in outlying areas of low 
population densities. That being said, this study showed that a number of regional 
towns in WA which have sufficient population to warrant the provision of these 
services, were lacking in their access to key components for respiratory care. This is 
likely to place greater pressure on the acute hospital services in these areas, as well as 
primary care in terms of the role of GPs who are already known to be overworked in 
these areas. Further investigation on the needs of rural and remote communities in 
WA is warranted based on these preliminary findings and such investigation would 
need to utilise specific spatial epidemiological studies and surveillance of chronic 
respiratory disease in WA. 
 
6.4 Conclusion 
In conclusion, though the need for an accurate diagnosis of chronic asthma leading to 
permanent airway obstruction in older adults versus ‘COPD’ remains contentious 
amongst the medical fraternity, this thesis highlights that differentiating those who 
have developed fixed airway obstruction from their asthma from individuals who 
have COPD has a number of clinical implications related to the prescription of, and 
provision of, exercise training for this population. In addition ‘getting the diagnosis 
right’ improves the accuracy of the evaluation of disease burden, not just at the 
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individual level but also at the community and government levels in terms of health 
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Please answer the questions on this form and bring 
it with you when you come for assessment.         
Thank you 
 
Participant ID number: _____________________ 
Please list ALL MEDICATIONS you are currently taking (include both 
asthma medications and any other medications) and the way in which you 




Dose Number of times 
taken per day 
Tablet, puffer, 
nebuliser, etc 
    
    
    
    
    
    
    
 
How many courses of prednisolone have you had in the last 12 months? 
 _________ 
Do you always go to the same GP or GP Practice?    
 YES   /   NO 
 
Please write below the name, address and telephone number of your 






How many times have you visited your GP in the last 12 months because of 
worsening asthma symptoms? (we are asking about any unplanned visits 
not routine appointments)? __________________________________ 
 
How many times have you seen your respiratory specialist in the last 12 
months because of worsening asthma symptoms? (we are asking about any 
unplanned visits not routine visits)_____________________________ 
 
How many times in the last 12 months have you had an attack of asthma 
that was so bad that you had to go to a hospital emergency department? 
______________________________________________________ 
 
Please give details of any emergency department visits in the last 12 
months. If you cannot remember exact dates please give as much 
information as you can. 





How many times in the last 12 months have you had an attack of asthma 
that was so bad that you had to be admitted to a hospital ward and stay 
there for at least one night? ________________________________ 
 
Please give details of any hospital stays for asthma in the last 12 months. 





days in hospital 
Name of hospital 
   











This is a scale for rating the tight feeling in your chest.  
The number 0 represents no tight feeling.  
The number 10 represents the most severe or greatest chest tightness 
you have ever experienced.  
 
Tell me the number which represents your level of chest tightness at 
this moment in time. Use the descriptions to the right to help guide 
your selection. 
“Tight’ Feeling in Chest 
 
0 Not at all  
 
0.5 
Very, Very Slight 
(Just Noticeable) 
 
































This is a scale for rating the tight feeling in your chest.  
The number 0 represents no tight feeling.  
The number 10 represents the most severe or greatest chest tightness 
you have ever experienced.  
 
Tell me the number which represents your level of chest tightness at 
this moment in time. Use the descriptions to the right to help guide 
your selection. 
“Tight’ Feeling in Chest 
 
0 Not at all  
 
0.5 
Very, Very Slight 
(Just Noticeable) 
 


























Appendix D   Permission to use the SF-36 Health 
Survey 
 
Dear  Sian, 
Thank you for returning the signed agreement and payment to license the 
QualityMetric SF-36® Health Survey.  Attached are the surveys in Microsoft 
Word (.doc) and Adobe Acrobat (.pdf) formats, and the corresponding Test Data Set.  
If you are hand-scoring your data, this Test Data Set will allow you to verify that your 
algorithm has been programmed correctly. 
Note:  If you have licensed other languages besides US English, please print a hard 
copy of the Adobe Acrobat file for each translation.  Please compare the Microsoft 
Word file against the Adobe Acrobat file before administering to assure that they are 
identical.  If you do not have Adobe Acrobat Reader installed on your computer, you 
can download if for free at http://www.adobe.com/support/downloads/main.html/. 
As part of your academic license, you are entitled to scientific support for the duration 
of your study.  In order to efficiently provide this service when needed, please fill out 
the attached Scientific Support Request Form and email it to my attention or fax it to 
401-642-9349.  I will ensure that your questions are responded to by the appropriate 
QualityMetric resource in a timely manner. 
If you purchased Scoring Software 2.0™, you will receive the download link, 
activation key and installation manual in a separate email. 
If you purchased any scoring manual(s), they will be mailed to you by United Parcel 
Service (UPS). 








Senior Administrator  
Office of Grants and Scholarly Research (OGSR) 
640 George Washington Hwy, Suite 201 | Lincoln, RI 02865 






Appendix E Asthma study feedback form 
 
 
We are committed to developing the most appropriate exercise program for 
people with asthma and to help us we would like you to answer this 
questionnaire which asks you about your experience of the exercise classes.  
Please answer the questions and be honest with your answers. 
 
Participant ID …………………… 
Answer the questions on this page by putting a tick in the box that best 




Agree Unsure Disagree Strongly 
Disagree 




     
The exercise program 
has improved my 
ability to deal with 
problems caused by 
my lung disease 
     
I was very satisfied 
with the place where 
the classes were held 
     
The times of the 
classes suited me well 
     
The length of time of 
each class was just 
right 
     
 
 








Please answer the following questions in the space provided 
 
What parts of the exercise class were most helpful to you?  Please be as 





Were there any parts of the exercise class that you did not like? Please 





How can these classes be improved?  Please think for a moment and write 











Thank you for taking the time to complete this questionnaire. We 






Appendix F  Exercise protocol for circuit training 
 
Station 1  
Step-ups: A 15 cm step was used for this station. The exercise sequence was up-up-
down-down leading with alternate legs. Subjects were asked to count the steps they 
managed initially within a 1.5 minute time interval. After a 2 minute rest, this station 
was repeated. Subjects were progressed in the following sequence: 
1. increase time interval to 2 minutes for first set 
2. increase time interval to 2 minutes for both sets 
3. increase time interval to 2.5minutes for first set 
4. increase time interval to 2.5 minutes for both sets 
5. increase time intervals to 3.0 minutes 
6. add in the use of upper limb hand weights  
 
The number of repetitions achieved in each time interval and Ratings of Perceived 























Unsupported bilateral arm elevation:  The subject sat upright on a chair facing the 
wall. An 84 x 2.5cm bar weighing 200g was held with both hands, shoulder width 
apart. The bar was lifted to one level below maximal reach, touching a coloured band 
or the space between the bands, and back to rest on thighs. Cadence was paced by a 
metronome (30rpm). The task was commenced for a 1 minute time interval, and then 
increased in 30 second increments to 3 continuous minutes. The weight of the bar was 
then increased and time was decreased when the task was no longer challenging for 
the subject. For example, once the subject reached 200g weight lifted continuously for 
3 minutes, they were progressed to lifting a 500g bar for 2 minutes. Once 3 minutes 
was again reached, the task was progressed in the following sequence: 
1. lift 1kg weight for 2 minutes 
2. lift 1kg weight for 3 minutes 
3. lift1.5kg weight for 2 minutes 
4. lift1.5kg weight for 3 minutes 
5. lift 2kg weight for 2 minutes 




















Station 3  
Wall Squats:  For this task the subject stood with their feet approximately 30cm 
away from a wall, arms by their sides, and back against the wall. They had to bend 
their knees and slide slowly down the wall and then back to the starting position. Each 
subject started with 3 sets of 4 to 6 repetitions and this was progressed by increasing 
the number of repetitions to a maximum of 8 in each set and then to include holding 
light hand weights during the squat. 
 
Station 4 
Arm Ergometer:  For this station the subject sat in a supportive chair in front of an 
arm ergometer positioned just below 90 degrees of shoulder elevation. Careful 
instruction on correct sitting posture and scapulo-humeral stability was given to all 
subjects. A pillow was given for back support if necessary. Subjects were instructed 
to cycle on the arm ergometer for 1.5 minutes initially against a 20 watt resistance. 
After resting, this time interval was repeated. The total number of revolutions 
displayed on the ergometer was recorded on the exercise sheet. Cycling time was 
increased in 30 second intervals up to a maximum 3 minute interval. This was 
progressed again according to the RPE levels and dyspnoea scores recorded. Subjects 
were screened for upper limb gleno-humeral dysfunction and pain prior to performing 




















Stationary Bicycle:  This station was performed on a stationary bicycle. Subjects 
began cycling for a 3 minute time interval. Dependent on levels of RPE (target 
intensity 12-14), they were progressed by increasing time in either 30 second or 1 
minute intervals to a maximum of 10 minutes. Subjects who reported leg fatigue of  
>5 on the Borg scale on more than two consecutive occasions had their initial time 
interval split into two halves and separated by a rest. Subjects were prompted to 




Appendix G Self-reported physical activity levels for 
30 minute walking sessions throughout 
a typical week by group status 
 
Exercise Group (n=19)  
5 or more days
3 or 4 days
1 or 2 days
 
Pie segments denote numbers of subjects (n) 
Control group (n=15) 
 
5 or more days
3 or 4 days
1 or 2 days
no exercise
 











Appendix H Self-reported triggers for asthma   
exacerbations by group status 
 











Pie segments denote numbers of subjects (n). Subjects could report >1 trigger 




































Appendix I Methods of managing asthma 
symptoms by group status 






Pie segments denote numbers of subjects (n) 
 


















Appendix J Regularity of peak flow meter usage by 
group status 
 









Pie segments denote numbers of subjects (n) 
 
























Appendix K Number of GP visits secondary to an 
asthma exacerbation in the preceding 
year by group status  
 









Pie segments denote numbers of subjects (n) 























Appendix L SF-36 Health Survey factor score coefficients 
for Australia used to calculate the physical 
component summary scores and mental 





Derivation of PCS Scores and MCS scores for the population norms for 
Australia 
 
 FACTOR SCORE 
COEFFICIENTS 





83.46290 23.22864 0.47268 -0.24358 
Role-limits 
physical 
80.28166 34.83783 0.38210 -0.13410 
Bodily pain 76.94163 24.83714 0.36750 -0.12414 
General 
health 
71.81575 20.35165 0.18993 0.05271 
Vitality 64.47694 19.77187 -0.01883 0.27100 
Social 
function 
85.05929 22.29047 -0.01324 0.26460 
Role limits 
emotional 
83.19165 32.15215 -0.14971 0.35922 
Mental health 75.97772 16.96210 -0.27145 0.48753 
 
PCS: Physical Component Summary Score; MCS: Mental Component Summary 
Score.  




Appendix M  Spatial relationships between health services, to health districts, local government 




Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
North Metro  NMAHS - Central  Bassendean (T)  Bassendean (T)  505100350 1 
North Metro  NMAHS - Central  Bayswater (C)  Bayswater (C)  505100420 0 
North Metro  NMAHS - Central  Bayswater (C)  Bayswater (C)  505100420 1 
North Metro  NMAHS - Central  Stirling (C)  Stirling (C) - Central  505157914 0 
North Metro  NMAHS - Central  Stirling (C)  Stirling (C) - Central  505157914 1 
North Metro  NMAHS - Central  Stirling (C)  Stirling (C) - South-Eastern  505157916 1 
North Metro  NMAHS - Central  Swan (C)  Swan (C)  505108050 0.457 
North Metro  NMAHS - Central  Wanneroo (C)  Wanneroo (C) - South  505158767 0.873 
North Metro  NMAHS - Coastal  Joondalup (C)  Joondalup (C) - North  505154171 1 
North Metro  NMAHS - Coastal  Joondalup (C)  Joondalup (C) - South  505154174 0 
North Metro  NMAHS - Coastal  Joondalup (C)  Joondalup (C) - South  505154174 1 
North Metro  NMAHS - Hills  Kalamunda (S)  Kalamunda (S)  505104200 0 
North Metro  NMAHS - Hills  Kalamunda (S)  Kalamunda (S)  505104200 1 
North Metro  NMAHS - Hills  Mundaring (S)  Mundaring (S)  505106090 0.626 
North Metro  NMAHS - Lower  Cambridge (T)  Cambridge (T)  505051310 0.827 
North Metro  NMAHS - Lower  Claremont (T)  Claremont (T)  505051750 1 
North Metro  NMAHS - Lower  Cottesloe (T)  Cottesloe (T)  505052170 1 
North Metro  NMAHS - Lower  Mosman Park (T)  Mosman Park (T)  505055740 1 
North Metro  NMAHS - Lower  Nedlands (C)  Nedlands (C)  505056580 1 
North Metro  NMAHS - Lower  Peppermint Grove (S)  Peppermint Grove (S)  505056930 1 
North Metro  NMAHS - Lower  Stirling (C)  Stirling (C) - Coastal  505157915 1 
North Metro  NMAHS - Midlands  Mundaring (S)  Mundaring (S)  505106090 0.374 
North Metro  NMAHS - Midlands  Swan (C)  Swan (C)  505108050 0.375 
North Metro  NMAHS - Perth City  Cambridge (T)  Cambridge (T)  505051310 0.173 





Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
North Metro  NMAHS - Perth City  Perth (C)  Perth (C) - Remainder  505057082 0 
North Metro  NMAHS - Perth City  Perth (C)  Perth (C) - Remainder  505057082 1 
North Metro  NMAHS - Perth City  Subiaco (C)  Subiaco (C)  505057980 1 
North Metro  NMAHS - Perth City  Vincent (T)  Vincent (T)  505058570 0 
North Metro  NMAHS - Perth City  Vincent (T)  Vincent (T)  505058570 1 
North Metro  NMAHS - Upper  Wanneroo (C)  Wanneroo (C) - North-East  505158761 1 
North Metro  NMAHS - Upper  Wanneroo (C)  Wanneroo (C) - North-West  505158764 1 
North Metro  NMAHS - Upper  Wanneroo (C)  Wanneroo (C) - South  505158767 0 
North Metro  NMAHS - Upper  Wanneroo (C)  Wanneroo (C) - South  505158767 0.127 
North Metro  NMAHS - Valley  Swan (C)  Swan (C)  505108050 0.168 
South Metro  SMAHS - Armadale  Armadale (C)  Armadale (C)  505250210 1 
South Metro  SMAHS - Armadale  Gosnells (C)  Gosnells (C)  505253780 0 
South Metro  SMAHS - Armadale  Gosnells (C)  Gosnells (C)  505253780 1 
South Metro  SMAHS - Armadale  Serpentine-Jarrahdale (S)  Serpentine-Jarrahdale (S)  505257700 0 
South Metro  SMAHS - Armadale  Serpentine-Jarrahdale (S)  Serpentine-Jarrahdale (S)  505257700 1 
South Metro  SMAHS - Bentley  Belmont (C)  Belmont (C)  505250490 0 
South Metro  SMAHS - Bentley  Belmont (C)  Belmont (C)  505250490 1 
South Metro  SMAHS - Bentley  Canning (C)  Canning (C)  505251330 0 
South Metro  SMAHS - Bentley  Canning (C)  Canning (C)  505251330 1 
South Metro  SMAHS - Bentley  South Perth (C)  South Perth (C)  505257840 1 
South Metro  SMAHS - Bentley  Victoria Park (T)  Victoria Park (T)  505258510 0 
South Metro  SMAHS - Bentley  Victoria Park (T)  Victoria Park (T)  505258510 1 
South Metro  SMAHS - Fremantle  Cockburn (C)  Cockburn (C)  505201820 1 
South Metro  SMAHS - Fremantle  East Fremantle (T)  East Fremantle (T)  505203150 1 
South Metro  SMAHS - Fremantle  Fremantle (C)  Fremantle (C) - Inner  505203431 1 
South Metro  SMAHS - Fremantle  Fremantle (C)  Fremantle (C) - Remainder  505203432 0 
South Metro  SMAHS - Fremantle  Fremantle (C)  Fremantle (C) - Remainder  505203432 1 
South Metro  SMAHS - Fremantle  Melville (C)  Melville (C)  505205320 0 
South Metro  SMAHS - Fremantle  Melville (C)  Melville (C)  505205320 1 





Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
South Metro  SMAHS - Peel  Murray (S)  Murray (S)  510016230 0 
South Metro  SMAHS - Peel  Murray (S)  Murray (S)  510016230 1 
South Metro  SMAHS - Peel  Waroona (S)  Waroona (S)  510108820 1 
South Metro  SMAHS - Rockingham-Kwinana  Kwinana (T)  Kwinana (T)  505204830 1 
South Metro  SMAHS - Rockingham-Kwinana  Rockingham (C)  Rockingham (C)  505207490 1 
South West  SWAHS - Blackwood  Boyup Brook (S)  Boyup Brook (S)  510200770 1 
South West  SWAHS - Blackwood  Bridgetown-Greenbushes (S)  Bridgetown-Greenbushes (S)  510200840 1 
South West  SWAHS - Blackwood  Nannup (S)  Nannup (S)  510206300 1 
South West  SWAHS - Bunbury  Bunbury (C)  Bunbury (C)  510031190 1 
South West  SWAHS - Bunbury  Capel (S)  Capel (S) - Pt A  510031401 1 
South West  SWAHS - Bunbury  Capel (S)  Capel (S) - Pt B  510101404 1 
South West  SWAHS - Busselton  Busselton (S)  Busselton (S)  510151260 1 
South West  SWAHS - Leeuwin  Augusta-Margaret River (S)  Augusta-Margaret River (S)  510150280 1 
South West  SWAHS - Leschenault  Dardanup (S)  Dardanup (S) - Pt A  510032661 1 
South West  SWAHS - Leschenault  Dardanup (S)  Dardanup (S) - Pt B  510102664 1 
South West  SWAHS - Leschenault  Harvey (S)  Harvey (S) - Pt A  510033991 1 
South West  SWAHS - Leschenault  Harvey (S)  Harvey (S) - Pt B  510103994 1 
South West  SWAHS - Warren  Manjimup (S)  Manjimup (S)  510205180 1 
South West  SWAHS - Wellington  Collie (S)  Collie (S)  510101890 1 
South West  SWAHS - Wellington  Donnybrook-Balingup (S)  Donnybrook-Balingup (S)  510102870 1 
WA Country  WACHS - Central Great Southern  Broomehill (S)  Broomehill (S)  515051050 1 
WA Country  WACHS - Central Great Southern  Gnowangerup (S)  Gnowangerup (S)  515053640 1 
WA Country WACHS - Central Great Southern  Katanning (S)  Katanning (S)  515054340 1 
WA Country  WACHS - Central Great Southern  Kent (S)  Kent (S)  515054480 1 
WA Country  WACHS - Central Great Southern  Kojonup (S)  Kojonup (S)  515054550 1 
WA Country  WACHS - Central Great Southern  Tambellup (S)  Tambellup (S)  515058120 1 
WA Country  WACHS - Central Great Southern  Woodanilling (S)  Woodanilling (S)  515059380 1 





Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
WA Country  WACHS - East Pilbara  Port Hedland (T)  Port Hedland (T)  540057280 1 
WA Country  WACHS - Eastern Wheatbelt  Bruce Rock (S)  Bruce Rock (S)  525151120 1 
WA Country  WACHS - Eastern Wheatbelt  Kellerberrin (S)  Kellerberrin (S)  525154410 1 
WA Country  WACHS - Eastern Wheatbelt  Merredin (S)  Merredin (S)  525155460 1 
WA Country  WACHS - Eastern Wheatbelt  Mount Marshall (S)  Mount Marshall (S)  525155880 1 
WA Country  WACHS - Eastern Wheatbelt  Mukinbudin (S)  Mukinbudin (S)  525155950 1 
WA Country  WACHS - Eastern Wheatbelt  Narembeen (S)  Narembeen (S)  525156370 1 
WA Country  WACHS - Eastern Wheatbelt  Nungarin (S)  Nungarin (S)  525156860 1 
WA Country  WACHS - Eastern Wheatbelt  Trayning (S)  Trayning (S)  525158400 1 
WA Country  WACHS - Eastern Wheatbelt  Westonia (S)  Westonia (S)  525159030 1 
WA Country  WACHS - Eastern Wheatbelt  Yilgarn (S)  Yilgarn (S)  525159660 1 
WA Country  WACHS - Gascoyne  Carnarvon (S)  Carnarvon (S)  535051540 1 
WA Country  WACHS - Gascoyne  Exmouth (S)  Exmouth (S)  535053360 1 
WA Country  WACHS - Gascoyne  Shark Bay (S)  Shark Bay (S)  535057770 1 
WA Country  WACHS - Gascoyne  Upper Gascoyne (S)  Upper Gascoyne (S)  535058470 1 
WA Country  WACHS - Geraldton  Geraldton (C)  Geraldton (C)  535033500 1 
WA Country  WACHS - Geraldton  Greenough (S)  Greenough (S) - Pt A  535033851 1 
WA Country  WACHS - Geraldton  Greenough (S)  Greenough (S) - Pt B  535153854 1 
WA Country  WACHS - Kimberley  Broome (S)  Broome (S)  545100980 1 
WA Country  WACHS - Kimberley  Derby-West Kimberley (S)  Derby-West Kimberley (S)  545102800 1 
WA Country  WACHS - Kimberley  Halls Creek (S)  Halls Creek (S)  545053920 1 
WA Country  WACHS - Midwest  Carnamah (S)  Carnamah (S)  535151470 1 
WA Country  WACHS - Midwest  Chapman Valley (S)  Chapman Valley (S)  535151610 1 
WA Country  WACHS - Midwest  Coorow (S)  Coorow (S)  535152030 1 
WA Country  WACHS - Midwest  Irwin (S)  Irwin (S)  535154060 1 
WA Country  WACHS - Midwest  Mingenew (S)  Mingenew (S)  535155530 1 
WA Country  WACHS - Midwest  Morawa (S)  Morawa (S)  535155670 1 
WA Country 
  
WACHS - Midwest  
 
Mullewa (S)  
 










Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
WA Country  WACHS - Midwest  Murchison (S)  Murchison (S)  535106160 1 
WA Country  WACHS - Midwest  Northampton (S)  Northampton (S)  535156790 1 
WA Country  WACHS - Midwest  Perenjori (S)  Perenjori (S)  535157000 1 
WA Country  WACHS - Midwest  Three Springs (S)  Three Springs (S)  535158260 1 
WA Country  WACHS - Kimberley  Wyndham-East Kimberley (S)  Wyndham-East Kimberley (S)  545059520 1 
WA Country  WACHS - Lower Great Southern  Albany (C)  Albany (C) - Central  515100081 1 
WA Country  WACHS - Lower Great Southern  Albany (C)  Albany (C) Bal  515100084 1 
WA Country  WACHS - Lower Great Southern  Cranbrook (S)  Cranbrook (S)  515102240 1 
WA Country  WACHS - Lower Great Southern  Denmark (S)  Denmark (S)  515102730 1 
WA Country  WACHS - Lower Great Southern  Jerramungup (S)  Jerramungup (S)  515054130 1 
WA Country  WACHS - Lower Great Southern  Plantagenet (S)  Plantagenet (S)  515107210 1 
WA Country  WACHS - Northern Goldfields  Coolgardie (S)  Coolgardie (S)  530051960 1 
WA Country  WACHS - Northern Goldfields  Kalgoorlie/Boulder (C)  Kalgoorlie/Boulder (C) - Pt A  530014281 1 
WA Country  WACHS - Northern Goldfields  Kalgoorlie/Boulder (C)  Kalgoorlie/Boulder (C) - Pt B  530054284 1 
WA Country  WACHS - Northern Goldfields  Laverton (S)  Laverton (S)  530054970 1 
WA Country  WACHS - Northern Goldfields  Leonora (S)  Leonora (S)  530055040 1 
WA Country  WACHS - Northern Goldfields  Menzies (S)  Menzies (S)  530055390 1 
WA Country  WACHS - Northern Goldfields  Ngaanyatjarraku (S)  Ngaanyatjarraku (S)  530056620 1 
WA Country  WACHS - South East Coastal  Dundas (S)  Dundas (S)  530103080 1 
WA Country  WACHS - South East Coastal  Esperance (S)  Esperance (S)  530103290 1 
WA Country  WACHS - South East Coastal  Ravensthorpe (S)  Ravensthorpe (S)  530107420 1 
WA Country  WACHS - Murchison  Yalgoo (S)  Yalgoo (S)  535109590 1 
WA Country  WACHS - Murchison  Cue (S)  Cue (S)  535102380 1 
WA Country  WACHS - Murchison  Meekatharra (S)  Meekatharra (S)  535105250 1 
WA Country  WACHS - Murchison  Mount Magnet (S)  Mount Magnet (S)  535105810 1 
WA Country  WACHS - Murchison  Sandstone (S)  Sandstone (S)  535107630 1 





Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
WA Country  WACHS - Southern Wheatbelt  Boddington (S)  Boddington (S)  510100630 1 
WA Country  WACHS - Southern Wheatbelt  Brookton (S)  Brookton (S)  520050910 1 
WA Country  WACHS - Southern Wheatbelt  Corrigin (S)  Corrigin (S)  520102100 1 
WA Country  WACHS - Southern Wheatbelt  Cuballing (S)  Cuballing (S)  520052310 1 
WA Country  WACHS - Southern Wheatbelt  Dumbleyung (S)  Dumbleyung (S)  520053010 1 
WA Country  WACHS - Southern Wheatbelt  Kondinin (S)  Kondinin (S)  520104620 1 
WA Country  WACHS - Southern Wheatbelt  Kulin (S)  Kulin (S)  520104760 1 
WA Country  WACHS - Southern Wheatbelt  Lake Grace (S)  Lake Grace (S)  520104900 1 
WA Country  WACHS - Southern Wheatbelt  Narrogin (S)  Narrogin (S)  520056510 1 
WA Country  WACHS - Southern Wheatbelt  Narrogin (T)  Narrogin (T)  520056440 1 
WA Country  WACHS - Southern Wheatbelt  Pingelly (S)  Pingelly (S)  520057140 1 
WA Country  WACHS - Southern Wheatbelt  Wagin (S)  Wagin (S)  520058610 1 
WA Country  WACHS - Southern Wheatbelt  Wandering (S)  Wandering (S)  520058680 1 
WA Country  WACHS - Southern Wheatbelt  West Arthur (S)  West Arthur (S)  520058890 1 
WA Country  WACHS - Southern Wheatbelt  Wickepin (S)  Wickepin (S)  520059100 1 
WA Country  WACHS - Southern Wheatbelt  Williams (S)  Williams (S)  520059170 1 
WA Country  WACHS - West Pilbara  Ashburton (S)  Ashburton (S)  540100250 1 
WA Country  WACHS - West Pilbara  Roebourne (S)  Roebourne (S)  540107560 1 
WA Country  WACHS - Western Wheatbelt  Beverley (S)  Beverley (S)  525100560 1 
WA Country  WACHS - Western Wheatbelt  Chittering (S)  Chittering (S)  525051680 1 
WA Country  WACHS - Western Wheatbelt  Cunderdin (S)  Cunderdin (S)  525102450 1 
WA Country  WACHS - Western Wheatbelt  Dalwallinu (S)  Dalwallinu (S)  525102520 1 
WA Country  WACHS - Western Wheatbelt  Dandaragan (S)  Dandaragan (S)  525052590 1 
WA Country  WACHS - Western Wheatbelt  Dowerin (S)  Dowerin (S)  525102940 1 
WA Country  WACHS - Western Wheatbelt  Gingin (S)  Gingin (S)  525053570 1 





Services  Health Districts  Local Government Areas  SLA Description  SLA_Main  SPLIT  
WA Country  WACHS - Western Wheatbelt  Koorda (S)  Koorda (S)  525104690 1 
WA Country  WACHS - Western Wheatbelt  Moora (S)  Moora (S)  525055600 1 
WA Country  WACHS - Western Wheatbelt  Northam (S)  Northam (S)  525106720 1 
WA Country  WACHS - Western Wheatbelt  Northam (T)  Northam (T)  525106650 1 
WA Country  WACHS - Western Wheatbelt  Quairading (S)  Quairading (S)  525107350 1 
WA Country  WACHS - Western Wheatbelt  Tammin (S)  Tammin (S)  525108190 1 
WA Country  WACHS - Western Wheatbelt  Toodyay (S)  Toodyay (S)  525108330 1 
WA Country  WACHS - Western Wheatbelt  Victoria Plains (S)  Victoria Plains (S)  525058540 1 
WA Country  WACHS - Western Wheatbelt  Wongan-Ballidu (S)  Wongan-Ballidu (S)  525109310 1 
WA Country  WACHS - Western Wheatbelt  Wyalkatchem (S)  Wyalkatchem (S)  525109450 1 
WA Country  WACHS - Western Wheatbelt  York (S)  York (S)  525109730 1 
 
(S): Shire; (T): Town; (C): Council; SLA: Statistical local area. 
'Split' is the proportion of the SLA in the selected area. This figure is derived from census population counts at the Collection District level and used to apportion the SLA's 
population between areas that share the SLA.  
 
Data sources: Epidemiology Branch web-site, Monday, 22 August 2005 and Australian Bureau of Statistics (ABS) - SLA and LGA boundary files (2001), Department of 
Land Information (DLI) - Australia Post postcode boundaries (Nov 2004). 
 
 
 
 
